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ABSTRACT   
 
Thiol-disulphide reactions are critical to the structure and function of von Willebrand factor 
(VWF). Intracellular multimerisation is catalysed by intrinsic thiol isomerase activity of 
CGLC motifs in its propeptide. Conserved CG(L/I)C motifs were identified in the D3, D4 
and C1 domains which may possess thiol isomerase activity and contribute to intracellular 
synthesis of VWF or to extracellular thiol-disulphide exchange. Nine cysteine residues are 
unpaired in a proportion of plasma VWF molecules and are hypothesised to participate in 
disulphide-mediated self-association. This thesis aimed to study VWF self-association, the 
participating individual cysteines and the intrinsic isomerase activity of VWF. 
 
To study the unpaired cysteines, point mutants and C domain deletion mutants (where 
most of these cysteines are located) were made. To study the role of the conserved 
CG(L/I)C motifs, two complementary types of mutant were made: replacement of D2 
domain (known isomerase activity) with either the D3 or D4 domain; and insertion of 
glycine between vicinal cysteines (known to disrupt isomerase function). Mutants were 
expressed in HEK293T cells. Mutants which were retained intracellularly were studied by 
measuring lysate pro-VWF and by EndoH digestion. Secreted mutants were studied by 
quantifying expression, static collagen binding activity and free thiol content.  Mutant VWF 
function was assessed by measuring its ability to capture platelets when perfused over 
collagen under shear stress. The lateral self-association of VWF was studied under both 
static and flow conditions using plasma-derived and recombinant VWF. 
 
The results demonstrate that the individual cysteine residues and the C domains of VWF 
play a crucial role in the folding of VWF during synthesis. Furthermore, the CGLC motif in 
D3 plays a critical role in the synthesis of VWF. However, extracellular self-association of 
VWF does not appear to play a significant role in the capture of platelets to collagen under 
physiological flow conditions. 
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ASGPR   asialoglycoprotein receptor 
AUC   area under the curve 
BCA    bicinchoninic acid 
Bmax    maximal binding 
bp    base pair 
BSA    bovine serum albumin 
b-VWF  biotinylated VWF 
CBA    collagen binding assay 
cDNA    complementary deoxyribonucleic acid 
°C    degrees Celsius 
CHO    chinese hamster ovary 
CK    cysteine knot 
CMV    cytomegalovirus 
CV    coefficient of variation 
DDAVP   1-deamino-8-D-arginine vasopressin 
ddH2O   double-distilled water 
DiOC6   3,3′-dihexyloxacarbocyanine iodide 
DMSO   dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
dNTP    deoxynucleotide triphosphate 
DTT   dithiothreitol 
E°’   biochemical standard redox potential (that is, defined at pH 7.0) 
EC    endothelial cells 
E.coli    Escherichia coli 
EDTA   ethylenediaminetetraacetic acid 
ELISA   enzyme-linked immunosorbent assay 
EndoH   endoglycosidase H  
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EM   electron microscopy 
ER    endoplasmic reticulum 
EtOH   ethanol 
FL-VWF   full length VWF 
FPLC    fast protein liquid chromatography 
FVIII    factor VIII 
g   gravitational acceleration, related to rcf  
g   gram 
GSH   glutathione (reduced) 
h   human 
HEK    human embryonic kidney fibroblast 
HMWM   high molecular weight multimer 
HRP    horseradish peroxidase 
HS   Heparin-Sepharose chromatography 
HT   HEPES-Tyrodes buffer 
HUVEC   human umbilical vein endothelial cells 
IE   ion exchange chromatography 
kb    kilobase 
kcat/km   catalytic efficiency or specificity constant 
KD    equilibrium dissociation constant 
kDa    kilodaltons   
L   litre 
LB    Luria-Bertani medium 
m   metre 
M   molar 
MCS    multiple cloning site 
mins    minutes 
mol    mole 
MPB   maleomide-PEO2-biotin 
MS   mass spectometry 
mRNA   messenger ribonucleic acid 
MW    molecular weight 
MWCO  molecular weight cut off 
NEM   N-ethylmaleimide 
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N-linked   asparagine linked 
O-linked  serine/threonine linked  
OPD    O-phenylenediamine dihydrochloride 
Pa    pascal 
pBS    pBlueScript 
PBS    phosphate buffered saline 
PBS-T   phosphate buffered saline and Tween 20 
pcDNA  p=plasmid, c=CMV promoter, DNA= deoxyribonucleic acid 
PCR    polymerase chain reaction 
PDI    protein disulphide isomerise 
pd    plasma derived 
PEI    polyethylenimine 
PGE1   prostaglandin E1 
PNGase F   peptide: N-Glycosidase F 
PNK   polynucleotide kinase 
PPACK  D-Phenylalanyl-L-prolyl-L-arginine chloromethyl ketone 
PPP   platelet-poor plasma 
PRP   platelet-rich plasma 
r    recombinant 
RBC   red blood cell 
rcf   relative centrifugal force, acceleration relative to ‘g’ 
rpm    revolutions per minute 
RT-PCR   reverse transcription-polymerase chain reaction 
s    seconds 
SD    standard deviation 
SDS   sodium dodecyl sulphate 
SDS-PAGE   sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM   standard error of the mean 
SPR    surface plasmon resonance 
t½   half-life 
TGN    trans-Golgi network 
TSP-1   thrombospondin-1 
TSR   thrombospondin repeat 
TTP   thrombotic thrombocytopenic purpura 
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UL-VWF   ultra large Von Willebrand Factor 
U   unit 
UV    ultraviolet 
V   volt 
v/v    volume per unit volume 
VWD    Von Willebrand disease 
VWF    Von Willebrand factor 
VWF:Ag   Von Willebrand factor antigen 
VWF:CB   Von Willebrand factor collagen binding activity 
w/v   weight per unit volume 
wt    wild-type 
WPB    Weibel-Palade body 
 
 
 
Symbol abbreviations 
~   approximately 
Δ   deletion 
%    percentage 
 
 
 
Power prefix abbreviations 
m    milli 
μ    micro 
n    nano 
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Amino acid abbreviations 
 
Alanine   Ala   A 
Arginine   Arg   R 
Asparagine   Asn   N 
Aspartic acid  Asp   D 
Cysteine   Cys   C 
Glutamic acid  Glu   E 
Glutamine   Gln   Q 
Glycine   Gly   G 
Histidine   His   H 
Isoleucine   Ile   I 
Leucine   Leu   L 
Lysine   Lys   K 
Methionine   Met   M 
Phenylalanine  Phe   F 
Proline   Pro   P 
Serine   Ser   S 
Threonine   Thr   T 
Tryptophan   Trp   W 
Tyrosine  Tyr  Y  
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CHAPTER 1: INTRODUCTION 
 
1.1 HAEMOSTASIS OVERVIEW 
Normal haemostasis is an intricately balanced system. It maintains the fluidity of circulating 
blood whilst being primed to prevent blood loss in case of injury by forming a haemostatic 
plug. Regulators are in place to ensure that premature activation does not occur, that the 
forming plug is localised and that it is eventually removed when healing is complete. There 
are five major components of the haemostatic system: the vessel wall, platelets, 
coagulation factors and their inhibitors, and the fibrinolytic system. A deficiency or 
exaggeration of any of the components in this system may result in either thrombosis or 
haemorrhage. 
 
At a site of vascular injury, circulating platelets adhere to the damaged endothelium to 
form an unstable plug (primary haemostasis). This is subsequently stabilised through the 
activation of the coagulation cascade and the formation of a cross-linked fibrin network 
(secondary haemostasis). This thesis focuses on von Willebrand factor (VWF) which plays 
a critical role in both primary and secondary haemostasis 
 
1.2 VON WILLEBRAND FACTOR OVERVIEW 
VWF is a large multimeric plasma glycoprotein. It supports platelet adhesion and 
aggregation at the site of vascular injury1. It also acts as the carrier protein for coagulation 
factor VIII (FVIII), protecting it from proteolytic degradation, extending its half-life in the 
circulation and increasing the local concentration of FVIII at sites of vascular injury2. The 
serious consequences which result from abnormalities in VWF, or its regulation, illustrate 
its importance. Quantitative or qualitative deficiencies of VWF result in the bleeding 
disorder von Willebrand disease (VWD) (section 1.4.3). An increase in plasma VWF 
activity is associated with pathophysiologic processes such as coronary artery thrombosis3 
and thrombotic thrombocytopenic purpura (TTP) in which an increase in high molecular 
weight VWF multimers causes microvascular thrombosis and significant morbidity and 
mortality.  
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1.2.1 Domain structure overview 
Each VWF monomer is composed of multiple domains. Knowledge of this structure is 
integral to understanding the expression, processing and function of multimeric VWF. 
Each pro-VWF monomer comprises four D domains, a truncated D domain, three A 
domains, six C domains and a CK domain arranged in the order:  
 
NH2- D1- D2- D’- D3- A1- A2- A3- D4- C1- C2- C3- C4- C5- C6- CK-COOH. 
 
The D1 and D2 domains represent the propeptide and are removed from pro-VWF by furin 
in the Golgi (section 1.2.4), to form the mature VWF subunit, D’-CK. Figure 1.1 illustrates 
the domain structure and the function of some of the individual domains. These are 
described in more detail in section 1.3.  
 
 
 
 
 
Figure 1.1 Domain structure of pro-VWF. Pro-VWF is comprised of three homologous 
repeating domains: four D domains, a truncated D’ domain, three A domains, six C 
domains and a cysteine knot domain (CK). The D1 and D2 domains (propeptide) are 
cleaved in the Golgi leaving the mature VWF subunit, D’-CK. VWF dimers are formed by 
intermolecular disulphide bonds at the C-terminus and multimers formed by intermolecular 
disulphide bonds at the N-terminus. The binding sites of various ligands and the 
ADAMTS13 cleavage site within the A2 domain are shown.  
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1.2.2 Gene expression and regulation 
The human VWF gene spans 178kb and is localised on the short arm of chromosome 12 
(12p13.2). It contains 52 exons: exon 1 is not translated4, exons 2-18 encode the signal 
peptide and propeptide, and exons 19-52 encode the mature VWF subunit5. Mature 
messenger (m)RNA is 8.8kb in length and encodes pre-pro VWF, a protein of 2813 amino 
acids (section 1.2.3). The majority of the VWF gene therefore comprises introns, 
characteristic of eukaryotic genes6. The role of introns is largely unknown, although they 
include regions of DNA which are enhancers, promoters, or perform other regulatory 
roles7. Chromosome 22 contains a VWF pseudogene (22q11) corresponding to exons 23-
34 and which has 97% sequence homology8 but contains multiple stop codons indicating 
that it is not a functional gene9. 
 
VWF is synthesised exclusively in endothelial cells (EC) and megakaryocytes10, with the 
majority of circulating VWF in the plasma derived from ECs11. Within an individual there is 
marked heterogeneity in VWF expression in ECs throughout the vasculature,12,13 with high 
mRNA levels found within the lungs14. Furthermore, within a given tissue VWF expression 
is in general greater on the venous side of the circulation14 and there is also substantial 
variation in plasma VWF levels between individuals15. The regulation and specificity of 
VWF synthesis is complex and not yet fully understood. It relies on both activators and 
repressors and varies according to pathophysiological conditions. There is a promoter 
region, spanning the sequence from -487 to +247 relative to the transcription start site, 
that consists of a core promoter, a strong negative regulatory element and a positive 
regulatory region16,17. There are several binding sites for transcriptional repressors 
including Oct-118, NFY19, and E4BPA20. Synthesis of VWF in ECs and megakaryocytes is 
promoted by transcription factors of the GATA family binding to the positive regulatory 
element17,21,22. This expression may be up- or down- regulated by pathophysiological 
conditions. For example, in a mouse model of endotoxemia, VWF mRNA levels were 
down-regulated in the ECs of the aorta, brain, liver, gut and skeletal muscle but increased 
in the kidney and heart14.  
 
1.2.3 Synthesis and processing 
Following transcription and translation of VWF mRNA, pre-pro VWF is synthesised. It is 
composed of a 21 amino-acid N-terminal signal peptide, a 741 amino acid propeptide, and 
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a 2050 amino acid mature protein. The signal peptide of the primary VWF translation 
product directs the protein to the rough endoplasmic reticulum (ER) where it is cleaved by 
a signal peptidase to leave pro-VWF.  
 
Pro-VWF undergoes extensive post-translational modifications including N- and O-linked 
glycosylation and sulphation. Initial N-linked glycosylation occurs in the ER, resulting in the 
addition of high-mannose sugar structures to sixteen asparagine residues; twelve in the 
mature subunit and four in the propeptide23. Following dimerisation (see section 1.2.4), 
VWF is transported to the Golgi apparatus for further carbohydrate processing: N-linked 
glycan chains are modified to produce complex glycan structures24 and ten O-linked 
glycan chains are added, eight of which are clustered either side of the A1 domain23. The 
N- and O- linked glycans together contribute approximately 20% of the molecular weight of 
VWF25 and play an important role in its normal function. N-linked glycans ensure correct 
protein folding in the ER by regulating the entry of newly synthesised glycoproteins into the 
calnexin-calreticulin cycle, important for disulphide bond formation and protein folding26,27.  
In addition, N-linked glycans on VWF are essential for dimerisation (treatment of 
endothelial cells with tunicamycin results in the accumulation of VWF monomers within the 
cell28); protect against proteolytic cleavage29,30 and play an important role in the clearance 
of VWF from the circulation31,32. The function of O-linked glycans on VWF has been less 
extensively studied, but a recent study showed that they regulate exposure of the GPIbα 
binding site in the A1 domain by helping maintain rigidity of VWF, particularly under 
conditions of shear stress33. 
 
1.2.4 Dimerisation and multimerisation 
The ER provides an optimal environment for disulphide bond formation. It contains thiol 
isomerases, such as protein disulphide isomerase (PDI), and has a suitable redox 
potential. In the ER, pro-VWF dimerises ‘tail-to-tail’ through the formation of disulphide 
bonds between C-terminal CK domains34,35 (Figure 1.2). Studies of recombinant VWF CK 
dimers localised the inter-subunit disulphide bond(s) to a subset of C2771, C2773 and 
C281135. Molecular modelling and mutagenesis data of mucin-like CK domains (the 
subclass that includes the VWF CK domain) suggest that VWF has just one inter-subunit 
disulphide bond corresponding to C2773, and that the other cysteine residues form intra-
subunit disulphide bonds36,37. Very large proteins are problematic to transport from the ER 
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to the Golgi, probably because the relevant cargo vesicles have restricted capacity38. To 
overcome this size limitation, VWF has evolved a unique mechanism of assembly whereby 
multimerisation occurs within the Golgi. 
 
 
 
Figure 1.2 Dimerisation and multimerisation of VWF. Within the ER, VWF dimers are 
formed by intermolecular disulphide bonds (red bar) between cysteine residues located in 
the C-terminal region of each mature VWF monomer. Multimerisation of pro-VWF dimers 
occurs in the Golgi by the formation of intermolecular disulphide bonds between cysteine 
residues located at the N-terminal ends of adjacent molecules. The propeptide is cleaved 
by furin and remains non-covalently associated with VWF. 
 
 
Pro-VWF dimers are transported to the Golgi where disulphide bonds form ‘head-to-head’ 
between cysteine residues located at the N-terminal D3 domains of adjacent 
molecules34,39 to form pro-VWF multimers (Figure 1.2). Sequencing of plasma VWF 
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identified a C1142-C1142 intersubunit disulphide bond40, and characterisation of a 
recombinant D’D3 fragment of VWF by mass spectrometry (MS) suggested that C1099 
also forms an intersubunit disulphide bond. Introducing the individual mutations C1099A or 
C1142A markedly impaired the formation of the N-terminal disulphide bonds, and the 
double mutation completely prevented their formation41. Disulphide-bond formation is 
generally a slow process requiring catalysis. Unlike the ER, the Golgi lacks a high 
concentration of resident thiol isomerases and is relatively acidic, which generally prevents 
disulphide rearrangement, although recent studies suggest that the Golgi contains some 
resident thiol isomerase-like enzymes and some non-resident thiol isomerases involved in 
‘recycling’ to the ER42-44. To overcome the lack of oxidoreductase enzymes and the lower 
pH of the Golgi, VWF appears to use its own propeptide to promote formation of the 
disulphide bonds linking VWF multimers (see section 1.6.2).  
 
Following its crucial role in multimerisation, the propeptide is cleaved from the mature 
VWF subunit by furin45, at the C-terminal end of the RSKR sequence. After furin cleavage, 
the propeptide remains non-covalently associated with VWF until secretion45. It is secreted 
with mature VWF in equimolar amounts, but is found in the circulation at an approximately 
10 fold lower concentration due to its shorter half-life46-48. 
 
1.2.5 Storage, secretion and the cell surface  
VWF synthesised in ECs is either constitutively secreted or stored in Weibel Palade bodies 
(WPB). VWF synthesised in platelets is stored in α-granules49 and released upon their 
activation. Storage of VWF allows cells to release VWF upon stimulation at a much faster 
rate than new synthesis would allow, and also to achieve a high local concentration at the 
site where it is needed. A great deal of research has focussed on WPBs, how VWF is 
stored within them and then released.  
 
WPBs are densely packed rod-shaped structures that are typically ~0.2µm wide and up to 
5μm long. Their distribution varies between vascular endothelial beds, with highest 
numbers present in the pulmonary artery14,50. They store VWF in longitudinally arranged 
tubular structures 150Å in diameter51,52. The exact mechanism governing the targeting of 
VWF to WPBs is unknown, although the propeptide is critical for both WPB targeting and 
formation53. An elegant series of mutational, cell biological and electron microscopy (EM) 
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studies have shown that in the presence of Ca2+ and low pH (conditions found in the trans-
Golgi and WPBs) the propeptide and D’D3 domains are sufficient for assembly into helical 
tubules comparable to those seen in intact WPBs39,54,55. EM has also been used to show 
that at acidic pH the C-terminus forms an elongated, dimeric bouquet. These spontaneous 
non-covalent interactions at low pH appear to be essential for correct VWF dimer 
incorporation into growing multimers, and for preventing cross-linking between 
neighbouring tubules56. It also allows a fifty fold compaction in the length of the tubules55. 
In addition to VWF, other proteins have been localised to WPBs revealing that they have 
an important role not only in haemostasis, but in inflammation and angiogenesis: factor 
VIII, P-selectin, endothelin, CD36/lamp3, interleukin-8, α1,3-fucosyltransferase VI, tissue-
type plasminogen activator and angiopoietin-257-67.  
 
VWF is released both constitutively and following specific stimulation. It was previously 
believed that the majority of newly synthesised VWF was spontaneously released from 
non-stimulated cells through a constitutive pathway. However, a recent study showed that 
blocking this constitutive secretion only has a minor effect on spontaneous release of 
VWF, suggesting that the majority of VWF is sorted into WPBs and subsequently released 
without cell stimulation. The spontaneous release of VWF that has first been sorted into 
WPBs has been termed basal secretion and this pathway accounts for 80% of VWF 
secreted from cultured human umbilical vein endothelial cells (HUVECS)68. Live-cell 
imaging studies have revealed the extraordinary plasticity of the regulated secretory 
pathway. Thrombin, histamine, fibrin, complement components C5a and C5b-9, oxidative 
stress and leukotrienes have been shown to induce VWF release by mediating a rise in 
the concentration of cytosolic free Ca2+ 60,69-75. Regulated secretion of VWF can also be 
induced by secretagogues, such as epinephrine, adenosine or the vasopressin analogue 
DDAVP (1-deamino-8-D-arginine vasopressin)76-78 which elevate intracellular cAMP. In all 
cases the secretion of WPB contents involves the translocation of the WPB from the 
cytoplasm towards the plasma membrane and the fusion of the vesicle with the plasma 
membrane. However, in a process which may allow differential release of WPB 
constituents, secretagogues cause a subset of WPBs to cluster at the microtubules and 
therefore not be involved in exocytosis79. Further modulation of the release of WPB 
contents may occur during exocytosis itself depending whether this occurs by ‘full-
collapse’ or a slow ‘lingering kiss’80. In the latter process, a 10-12nm fusion pore is formed 
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which allows selective release of smaller molecules while larger molecules, such as VWF, 
are retained. 
 
When WPBs undergo exocytosis, a proportion of ultra-large (UL)-VWF multimers remain 
attached to the surface of activated ECs and appear as long strings, particularly in the 
absence of functioning ADAMTS13 (A Disintegrin And Metalloproteinase with 
ThromboSpondin type-1 repeats, section 1.2.6)81,82. In vitro P-selectin and αvβ3 have been 
identified as controlling VWF string attachment to ECs83,84, although in vivo the mechanism 
appears to be different as the numbers and lengths of VWF strings in P-selectin or αvβ3 
deficient mice do not differ from wild-type (wt) mice. The formation of long strings appears 
to rely upon well-ordered tubular storage as disruption of tubular structure by pH 
neutralisation with monensin prevents VWF string formation upon exocytosis85. Strings are 
typically several 100µm long, but can reach lengths of up to 1mm81. Hypothetically, a VWF 
tubule that extends the entire length of a 5µm WPB would be predicted to be composed of 
approximately 3900 VWF monomers and an extended length of 250µm38,55. Based on 
these observations, strings with lengths greater than about 250µm must presumably be 
composed of different VWF multimers. VWF strings composed of different multimers have 
been visualised as intertwined bundles by EM83. It has been suggested that this occurs 
through the self-association of VWF multimers by thiol-disulphide exchange (see section 
1.5). Of note, when VWF was added to the perfusate the average length of the strings 
increased83 and it was suggested that circulating VWF also bound to the VWF strings 
through self-association. 
 
However the physiological role of these strings is debated. They behave similarly to UL-
VWF, spontaneously binding platelets, presumably as a result of the unfurled conformation 
exposing the large number of GPIbα binding sites. They therefore have significant pro-
thrombotic potential. However, in vivo platelet decorated VWF strings are only observed 
transiently on the surface of the activated endothelium, and are rapidly cleaved by 
endogenous ADAMTS13 in wild-type (wt) mice. It is only in mice with ADAMTS13 
deficiency that the life-time of these VWF strings is prolonged86. These strings may play a 
pathological role in thrombotic thrombocytopenic purpura (section 1.4.4). Additionally, it 
has been suggested that they play a pathological role in sickle cell disease and in 
inflammation, however the evidence is currently not strongly supportive87.  
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1.2.6 ADAMTS13 and regulation of multimer size 
As already discussed, VWF is secreted as a series of multimers ranging in size from 
dimers of 500kDa up to UL-multimers in excess of 20000kDa. The largest multimers have 
the highest avidity for collagen and the platelet receptor GPIbα and are thus the most 
biologically active88. As a result of this, the multimeric size of VWF needs to be carefully 
regulated to prevent abnormal thrombus formation. This is achieved in plasma by the VWF 
cleaving protease ADAMTS13. 
 
ADAMTS13 is a multi-domain protein consisting of a signal peptide, a propeptide, a 
metalloproteinase domain, a disintegrin domain, a thrombospondin type-1 motif (TSP), a 
cysteine-rich domain, a spacer domain, seven additional TSRs and two CUB domains 
(complement C1r/C1s, Uegf, Bmp1)89 (Figure 1.3). The metalloproteinase domain contains 
the active enzymatic site and its activity is dependent on the presence of Zn2+ and Ca2+ 
ions88. 
 
 
 
Figure 1.3 Domain structure of ADAMTS13. ADAMTS13 is a multi-domain protein 
containing a metalloproteinase domain (MP), a disintegrin domain (Dis) a thrombospondin 
type-1 motif (TSP), a cysteine-rich domain, a spacer domain, seven additional TSPs, and 
two CUB domains (for complement C1r/C1s, Uegf, Bmp1).  
 
 
ADAMTS13 regulates VWF multimeric size by cleaving VWF at the Y1605-M1606 bond in 
the VWF A2 domain, generating the 176kDa and 140kDa fragments found in the 
circulation90 and generating the characteristic triplet pattern seen on multimer-gel analysis 
of plasma VWF. ADAMTS13 is constitutively active and its activity is regulated by the 
conformation of VWF (unlike most proteinases it does not have a specific inhibitor)91. VWF 
circulates in globular form and in this conformation the Y1605-M1606 bond is buried within 
the A2 domain92,93. Cleavage of VWF requires this bond to be exposed, as it is when VWF 
is in its extended conformation. In vivo VWF unfurls under elevated shear (which can 
occur on secretion, on collagen binding or in the microvasculature) as a result of 
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unclustering between different domains and also unfolding within domains, in particular the 
A2 domain94 (sections 1.3.5 and 1.4). This exposes the Y1605-M1606 bond allowing 
cleavage (Km 0.16-1.6µM)
95,96. This may be partially mimicked in vitro by the use of urea, 
guanidine, HCl or ristocetin88.  
 
ADAMTS13 binds to the D4 domain of globular VWF via its TSP(5-8) and CUB domains 
with KD~80nm
97,98. Of note, although only about 3% of ADAMTS13 circulates bound to 
globular VWF this may still be particularly important for co-localising VWF and ADAMTS13 
at the site of injury91,99,100. The unfolding of VWF reveals further multiple binding sites, 
within the A2 domain in particular, which increase the affinity of the reaction to 
KD~10nm
91,96,101.   
 
As well as cleavage by ADAMTS13, it has been suggested that VWF multimer size may 
be regulated by the thiol reductase thrombospondin-1 (TSP-1). Incubation of VWF with 
purified TSP-1 resulted in the formation of thiol dependent complexes of VWF and TSP-1, 
the generation of free thiols in VWF, and a reduction in the multimeric size of VWF102. An 
inverse relationship is seen between the plasma molar ratio of TSP-1/ VWF and VWF 
multimeric size, and the administration of TSP-1 to mice resulted in a reduction of VWF 
multimeric size102. However a subsequent study demonstrated that average VWF 
multimeric size was actually reduced in TSP-1 null mice103. The cause of this remains 
unclear. It was initially suggested that in vivo TSP-1 may compete with ADAMTS13 for 
binding to VWF and inhibit to some degree ADAMST13 proteolysis104. However, as TSP-1 
has been shown to interact with the VWF A3 domain102,103, and it has been recently shown 
that ADAMTS13 binds to the D4 domain of globular VWF and mainly the A2 domain of 
extended VWF, it is not obvious that there would be competitive binding. This study also 
showed that TSP-1 is stored in the α-granules of platelets and is able to reduce platelet 
VWF multimeric size upon platelet lysis or activation. This was unable to occur in the TSP-
1 null mice, and resulted in increased collagen and platelet binding103. This implies that 
TSP-1 may regulate plasma-derived and platelet-derived VWF in different ways and the 
action of TSP-1 maybe more relevant to platelet derived VWF103. However the 
physiological role and importance of TSP-1 for VWF remains far from clear. 
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1.2.7 Clearance 
It is still not yet known exactly how and where VWF is cleared from the circulation. 
However there is a great deal of indirect evidence pointing to the importance of glycan-
mediated binding to macrophages and hepatocytes. Individuals with blood group O have 
average VWF levels 25% lower than non-O individuals. The VWF propeptide does not 
vary in this way and the propeptide to VWF antigen ratio has therefore been used as a 
measure of VWF clearance to demonstrate a significantly higher rate of VWF clearance in 
blood group O than non- O subjects105. Recently a genome wide association study 
identified CLEC4M (C-type lectin domain family, member 4) as a genetic determinant of 
VWF:Ag levels106. Expression of VWF without its O-linked glycans results in a significantly 
reduced half-life in a rat model107. VWF with enzymatically removed terminal sialic acid 
residues was cleared more rapidly from the circulation in a rabbit model and the clearance 
was inhibited by simultaneous infusion of asialo-α-1-acid glycoprotein that binds to the 
asialoglycoprotein-receptor31. Bacterial neuraminidase desialylates VWF in septic mice, 
resulting in desialylated VWF binding to the Ashwell receptor, the major lectin of 
hepatocytes108. Other mouse studies have also suggested that macrophages residing in 
the liver and kidney tissue are responsible for VWF clearance109.   
 
However, glycan mediated binding does not appear to be the sole mechanism involved in 
VWF clearance. Various VWF mutations (including VWD Vicenza110) have been linked to 
increased clearance110,111 although the mechanisms are currently poorly defined and their 
relation to physiological clearance uncertain. The roles of various VWF domains in 
clearance have been investigated using a knockout mouse model. Clearance rates of 
recombinant A1A2A3 were comparable to full-length (FL) VWF suggesting that a major 
receptor site for clearance may be located in the A1A2A3 domains112.  Additionally, 
deletion of D'D3 resulted in increased VWF clearance, suggesting that this region may be 
important in inhibiting VWF clearance112.  
 
Despite a great deal of circumstantial evidence regarding the importance of glycans, the 
structural basis for VWF clearance remains poorly understood. 
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1.3 VWF STRUCTURE AND FUNCTION 
As discussed briefly previously, each pro-VWF monomer is comprised of three types of 
homologous repeating domains. There are four D domains, a truncated D domain, three A 
domains, six C domains and a CK domain arranged in the order:  
 
NH2- D1- D2- D’- D3- A1- A2- A3- D4- C1- C2- C3- C4- C5- C6- CK-COOH. 
 
The D1 and D2 domains represent the propeptide and are removed from the mature 
molecule in the Golgi.  
 
1.3.1 The D domains 
VWF contains four D domains and a truncated D domain (D’). The D1 and D2 domains 
(residues 22-763) comprise the VWF propeptide, and the truncated D’ and D3 domains 
(residues 764-1242) comprise the N-terminal portion of the mature VWF monomer. Each 
D domain consists of approximately 200 amino acids and is rich in cysteine residues (D1 
9.1%, D2 8.9%, D’ 17%, D3 9.6% and D4 8.8%)113.  The D domains share 28% sequence 
homology (9.4% identical) and the majority of the identically conserved residues are 
cysteines, suggestive of similar tertiary structures. However the tertiary structures of these 
domains have not yet been solved. 
 
The propeptide (D1D2) is required for multimerisation of VWF114 and direction of VWF to 
storage granules53 (see sections 1.2.4 and 1.2.5). The D’ and D3 domains contain the 
cysteines for multimerisation (see section 1.2.4) and the binding site for P-selectin by 
which newly secreted ultralarge VWF multimers may be anchored to ECs84,83,115. 
Additionally a region in D' (841-859) has been identified as the critical FVIII binding site116-
118. FVIII is an essential haemostatic plasma glycoprotein. It is the cofactor for the serine 
protease FIXa and facilitates explosive thrombin generation as part of a positive feedback 
loop. FVIII binds to VWF with high affinity (KD 0.2-0.5nM)
119 and with a rapid association 
rate (Kon = 5.9 x 10
6 M-1s-1) 120. The affinity of FVIII for VWF is decreased when VWF is 
bound to collagen (KD ~5nM)
121. Propeptide cleavage and N-terminal inter-dimer 
disulphide bonds are required to create the high affinity binding site122, however all sizes of 
VWF multimers bind FVIII with the same affinity123. The interaction of FVIII with VWF 
increases local FVIII concentration at the site of injury, facilitating coagulation and 
explosive thrombin generation. It also significantly increases FVIII’s circulatory half-life 
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from 2.5 hours to approximately 12 hours124. Consequently, absent VWF or reduced VWF-
FVIII binding (caused by well described mutations in either VWF or FVIII) is associated 
with reduced plasma FVIII level120,125. Type 2N von Willebrand disease (VWD), 
characterised by decreased FVIII binding, leads to bleeding symptoms typical of 
haemophilia with haemarthrosis and deep tissue bleeding (see section 1.4.3).  
 
Little investigation has focused on the function of the D4 domain. Expression of D4 
domain-deleted recombinant VWF had no effect on multimeric structure and did not alter 
binding of VWF to type III collagen126. Further investigation is needed to ascertain the role 
of this domain. 
 
 
 
1.3.2 The A domains 
VWF contains three A domains which share approximately 30% homology and span 
residues 1260-1874 (A1 domain 1260-1453, A2 domain 1498-1668, A3 domain 1691-
1874)127. The structures of all three VWF A domains have been solved by X-ray 
crystallography, which has revealed a characteristic fold consisting of a central β-sheet 
flanked on both sides by α-helices128-133. Both the A1 and A3 domains contain an intra-
molecular disulphide bond that results in loops of 185 residues. The A2 domain lacks this 
disulphide bond and consequently its structure is more flexible (Figure 1.4).  
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Figure 1.4 Structure of the A domains.  Both the A1 and A3 domains contain an intra-
molecular disulphide bond (red bar) that results in loops of 185 residues. The A2 domain 
lacks this disulphide bond and consequently its structure is more flexible. The site of 
cleavage by ADAMTS13 is shown (Y1605 – M1606). 
 
 
The A1 domain fulfils a crucial role in the function of VWF by binding GPIbα on the surface 
of platelets. Sites of interaction between the A1 domain and GPIbα on platelets have been 
well characterised by co-crystal structures of A1 and GPIbα128,129 and by site-directed 
mutagenesis134,135. The GPIbα binding site in A1 is hidden in globular circulating VWF and 
only becomes exposed after VWF unfolds under elevated shear stress or when bound to 
collagen136-139. Under high shear stress the fast on/off rates of this interaction allow initial 
capture and then release of platelets resulting in platelets rolling on the vascular 
surface140,141. The importance of the GPIb-VWF interaction has been illustrated in vivo 
using a mouse model: a GPIb binding mutant failed to form thrombus following ferric-
chloride injury and failed to correct tail bleeding142. The A1 domain of VWF also contains 
the major binding site for heparin143,144, minor binding sites for collagen types I and III145,144 
and a binding site for collagen type VI.  
 
The A3 domain contains the principal collagen binding site130,131,146,147. It has a fast 
association rate that can decelerate and capture circulating VWF under shear148. Collagen 
is a structural matrix protein that is not normally exposed to the flowing blood. The 
collagen involved in interaction with VWF is predominantly of type I and III149,150. Collagen 
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type III is present in the subendothelium and is exposed to circulating blood after limited 
vessel wall damage, whereas collagen type I lies deeper in the vessel wall and requires 
more extensive injury to be exposed. Based on the crystal structure of the A3 domain133 
and site-directed mutagenesis of its residues130,131, the binding to collagen is achieved 
through interactions between negatively charged residues on the A3 domain and positively 
charged residues on collagen. There is not a marked binding groove, which prevents a 
large van der Waals surface interaction between collagen and the A3 domain, and results 
in a single A3 domain having a low affinity for collagen. Multimeric VWF is required for 
high affinity association with collagen133. The highest molecular weight multimers bind to 
collagen with the highest affinity (KD 1-7nM)
126.  
 
Whilst the crystal structure of A2 shows that it has a similar general fold to the A1 and A3 
domains there are 2 major differences: no homologous disulphide bond or an α-helix. 
These stabilise the general fold of the A1 and A3 domains and without them the A2 
domain unfolds more easily under shear stress and in response to the binding of 
ligands132,151. This unfolding allows ADAMTS13 to cleave the scissile bond (Y1605-M1606) 
which is otherwise hidden in the core of globular VWF (see section 1.2.6).  
 
 
1.3.3 The C domains 
Contrary to the domain structure of VWF described previously (Figure 1.1), VWF was 
originally described as having three B domains and two large C domains spanning 
residues 2255-264523,127 (Figure 1.5). However recent work has resulted in the re-
annotation of the C terminus as comprising six C domains152. 
 
Whilst there is still no crystal structure of VWF C domains, there are now crystal structures 
for two typical C domains in other proteins (crossveinless2153 and collagen IIA154) (Figure 
1.6). The canonical C domain is 60-80aa in length and comprises 10 cysteine residues, 
forming 5 disulphide bonds in the pattern: Cys1-Cys4, Cys2-Cys8, Cys3-Cys5, Cys6-Cys9, 
and Cys7-Cys10. 
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Figure 1.5 Original domain annotation of VWF. The C-terminus of VWF was originally 
described as three B domains and two large C domains23,127. 
 
 
 
Figure 1.6 Ribbon structure of the typical C domain in crossveinless2. The crystal 
structure of the C domain in crossveinless2 has been determined (X-ray structure, PDB ID 
3BK3). Ribbon structure drawn using PyMOL (www.pymol.org). The 10 conserved 
cysteines are numbered and the 5 disulphide bonds are shown (blue).  
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When the sequences of these two classical C domains are aligned with the C-terminus of 
VWF it reveals 6 similar domains152,155. There are 3 classical C domains (C1, C3, C5) and 
3 C-like domains (C2, C4, C6), which share 8 of the 10 conserved cysteine residues but 
lack Cys3 and Cys5144,147. However, persuasively EM of a recombinant C-terminus 
fragment (A2-CK) showed a ‘stem’ of six globular domains, consistent with these newly 
proposed six C domains. Expression work of some of these C domains was carried out to 
support the suggested domain boundaries from sequencing152. 
 
Little is known about the function of the C domains overall, although it has been suggested 
that they may play a role in the lateral self-association of VWF (section 1.5). The C4 
domain contains the 2507RGDS sequence required for binding to GPIIbIIIa on the surface 
of activated platelets156. It forms an irreversible bond that arrests the platelet’s movement, 
stabilises the GPIbα interaction and thus mediates platelet adhesion157,158. When platelets 
were perfused over recombinant RGDS mutant (RGGS, that is D2509G) bound to 
collagen, the platelets failed to spread and aggregate159. Interestingly, in vivo mouse 
models suggest that this GPIIbIIIa interaction may be particularly important for arterial 
thrombosis but not for bleeding. When murine RGGS-VWF was transiently expressed in a 
VWF knockout mouse, there was a decrease in thrombus growth and an increase in the 
time to vessel occlusion following ferric chloride-induced injury of the mesenteric arterioles 
compared to mice expressing wt-VWF142. However, time taken to correct tail bleeding was 
similar. Although in a mouse stroke model, using transient middle cerebral artery 
occlusion, the RGGS-VWF mice had a similar infarct volume to wt-VWF mice160. The C 
domains also contain a binding site for fibrin, important for platelet capture under high 
shear stress161, and it has been suggested that VWF binding fibrin at sites of injury may 
contribute to the formation of a stable thrombus162. 
 
1.3.4 The CK domain 
The CK domain comprises the final 90 C-terminal residues of VWF (2724-2813). CK 
domains are characterised by six conserved cysteine residues forming disulphide bonds in 
the pattern Cys1-Cys4, Cys2-Cys5, Cys3-Cys6, resulting in a ‘knot’ like structure. 
Additional non-conserved cysteine residues, that differ between CK domains, may mediate 
dimerisation163. Molecular modelling and mutagenesis data indicate that, in VWF, the 
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unconserved cysteine residue C2773 forms the intra-subunit disulphide bond causing 
dimerisation35-37,164 (section 1.2.4). 
 
1.3.5 Quaternary structure 
The quaternary structure of VWF has been visualised using EM and atomic force 
microscopy (AFM). In the absence of shear, VWF is a loosely coiled mass of multimers. 
Above a critical shear stress of ~35dyne/cm2 VWF multimers undergo a conformational 
change from this globular state to an extended conformation136,165,166. This structural 
transition is critical for its physiological function, exposing binding sites for the platelet 
GPIbα receptor. It is noteworthy that this critical shear stress of 35dyne/cm2 corresponds to 
the wall shear rate (~1000s-1) at which VWF becomes predominant over fibrinogen as the 
principal mediator of platelet adhesion140. Blood flow dynamics are further discussed in 
section 1.4.1, but it is useful here to conceptualise shear flow as elongational flow 
superimposed on rotational flow, as this helps convey the fluctuating quaternary structure 
of VWF under shear167. Rotational flow results in VWF ‘tumbling’168. A globular VWF 
molecule will elongate if its ends are in lamina with different velocities. As VWF tumbles 
the ends will change lamina and the hydrodynamic forces may then cause compaction of 
VWF. At sites of rupture, elongational flow is relatively increased, and this results in 
increased and prolonged extending of VWF, at the point where its adhesive haemostatic 
function is required95,167,169,170. 
 
It might seem paradoxical that the extended VWF conformation, which is required for initial 
tethering of VWF to platelets, also results in susceptibility of VWF to cleavage by 
ADAMTS13, and therefore a reduction in its haemostatic potential. However an elegant 
theory has been proposed in which this allows careful regulation of thrombus growth91. 
Following vessel damage, VWF binds to collagen and unfolds in response to shear forces. 
The binding of GPIb to VWF occurs rapidly, with a fast on-rate which exceeds the rate of 
VWF proteolysis (Km 0.16-1.6M). Additionally activation of the coagulation cascade will 
result in a high local concentration of thrombin which can activate recruited platelets 
resulting in VWF-independent adhesion and aggregation. As the platelet plug grows 
beyond the site of injury (and the primary source of collagen and thrombin), unravelled 
VWF may still tether platelets, but there is probably more time for ADAMTS13 to cleave 
VWF, thus regulating thrombus growth and confining it to the site of injury. This is 
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supported by the visualization of ADAMTS13 function on the surface of developing thrombi 
using whole blood flow models171. Thus the changes in quaternary structure of VWF 
appear to be critical to both its physiological function and its regulation. 
 
The unravelling effect of shear stress on VWF structure can be mimicked in vitro by 
denaturants or other modulators, such as urea and ristocetin. However it is unlikely that 
these reproduce the conditions in vivo. Interestingly, hydrophobicity of the surface has also 
been shown to influence the structure of VWF: on hydrophobic surfaces VWF displayed a 
compact structure, while on hydrophilic surfaces it appeared extended172. 
 
 
1.4 ROLE OF VWF IN PRIMARY HAEMOSTASIS 
1.4.1 Blood flow dynamics 
Blood is a viscous suspension of cells in fluid. The red blood cells comprise the majority of 
the circulating mass and force the white blood cells and platelets to the side of the 
vessel173. This distribution facilitates the interaction of platelets with a damaged vessel 
wall. Above shear rates of 200s-1 blood behaves as a Newtonian fluid173, thus the velocity 
of the blood flow through the vessel will be maximal in the centre and will decrease 
towards the vessel wall. This changing velocity of the blood across the vessel’s diameter 
creates shearing flow (the sliding movement between 2 adjacent laminae travelling at 
different speeds). Shear rate is defined as the difference in flow velocity between laminae 
as a function of the distance from the wall, expressed as velocity divided by distance, in 
units of s-1. Shear stress is defined as the tangential force per unit area of contact between 
laminae and can be expressed either in Pascal (Pa) using the International System of 
Units or dyne/cm2 using the CGS system (1Pa = 10 dyne/cm2). In Newtonian fluids there is 
a linear relationship between shear rate and shear stress which is determined by the 
viscosity of the liquid. Maximal shear rate occurs at the sides of the vessel, while minimal 
shear rate occurs at the centre of the vessel. The range of typical wall shear rates and 
shear stresses is shown (Table 1.1). 
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Blood vessel Shear rate (s-1) Shear stress (dyne/cm2) 
Veins 
Large arteries 
Arterioles 
Stenotic vessels 
20-200 
300-800 
500-1600 
800-10000 
0.76-7.6 
11.4-30.4 
19.0-60.8 
30.4-380 
 
Table 1.1 Typical wall shear rates and shear stresses. Viscosity of blood assumed to 
be 3.8milliPoise (adapted from Kroll et al174). 
 
1.4.2 The role of VWF in primary haemostasis  
At a site of vessel injury, platelets must rapidly adhere to the damaged endothelium to 
prevent blood loss. The interaction between the platelet and the vessel wall requires a fast 
on-rate (bonds can only form whilst platelets are within 10nm of the vessel wall) and also 
needs to be able to withstand the force (drag) applied to it by the moving fluid. The higher 
the shear forces, the higher the drag.  
 
Under conditions of low shear stress platelets are able to interact directly with collagen 
exposed by the damaged endothelium through the platelet receptors GPVI161,162 and 
GPIaIIa (integrin α2β1)
175. These receptors mediate platelet adhesion and promote 
activation176. At higher shear rates whilst GPIaIIa (integrin α2β1) can still bind to type 1 
collagen177 (which lies deeper in the vessel wall and is therefore only exposed on more 
extensive injury) GPVI on non-activated platelets is unable to bind to collagen178. The 
relative importance of these receptors remains debated but is likely to depend on shear 
stress and the type and extent of injury. Following local injury to the carotid artery, mice 
with combined deficiency of GPVI and integrin α2β1 showed almost complete inhibition of 
thrombus formation compared to only a minor reduction in thrombus formation when there 
was deficiency of only one of the receptors179,180. However, deficiency of either one or both 
of these receptors led to prolonged tail bleeding in mice180. Interestingly, GPVI or integrin 
α2β1 deficiency in humans does not cause a strong bleeding phenotype
181,182. 
 
Above shear rates of 1000s-1 the interaction of VWF with GPIbα is critical for initiating 
platelet adhesion on type III collagen183. After exposure of the subendothelium, circulating 
globular VWF interacts with exposed matrix proteins, principally collagen via the A3 
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domain, anchoring it to the subendothelium. This induces a conformational change 
allowing interaction of the A1 domain with collagen as well148. Of note, whilst circulating 
VWF is sufficient to support platelet adhesion184,185, stimulated ECs release UL-multimers 
(that are the most biologically active) from the WPBs. Additionally, the subendothelial 
matrix may contain sufficient endogenous VWF, depending on the vascular bed, to support 
platelet adhesion alone186,187. The shear forces cause the anchored VWF to undergo a 
conformation change from its globular to its extended conformation136. This exposes the 
binding site for GPIbα. The binding of platelet GPIbα to VWF has a rapid association rate, 
and shows an increase in bond-life with increasing shear rates (catch bond) allowing 
platelets to be tethered even at high shear rates140,141. Although the interaction cannot 
provide irreversible platelet adhesion as it also has a fast dissociation rate, it serves to 
slow the movement of the platelet and results in platelet activation188. Activation results in 
a morphological change, with the platelet extruding long pseudopods that enhance 
interaction with adjacent platelets, and expose more negatively charged phospholipids on 
its membrane which provide an optimal surface for binding of coagulation factors.  In 
addition it leads to the activation of platelet receptor GPIIbIIIa (integrin αIIbβ3) and 
expression of P-Selectin on the platelet surface. GPIIbIIIa interacts with the RGDS 
sequence in the VWF C4 domain, forming an irreversible bond that arrests the platelet’s 
movement, stabilises the GPIbα interaction, and thus mediates platelet adhesion157,158. 
 
Following initial adhesion of platelets, VWF allows recruitment of further platelets to form 
the platelet-rich plug by supporting platelet-platelet interactions, through GPIbα and 
GPIIbIIIa. Although fibrinogen interacts with GPIIbIIIa to form the predominant link 
between aggregated platelets at very low shear189, at higher shear VWF is essential in 
supporting platelet aggregation139,190,191. Platelets can also be recruited by binding to P-
Selectin on activated platelets, via GPIbα192. The stability of the platelet plug is finally 
secured by the cross-linked fibrin mesh produced by the coagulation cascade. 
 
Platelet VWF is released from the α-granules upon platelet activation. Whilst it is thus 
unlikely to be involved in the initial adhesion of platelets to the subendothelium,  it is 
involved in the extension of the platelet aggregate191. 
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Localisation of the thrombus to the site of injury occurs as a result of the balance of many 
regulatory mechanisms including ADAMTS13, coagulation inhibitors, the fibrinolytic 
system, and possibly the conformation of VWF itself (see section 1.3.5). 
 
1.4.3 Von Willebrand disease  
Von Willebrand disease (VWD) is the most common congenital bleeding disorder affecting 
approximately 1% of the population. It is caused by deficiency in the functional activity of 
VWF, either quantitative or qualitative. It gives rise to a bleeding disorder directly through a 
defect in primary haemostasis, preventing platelets from adhering at sites of injury. As it is 
a carrier for coagulation FVIII, the more severe forms also give rise to a secondary 
haemostatic defect through reduced FVIII levels. Symptoms vary according to severity of 
the disease and include prolonged bleeding from minor wounds, menorrhagia, epistaxis 
and gingival bleeding. Severe forms, in which the FVIII level is reduced to 1-2%, have a 
clinical bleeding tendency that is similar to severe haemophilia A with joint and muscle 
bleeds and life-threatening haemorrhage after trauma. VWD is classified into three primary 
categories. Type 1 is defined as a quantitative partial deficiency, type 2 as a qualitative 
functional deficiency, and type 3 as a quantitative complete deficiency. 
 
Type 1 VWD accounts for 70% of cases.  Whilst it is defined simply as a quantitative 
partial deficiency of VWF, individuals with type 1 VWD frequently show subtle 
abnormalities in multimer composition and distribution. This is consistent with the 
dominant-negative effect of many of the associated mutations.  
 
Type 2 VWD is divided into four secondary categories: 2A, 2B, 2M, 2N.  
Type 2A refers to patients with a selective loss of high molecular weight multimers 
(HMWM) resulting in decreased platelet associated function. This results either from 
mutations located within VWF (D1, D2, D3 or CK domains) causing defective assembly 
and secretion of VWF multimers; or from mutations in the A2 domain of VWF resulting in 
increased proteolysis by ADAMTS13 after secretion.  
Type 2B refers to VWF mutants with an increased affinity for platelet GPIbα. The 
responsible mutations are clustered within the A1 domain which contains the GPIbα 
binding site. Mutant VWF shows increased ristocetin-induced platelet aggregation (RIPA) 
at low concentrations of ristocetin. There is increased clearance of both VWF and 
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platelets, leading to absence of haemostatically active HMWMs and a variable 
thrombocytopenia. 
Type 2M refers to VWF mutants with decreased platelet adhesion but normal VWF 
multimer distribution. It also results from mutations in the GPIbα binding site in the A1 
domain. 
Type 2N refers to mutants with markedly reduced FVIII binding capacity, resulting in low 
FVIII levels due to enhanced clearance. These mutations are mainly localised to the D’D3 
domains, which are the major FVIII binding site.  
 
Type 3 VWD is characterised by the complete absence of VWF, and consequently a 
profound deficiency in FVIII. It is autosomal recessive, caused by null mutations or 
inactivating mutations in both VWF alleles. It results in a severe bleeding disorder. 
 
 
1.4.4 Thrombotic thrombocytopenic purpura 
Thrombotic thrombocytopenic purpura (TTP) is characterised by microangiopathic 
haemolytic anaemia and thrombocytopenia. It is a rare disorder (incidence 6 in a million 
per year) with >90% fatality untreated193. It is caused by a deficiency of ADAMTS13, 
generally due to acquired autoantibodies directed against ADAMTS13 but may be due to a 
congenital deficiency (~5% of cases)194-196. Lack of functioning ADAMTS13 results in the 
loss of proteolysis of UL-VWF released from ECs, which then spontaneously binds 
platelets195. Platelet aggregates form in the microvasculature, particularly of the kidneys, 
heart and brain, resulting in organ dysfunction. Acquired TTP is treated by plasma 
exchange, to remove the autoantibody and replace ADAMTS13197. 
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1.5 SELF-ASSOCIATION 
1.5.1 Self-association 
VWF self-association was first reported by Savage et al198 who showed that fluid-phase 
VWF multimers could homotypically associate with VWF multimers immobilised onto a 
glass surface. Platelets were perfused over immobilised VWF lacking the A1 domain (ΔA1-
VWF), which contains the GPIbα binding site required for initial platelet tethering. Platelets 
in plasma-free blood failed to bind, but platelets in either whole blood or in plasma free 
blood with additional soluble wt VWF adhered promptly. This implies that the soluble VWF 
bound to the ΔA1-VWF on the slide and mediated platelet adhesion. It has subsequently 
been shown that VWF self-association occurs above critical shear stress thresholds in a 
cone-plate viscometer, and perhaps under certain static conditions. However it is not yet 
known whether the same mechanism underlies all these phenomena.  
 
Light scattering studies showed that plasma-derived (pd) VWF aggregates in suspension 
when subjected to high shear (2000-6000s-¹) in a cone-plate viscometer199. Perfusion 
studies using a linear flow chamber found that at shear stresses above 20dyne/cm² 
plasma VWF forms filamentous spider-web like structures on a collagen surface200. This 
network may represent an ideal anchor to capture flowing platelets during primary 
haemostasis.  Atomic force microscopy (AFM) images indicate that shear stress most 
likely drives the unrolling of immobilised globular molecules to fine filamentous multimers 
of variable length that elongate in the direction of flow. Large numbers of these fine fibres 
were found to merge and combine into fibres with extended dimension and rather irregular 
and complex structure200. 
 
VWF self-association has also been described in the absence of shear, but in the 
presence of a different stimulus to conformational change. Light scattering and 
turbidimetry showed that VWF can self-aggregate in solution in the absence of shear but in 
the presence of high ristocetin concentration201. Ristocetin binds to the A1 domain of VWF 
and induces a conformational change in VWF allowing binding to platelet GPIbα, 
mimicking the conformational change which occurs under shear202.  Using an ELISA 
technique, Ulrichts et al203 reported that biotinylated VWF (b-VWF) interacted dose-
dependently with immobilised VWF (KD~90nM) and that VWF fragments containing 
domains D’-D4 (residues 1-1365) and D4-CK (residues 1366-2050) also interacted with 
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immobilised VWF with a similar KD. This reaction was found to be reversible (bound b-
VWF was almost undetectable following a 45 minute incubation with unlabelled VWF) and 
was considered to be specific. It was concluded that this suggested a multiple domain 
interaction and that VWF could self-associate under static conditions. However, the VWF 
was immobilised by direct coating onto a plate which opens up its usual static globular 
conformation.  Thus it appears that a conformational change is required to expose the 
VWF regions required for self-association.  
 
In addition to shear, the presence of platelets may contribute to the required 
conformational change and therefore VWF self-association. Soluble VWF interacts with 
platelet GPIbα under flow204. Large multimers may unfold more readily in response to 
shear forces when bound to the surface of a platelet, and subsequently associate more 
easily with immobilised VWF. Furthermore, transient interactions of soluble VWF with 
GPIbα on the surface of platelets may increase the local concentration of VWF multimers, 
which may again favour VWF self-association. 
 
1.5.2 Free thiols 
VWF has an unusually high content of cysteine residues (8.2%) compared to the protein 
average (2.3%)i. It was previously thought that all 172 cysteine residues were engaged in 
intra-chain or inter-chain disulphide bonds205-207. However, in 2007 Ganderton et al104 
reported that pdVWF bound to maleomide-PEO2-biotin (MPB). MPB is a thiol-reactive 
agent with a hydrophilic polyethylene oxide spacer arm. Maleomide reacts with the thiol 
group on a cysteine residue to form a stable carbon-sulphur bond. The presence of free 
thiols has subsequently been confirmed by other groups by detecting binding of pdVWF to 
both MPB and activated Thiol-Sepharose beads (which form mixed disulphides with 
surface-exposed free thiols of VWF multimers) 208,209. The ratio of pdVWF with exposed 
free thiols to VWF with no exposed free thiols was estimated to be approximated 3 to 7208. 
Recombinant wt VWF has been shown to have a similar proportion of free thiols as 
pdVWF155,210. 
__________________________________________________ 
i
 The role of cysteines in forming disulphide bonds and thiol-disuphide exchange is discussed in section 
1.5.3. Additionally, s-nitrosylation of thiols has been studied for many proteins and plays a role in both ER 
folding and signal transduction
211
. S-nitrosylation may be physiological or pathological; for example, the s-
nitrosylation of PDI plays a role in the neurodegeneration of Alzheimer’s disease
212
. However, s-nitrosylation 
of VWF has not yet been studied and has not been noted to occur in mass spectroscopy studies to date. 
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In order to identify which cysteines were free in pdVWF, Choi et al208 incubated  pdVWF 
with thiol-active beads, trypsinised, and eluted the VWF tryptic peptides with dithiothreitol 
(DTT). These tryptic peptides were then analysed using tandem mass spectrometry. This 
revealed that nine cysteine residues in four tryptic peptides may exist in the form of free 
thiols: two cysteine residues in D3 (C889, C898) and seven in the C domains (C2448, 
C2451, C2490, C2491, C2453, C2528, C2533) (Figure 1.7). Because each tryptic 
fragment contains more than one cysteine residue it has yet to be determined whether all 
these cysteine residues are in free thiol form. It is also possible that some of the tryptic 
fragments did not contain free thiols but rather formed covalent association with free-thiol 
containing peptides and therefore were co-purified from the beads.  
 
 
 
 
Figure 1.7 Identification of free thiol residues. Free thiol residues were located to nine 
cysteine residues, two in the D3 domain and seven in the C domains208.  
 
 
Whilst no one has verified that the same cysteines are unpaired in full-length recombinant 
wt VWF as in pdVWF, Ganderton et al155 examined the free cysteines in a C1-CK VWF 
fragment  (2255-2813) from HEK293 cells. The authors labelled unpaired and paired 
cysteines as Cys-carboxyamidomethyl and Cys-methyldisulphide, respectively. Analysis 
using tandem mass spectrometry covered 68% of the cysteines. C2453 had a ratio of 
unpaired to paired of 3 (much higher than any of the others analysed). This cysteine was 
one of those identified in free thiol form by Choi et al208.  
 
Interestingly, the most recent modelling of the structure of the C domains of VWF, based 
on sequence homology with typical C domains for which the crystal structure is known 
(section 1.3.3), predicts that all seven of the C domain free thiols208 are in fact paired152,155. 
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1.5.3 Thiol-disulphide exchange  
Most disulphide bonds play an important structural role. They decrease the entropy of the 
folded form and are therefore important in stabilising tertiary and quaternary structure. A 
small fraction of disulphide bonds play a functional role, either catalytic or allosteric. 
Allosteric bonds affect the function of their protein by mediating a change when they are 
oxidised or reduced, whereas catalytic bonds are located at the active sites of 
oxidoreductases which mediate the thiol-disulphide exchange of another protein213. The 
two types of functional disulphide bond are coupled, as the redox state of the allosteric 
disulphides is regulated by the catalytic disulphides.  Disulphide bonds can be categorised 
according to the angle of the central bonds linking the atoms together. The three basic 
types of disulphide bonds are spirals, hooks and staples, and these may be right-handed 
(RH) or left-handed (LH) and positive (+) or negative (-). With few exceptions, all the 
catalytic disulphides are +/-RHHooks, while the majority of known allosteric disulphides are 
–RHStaples213. 
 
Extracellular thiol-disulphide exchange is increasingly being recognised as a way to 
regulate protein function. For example, within haemostasis proteins both tissue factor and 
the platelet fibrinogen receptor GPIIbIIIa contain a critical –RHStaple disulphide bond 
which has been well-studied. Redox change of these –RHStaple disulphide bonds is 
critical for activation of both proteins (reviewed213). There is evidence that platelet protein 
disulphide isomerase (PDI) and perhaps also glutathione and nitric oxide play a role in this 
thiol-disulphide exchange214.  Other haemostasis proteins also contain –RHStaple 
disulphide bonds, although these have currently been less extensively studied: 
plasminogen, vitronectin, GPIbα, thrombomodulin, fibrinogen, tissue plasminogen 
activator, and not least VWF. In both the published crystal structures of the VWF type C 
domains153,154 the Cys3-Cys5 bond is a –RHStaple. This corresponds to the predicted 
C2451-C2468 bond in the C3 domain of VWF152,155. C2451A was found to be reduced in a 
proportion of pdVWF208, compatible with a functional allosteric role. It has been suggested 
that these cysteines, as well as the others which were found to be free on pdVWF208, may 
serve as a critical regulator of VWF activity, regulating both self-association and platelet 
adhesion. Of note, the C3 and C5 domains of VWF also contain a predicted Cys3-Cys5 
bond (–RHStaple), but none of the cysteines involved were detected as unpaired using 
mass spectroscopy208. 
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As previously described, Choi et al208 showed that in plasma, the ratio of VWF free thiol: 
disulphide form is approximately 3:7. Physiological and pathological levels of shear stress 
(50 and 100 dyne/cm2) applied to VWF in a plate-cone viscometer resulted in a significant 
reduction in free thiols, as detected by both activated Thiol-Sepharose beads and 
MPB208,209. This suggests that shear stress promotes the formation of disulphide bonds, 
utilising these free thiols. In addition it was found using flow cytometry, that shear 
increased VWF binding to platelets through GPIb mediated binding (geo-mean 
fluorescence 30% compared to 5%), consistent with previous observations191. However, 
this increase in platelet binding was significantly reduced when plasma VWF multimers 
were exposed to shear stress in the presence of MPB (geo-mean fluorescence 12%)208. 
This resulted in the hypothesis that VWF contains free thiols which are utilised under shear 
conditions to form disulphide bonds between adjacent VWF multimers, resulting in lateral 
self-association and leading to an overall increase in VWF size. The self-associated VWF 
bound to platelets more readily due to an increase in the number of GPIbα binding sites, 
and possibly also due to a more unravelled conformation. 
 
Li et al215 demonstrated directly that self-association is dependent on the thiol-disulphide 
state of VWF. When ECs are stimulated they release active UL-VWF multimers which form 
long string-like structures to which platelets adhere81. These strings can be further 
elongated by flowing over pdVWF. However, the propagation of these strings by pdVWF 
was dose-dependently reduced by blocking thiols on pdVWF with N-ethylmaleimide 
(NEM), both before and during perfusion. Additionally, the strings formed on ECs after 
incubation with NEM appeared more rigid with fewer adherent platelets. 
 
Most recently, Ganderton et al155 proposed a model by which lateral self-association 
occurs. The authors analysed the expression and oligomer formation of individual and 
double cysteine point mutations in the C3C4 fragment of VWF (2429-2495). The wt 
fragment was detected in the media as oligomers, C2431A and C2431A-C2453A as 
monomers only, C2451A as monomers and dimers, C2453A and C2468A showed 
enhanced oligomerisation compared to wt, and C2451A-C2468A was not detected in the 
media. This pattern resulted in the following model being proposed: a C2431-C2453 bond 
in one molecule of VWF is reduced by a reductase; the resulting C2431 thiolate anion 
attacks the same disulphide in another VWF molecule to form a dimer. Trimers may be 
formed either by the same mechanism or by a reduced C2451 thiolate anion of one of 
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these molecules attacking the C2431-C2453 disulphide bond of a third molecule (Figure 
1.8). 
 
 
 
 
Figure 1.8 Proposed mechanism of lateral self-association of VWF. A C2431-C2453 
bond in one molecule of VWF is reduced by a reductase. The resulting C2431 thiolate 
anion attacks the same disulphide in another VWF molecule to form a dimer. Trimers and 
higher order oligomers may either be formed by the same mechanism or by a reduced 
C2451 thiolate anion of one of these molecules attacking the C2431-C2453 disulphide 
bond of a third molecule. Hypothesis and diagram based on Ganderton et al155.  
 
 
This model does not explore the kinetics of the reaction. Studies looking at VWF capture to 
collagen and platelets have considered the time available and proximity of the molecules 
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under shear (section 1.4.2). Uncatalysed, disulphide bond formation is slow. However, 
thiol-disulphide exchange resulting in self-association in vivo might be catalysed by a thiol 
isomerase intrinsic to VWF, or by PDI on the surface of platelets. It seems unlikely that 
even this would occur rapidly enough to capture circulating VWF molecules. Perhaps this 
type of association only takes place when VWF has been slowed down, perhaps as a 
result of complex linear flow. However, shear stress itself may have a role in promoting 
thiol-disulphide exchange.  Indeed shear stress induced thiol-disulphide exchange has 
been shown to occur in the presence of unpaired cysteine thiols and shear stress alone in 
α-keratin104. .  
 
 
1.6 THIOL ISOMERASES 
1.6.1 Thiol isomerases  
The thioredoxin family, of which ER based protein disulphide isomerase (PDI) is a 
member, is characterised by the ability to catalyse thiol-disulphide interchange reactions. 
The members are characterised by having at least one domain with a thioredoxin-like 
structural fold, βαβαβαββα, and a catalytic CXXC motif. The non-catalytic domains are 
generally responsible for substrate binding and conferring substrate specificity. The family 
comprises proteins with redox potentials that range from strongly reducing (thioredoxin, E°’ 
-0.270V) to strongly oxidising (periplasmic protein thiol:disulphide oxidoreductase, DsbA, 
E°’ -0.120V) allowing these proteins to perform specialised roles. The ability of the active 
site to be an efficient isomerase, oxidant or reductant depends on the reduction potential 
of the active site disulphide bond and the acid dissociation constant of the nucleophilic 
active-site thiol. The reduction potential of the active sites is modulated by variations in the 
-XX- residues216, the conformational flexibility of the active site motif217, and the 
electrostatic charges of nearby amino acids (such as positively charged histidines)218. In 
humans, members of this family have broadly similar reduction potentials and are mainly 
localised and active within the ER although one transmembrane protein, TMX2, probably 
has its catalytic site on the cytoplasmic side of the ER membrane. However, because the 
proteins have unique structural features and differing tissue distribution they have mainly 
distinct physiological functions. They are essential for oxidative folding of different proteins.  
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1.6.2 Intrinsic thiol isomerase activity of VWF 
Unlike the ER the Golgi lacks a high concentration of resident thiol isomerases and is 
relatively acidic, which generally prevents disulphide rearrangement (section 1.2.4). To 
overcome these conditions, VWF appears to use its own propeptide to promote formation 
of the disulphide bonds at the N-terminus of dimers to form multimers.  The isomerase 
activity of the propeptide has not been shown directly in a general assay for PDI activity. 
PDI activity may be assessed by measuring the ability of a protein to catalyse the 
reactivation of sRNase, which contains incorrectly paired disulphide bonds. When the 
sRNase assay was applied to the propeptide it did not appear able to promote the 
disulphide interchange required219. However this assay requires dithiothreitol (DTT) which, 
as the propeptide contains 62 cysteines, may have rendered it non-functional due to 
reduction of disulphides important for its structure. Nonetheless, there is significant indirect 
evidence to suggest the propeptide has thiol isomerase activity which is essential for 
multimerisation.  
 
Recombinant expression of VWF with the propeptide sequence deleted resulted in the 
secretion of VWF dimers only220. Co-transfection of cells with sequences encoding for the 
propeptide and the mature subunit (D’-CK) in trans resulted in the secretion of fully 
multimerised VWF, demonstrating that the propeptide does not need to be a continuous 
part of the VWF structure221. Each D domain in the propeptide contains a CXXC motif 
(159CGLC and 521CGLC). Insertion of a glycine between these vicinal cysteines inhibited 
multimer assembly219. Furthermore, in the ER the VWF propeptide and the D3 domain 
formed an intra-chain disulphide-bonded intermediate that rearranged in the Golgi to 
produce VWF subunits linked by inter-chain disulphide bonds222. This is typical of the 
rearrangements catalysed by thiol isomerases which progress through a disulphide-linked 
intermediate between the catalytic cysteine on the isomerase and the cysteine to be 
altered on the substrate protein. The lower pH of the Golgi is required for this 
multimerisation because it was inhibited by raising the pH of the Golgi with ammonium 
chloride 28,223. In addition, mutation of the positive charged histidine residues H395 and H460 
to alanine prevented multimerisation224. Therefore VWF multimerisation appears to be 
catalysed by a thiol isomerase within the VWF propeptide that is activated at the low pH of 
the Golgi. 
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CXXC motifs are relatively unusual, identified in 3.7% of protein sequences225. Other 
proteins possessing CXXC motifs which are thought to have thiol isomerase activity 
include the chaperone proteins Erp61 and Erp72226, the gonadotrophin follitropin225 and 
the integrin receptor GPIIbIIIa227. During preliminary work carried out for this PhD, it was 
found that VWF actually contains 16 CXXC sites. Three of these sites are similar to the 
CGLC motifs in D1 and D2 (994CGLC in D3, 2085CGIC in D4 and 2304CGLC in C1) and are 
conserved across domains and species (section 4.2). Yet the potential thiol isomerase 
activity and function of these CG(L/I)C motifs in D3, D4 and C1 have not been reported. 
These motifs might either be important for the intracellular synthesis of VWF or play a role 
extracellularly, for example in catalysing the thiol-disulphide exchange of lateral self-
association. 
 
 
 
1.7 AIMS OF PROJECT 
This thesis aims to: 
 Develop a physiologically relevant perfusion assay to examine the self-association 
of VWF when perfused over a collagen surface. 
 Determine whether the unpaired cysteines detected in mature VWF have become 
unpaired following VWF secretion or whether they are simply not paired during 
VWF synthesis. 
 Explore the role of free thiols in the self-association of VWF, both statically and 
under physiologically relevant flow conditions. 
 Determine whether the conserved CG(L/I)C motifs in D3, D4 and C1 (994CGLC, 
2085CGIC and 2304CGLC respectively) possess thiol isomerase activity. 
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CHAPTER 2: MATERIALS AND METHODS  
 
2.1 GENERAL MOLECULAR BIOLOGY TECHNIQUES  
2.1.1 Cloning and expression vectors 
2.1.1.1 pcDNA3.1 FLVWF and derivatives 
pcDNA3.1/Myc-His(A+) vector (Invitrogen, UK) is 5.5kb in length. It includes the following 
elements: a multiple cloning site; a pUC origin allowing high-copy number replication and 
growth in E.coli and an ampicillin resistance gene to allow selection of the vector in E.coli; 
a human cytomegalovirus (CMV) immediate-early promoter/enhancer to permit high-level 
gene expression in mammalian cells and a SV40 origin allowing episomal replication in 
cells expressing SV40 large T antigen. Full-length (FL) VWF had been previously cloned 
in-frame into the EcoRI-AgeI site in our laboratory with a stop codon before the 6xHis tag 
so that it was not expressed. Similarly, smaller fragments of VWF had previously been 
cloned into this vector in our lab: A2-CK (residues 1498-2813), A3-CK (residues 1691-
2813), D4-CK (residues 1949-2813), and C1-CK (residues 2154-2813) 
 
2.1.1.2 pBS VWFEcoRI-BamHI 
The pBlueScript® II SK Phagemid vector (Stratagene, USA) is a high-copy number 3kb 
cloning vector. It contains a multiple cloning site, a pUC origin allowing high-copy number 
replication in E.coli and an ampicillin resistance gene to allow for selection of the vector.  
The 3kB EcoRI-BamHI VWF fragment had been previously cloned into this vector in our 
laboratory. It contains the VWF sequence from upstream of the start codon to residue 905 
(within the D3 domain). 
 
2.1.1.3 pGEM VWFXhoI-KpnI 
pGEM-7zf(+) (Promega, USA) is a 3kb cloning vector that shares the same features as 
those described for the pBS vector. The 4.1kb XhoI-KpnI fragment of VWF (amino acids 
786-1584) had previously been cloned into this vector in our laboratory.  
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2.1.2 Site-directed mutagenesis 
Mutations were introduced into VWF cDNA using the KOD Hot Start DNA polymerase kit 
(Novagen, Germany) in accordance with manufacturer’s instructions. Briefly, polymerase 
chain reactions (PCR) were performed using 0.5U high fidelity KOD Hot Start DNA 
polymerase, 187.5ng of complementary primers containing the desired mutation, 15ng of 
DNA template, 1x reaction buffer, 0.2mM dNTPs and 1.5mM magnesium sulphate, made 
up to a final volume of 25µl. The PCR amplification consisted of a step for polymerase 
activation (95°C, 2min); 18 cycles of denaturation (95°C, 20 sec), annealing (60°C, 10s) 
and extension (70°C, 25s per kb); and a final extension at 70°C for 4.5 minutes. 
Subsequently, PCR products were digested with 10U of DpnI for 1 hour at 37°C in order to 
remove the methylated parental DNA template that did not contain the desired mutation. 
The mutation reactions were used to transform XL10-Gold ultra-competent E.coli cells or 
NEB Turbo cells (New England Biolabs, UK) (section 2.1.6). 
 
2.1.3 Subcloning 
2.1.3.1 Restriction endonuclease digestion of plasmid DNA  
Restriction endonucleases recognise specific sequences in double stranded DNA and 
induce strand breaks, creating blunt or overlapping ends. New England Biolabs (UK) 
restriction enzymes and buffers were used to perform all restriction digests. Digests were 
performed using ~5ng DNA and 20U of the appropriate enzymes, diluted in the 
appropriate NEB buffer, for 1 hour at 37°C. The digestion products were separated by 
agarose gel electrophoresis (section 2.1.3.2) and purified using the gel extraction kit 
(Qiagen, UK) (section 2.1.3.3). 
 
2.1.3.2 Agarose gel electrophoresis of DNA 
Agarose gel electrophoresis was used to separate DNA fragments according to size and to 
then visualise them. Agarose gels, 0.8%(w/v), were prepared by adding agarose (Bioline, 
UK) to TBE buffer (TBE: 40mM Tris, 40nM boric acid, 1mM EDTA, pH 8.0). After heating 
in a microwave, 5μg/ml SYBR™ safe DNA gel stain (Invitrogen, UK) was added. The gels 
were then poured and allowed to set for 20 minutes at 4°C.  
 
57 
 
Samples were mixed with 6x gel loading buffer (40%(w/v) sucrose, 0.1%(w/v) 
bromophenol blue in deionised H20) and loaded into the wells. A 1kb DNA ladder (New 
England Biolabs, UK) was run alongside all samples. Electrophoresis was carried out at 
75V for 20-60 mins. The gel was examined on a Bio-Rad FluorS machine equipped with a 
UV filter to enable visualisation of the DNA fragments. 
 
2.1.3.3 Gel extraction 
Bands containing DNA fragments of desired size were purified from agarose gels using the 
Qiagen quick gel extraction kit (Qiagen, UK) as per manufacturer’s instructions. Briefly, 
bands were excised from the gel, weighed, and solubilised with 3x volume buffer QG for 
10mins at 50°C. Then 1x volume isopropanol was added and the sample was applied to 
the silica-gel column and centrifuged for 1 minute at 13000rpm to bind DNA. 0.5ml buffer 
QG was applied to the column which was again centrifuged for 1 minute to remove traces 
of agarose. To wash the DNA, 0.75ml buffer PE was added to the column and centrifuged 
for 1 minute. To remove all traces of wash buffer, a further 1 minute spin was performed. 
To elute the DNA, 30μl buffer EB was added to the column followed by centrifugation for 
1min at 13000rpm.   
 
2.1.3.4 Ligation of insert DNA and plasmid vector 
DNA ligase catalyses the formation of a phosphodiester bond between the 5' phosphate of 
one strand of DNA and the 3' hydroxyl of another.  After gel extraction, in order to roughly 
quantify the DNA present, the insert and vector fragments to be ligated were visualised on 
an agarose gel (section 2.1.3.2). Vector and insert were mixed together in an approximate 
ratio of 1:3, with 2μl 5x ligase buffer (50mM Tris-HCl, 10mM dithiothreitol, 1mM adenosine 
triphosphate and 25μg/ml BSA, pH7.5), and 1μl T4 DNA ligase (Invitrogen, UK) made up 
to 10μl with ddH2O. After incubation overnight at 4°C, the ligation mixture was used for 
transformation (section 2.3.3). 
 
2.1.4 PCR for domain deletion 
PCR was used to make domain deletion mutants. The KOD Hot Start DNA polymerase kit 
(Novagen, Germany) was used in accordance with manufacturer’s instructions. Briefly, 
polymerase chain reactions (PCR) were performed using 1U high fidelity KOD Hot Start 
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DNA polymerase, 375ng each of designed forward and reverse primers (primer design 
described in section 2.2.2), 30ng of DNA template, 1x reaction buffer, 0.4mM dNTPs and 
3mM magnesium sulphate, made up to a final volume of 50µl in ddH20. The PCR 
amplification consisted of a step for polymerase activation (95°C, 2min); 27 cycles of 
denaturation (95°C, 20 sec), annealing (lowest primer Tm 53-55°C, 10s) and extension 
(70°C, 25s per kb); and a final extension at 70°C for 4.5 minutes. Subsequently, PCR 
products were digested with 20U of DpnI for 1 hour at 37°C in order to remove the 
methylated parental DNA template that did not contain the desired mutation. The PCR 
product was run on an agarose gel and bands of the desired size were excised and 
purified using the Qiagen quick gel extraction kit (Qiagen, UK). 
 
2.1.5 Ligation of blunt end DNA 
As explained above, DNA ligase catalyses the formation of a phosphodiester bond 
between the 5' phosphate of one strand of DNA and the 3' hydroxyl of another. Following 
PCR resulting in domain deletion, there is no phosphate at the end of the DNA, so prior to 
ligation polynucleotide kinase (PNK) is used to catalyse the transfer of a phosphate from 
ATP to the free hydroxyl end of the 5' DNA. 2µl of the purified PCR product was mixed 
with 2μl 5x T4 ligase buffer, 0.5μl T4 DNA ligase (Invitrogen, UK) and 0.5µl T4 PNK 
(Ambion, UK) and made up to 10μl with ddH20. After incubation overnight at 4°C, the 
ligation mixture was used for transfection (section 2.3.3). 
 
2.1.6 Transformation of competent bacterial cells 
0.5-2μl of plasmid or ligation reaction were incubated with 20μl of XL10-Gold ultra-
competent E.coli cells (Stratagene, USA) or NEB Turbo cells (New England Biolabs, UK) 
on ice for 30 minutes. Then cells were heat shocked at 42°C for 30 seconds and returned 
to ice for 1 minute. Cells were supplemented with 200μl of pre-warmed SOC media 
(Invitrogen, UK) and incubated at 37°C for 1 hour on a shaker at 250rpm. The suspension 
of cells was then plated onto pre-warmed agar plates containing 100µg/ml ampicillin and 
incubated at 37°C overnight.  
 
59 
 
2.1.7 Isolation of plasmid DNA  
Plasmid DNA was isolated on a small scale (up to 20μg DNA) using Miniprep kits (Qiagen, 
UK) and on a larger scale (up to 500μg DNA) using Maxiprep kits (Qiagen, UK) according 
to manufacturer’s instructions. The principles of isolation are bacterial cell lysis, then 
precipitation of chromosomal DNA, denatured proteins and cellular debris, followed by 
elution of plasmid DNA. 
 
 
2.2 GENERATION OF VWF MUTANTS 
Detail of the primers designed for each mutation can be found in Appendix I. All the 
mutations were generated using the KOD Hot Start DNA polymerase kit (Novagen, 
Germany) (sections 2.1.2 and 2.1.4). The mutations generated were verified by both 
restriction digest and sequencing to confirm the presence of mutations introduced and to 
confirm that there were no PCR-introduced errors. The sequencing was carried out using 
an ABI 3700 DNA analyser (Perkin-Elmer) by Imperial College-MRC Genetics Core 
Facility. 
 
As manipulating smaller pieces of DNA is easier and more efficient, the mutants were 
initially made in a vector containing only a fragment of VWF cDNA, and then subcloned 
into a vector containing FL-VWF cDNA (section 2.1.3). The subcloning technique was 
similar in all cases, but the enzymes used varied dependent on the initial vector used for 
mutagenesis. Briefly, pGEM VWFXhoI-KpnI vectors containing the mutants were digested 
with BamHI and KpnI and the digested BamHI–KpnI DNA fragment was inserted into the 
pcDNA 3.1 FL-VWF vector which had been digested with the same enzymes. The pBS 
VWFEcoRI-BamHI vectors containing the mutants were digested with EcoRI and BamHI and 
the released EcoRI-BamHI DNA fragment was inserted into the pcDNA 3.1 FL-VWF vector 
which had been digested with the same enzymes. The pcDNA3.1 A2-CK vectors 
containing mutants were digested with EcoRI and AgeI and the digested EcoRI-AgeI 
fragment was inserted into pcDNA 3.1 FL-VWF that had been digested with the same 
enzymes (an example of this subcloning technique is illustrated in Figure 2.4). 
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2.2.1 Generation of cysteine to alanine point mutations  
Primers were designed to mutate an individual cysteine residue to an alanine residue. 
pGEM VWFXhoI-KpnI was used for the initial cloning of the mutants in D3 (C889A and 
C898A) and pcDNA3.1 A2-CK vector was used for the initial cloning of the mutants in the 
C domains (C2431A, C2448A, C2451A, C2453A, C2468A, C2490A, C2491A, C2528A and 
C2533A). The double point mutant C2431A-C2453A was made in sequential steps. 
Following sequencing, the fragments of VWF cDNA containing the mutations were 
subcloned into the pcDNA3.1 FL-VWF vector. 
 
In addition, some of these point mutants were made in smaller fragments of VWF. They 
were cloned directly into pcDNA3.1 A3-CK, pcDNA3.1 D4-CK and pcDNA3.1 C1-CK. 
Primers were also designed to insert a stop codon just prior to the CK knot (at residue 
2724) allowing expression of each fragment as a monomer rather than a dimer. 
 
2.2.2 Generation of C domain deletion mutants 
PCR was used to remove specific residues from the pcDNA3.1 A2-CK expression vector. 
Briefly, for ∆D4-C6 (Δ1875-2720) (reverse and forward primers starting either side of the 
region to be deleted that is, 1876 and 2721 respectively) were designed. PCR was 
performed using the KOD Hot Start DNA polymerase kit as described for domain deletion 
(section 2.1.4).  The PCR product was purified, phosphorylated with PNK and ligated 
(section 2.1.5) (Figure 2.1). The same technique was used to make the other C domain 
deletion mutants in pcDNA3.1 A2-CK: ∆C3-C6- (∆2400-2662), ∆C3C4- (∆2400-2515), ∆C1-
C6 (∆2255-2720), ∆C1C2 (∆2255-2428), and ∆C3 (∆2431-2494). The EcoRI-AgeI VWF 
fragment containing the domain deletion was then subcloned into the pcDNA3.1 FL-VWF 
vector. Of note, ΔD4-C6, ΔC1-C6 and ΔC1C2 pcDNA3.1 FL-VWF vectors were made in 
our lab by Imperial College BSc student Thomas McWilliams, supervised by Tom 
McKinnon. 
 
In addition, as for the cysteine point mutants, some of these deletion mutants were made 
in smaller fragments of VWF. They were cloned directly into pcDNA3.1 A3-CK, pcDNA3.1 
D4-CK and pcDNA3.1 C1-CK. Primers were also designed to insert a stop codon just prior 
to the CK knot (at residue 2724) allowing expression of each fragment as a monomer 
rather than a dimer. 
61 
 
 
 
Figure 2.1 Generation of ∆D4-C6 in pcDNA3.1 A2-CK.  (A) Forward and reverse primers 
were designed, starting from amino acids 2721 and 1876 respectively. PCR was 
performed using the KOD Hot Start DNA polymerase kit allowing deletion of the planned 
section of DNA and then amplification of the remainder (B). (C) After purification, the PCR 
product was phosphorylated with PNK and ligated. The other C domain deletion mutants 
were created using the same technique. 
 
2.2.3 Generation of RGGS mutant 
The C3 domain contains the RGDS sequence which is important for binding activated 
platelets and fibrinogen. In order to control for the loss of this motif in some of the C 
domain deletion mutants, an RGDS mutant was made (RGGS). Primers were designed to 
mutate aspartate 2509 (GAC) to glycine (GGC). The pcDNA3.1 A2-CK vector was used for 
the initial cloning. The fragment of VWF containing this mutation was subcloned into the 
pcDNA3.1 FL-VWF vector.  
62 
 
2.2.4 Generation of glycine insertion mutants GlyD2, GlyD3, GlyD4 and GlyC1 
Mutagenesis primers were designed to insert a glycine into the CXXC motifs, creating a 
CXGXC sequence. The vectors used were: pBS VWFEcoRI-BamHI for GlyD2 and GlyD3, and 
pcDNA3.1 A2-CK for GlyD4 and GlyC1. The fragments of VWF containing the mutations 
were then subcloned into the pcDNA3.1 FL-VWF vector. Of note, GlyD3, GlyD4 and GlyC1 
were made in the pcDNA3.1 FL-VWF vector in our lab by Imperial College BSc student 
Waqaar Hameed, supervised by Tom McKinnon.    
 
In order to express GlyD3 in a smaller fragment of VWF (D’D3, residues 764-1270) the 
expression vector pcDNA3.1 D’D3 was made. First, primers were designed to remove 
VWF residues 1271-2813 from the template vector pcDNA3.1 D’-CK (764-2813) by PCR 
as previously described (reverse primer from 1270, forward primer from start of vector 
after 2813, example illustrated in Figure 2.1). Then primers were designed to mutate the 
TGA stop codon, prior to the 6xHis-tag, into tyrosine (TAC) resulting in pcDNA3.1 D’D3-
His (764-1271). The 6xHis tag was added in order to allow detection and purification of the 
D’D3 fragment. Finally the mutagenesis primers were used as before to insert a glycine, 
creating GlyD3 in D’D3. 
 
2.2.5 Generation of D2 domain replacement mutants: D3→D2 and D4→D2 
Mutants were designed in which the D2 domain of VWF was replaced by a D3 or D4 
domain (D3→D2 and D4→D2 respectively). They were made using a technique described 
for the integration of PCR fragments into a vector without the use of restriction enzymes 
and DNA ligase228. Initially, PCR was used to remove the D2 domain (residues 387-598) 
from the pBS VWFEcoRI-BamHI vector, creating the vector ∆D2-pBS VWFEcoRI-BamHI. Briefly, 
reverse and forward primers starting either side of the D2 domain (that is, end of D1 and 
start of D’ respectively) were designed, and PCR was performed as described for domain 
deletion, using the KOD Hot Start DNA polymerase kit (section 2.1.4). New primers were 
then designed which flanked both the D3 (or D4) domain to be inserted and the 
surrounding region of the vector (that is, forward primer last 20 base pairs of D1 and first 
20 of D3 or D4, reverse primer last 20 base pairs of D3 or D4 and first 20 of D’) (Figure 
2.2, A and B). To amplify the D3 domain by standard PCR techniques, these primers were 
used with the vector pGEM VWFXhoI-KpnI as template (which had previously had the BamHI 
restriction site at position 907 removed by site-directed mutagenesis). To amplify the D4 
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domains, these primers were used with the vector pcDNA3.1 D’-CK as template DNA 
(Figure 2.2, C). The amplified domain (with flanking regions) was purified using the Qiagen 
gel extraction/purification kit, according to manufacturer’s instructions (Figure 2.2, D) 
(section 2.1.3.3).  
 
 
 
Figure 2.2 Generation of domain with flanking regions to be inserted. (A and B) Using 
a technique described for integration of PCR fragments within a vector by PCR228, primers 
were designed which flanked both the D3 (or D4) domain to be inserted and the 
surrounding region of the vector (that is, forward primer last 20 base pairs of D1 and first 
20 of D3 or D4, reverse primer last 20 base pairs of D3 or D4 and first 20 of D’). (C) These 
primers were used to amplify the D3 or D4 domains by standard PCR using the vectors 
pGEM VWFXhoI-KpnI or pcDNA3.1 D’-CK respectively as DNA templates. (D) The amplified 
domain (with flanking regions) was purified using the Qiagen gel extraction/purification kit, 
according to manufacturer’s instructions (section 2.1.3.3).  
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This purified amplified fragment was quantified on a gel against a known standard (1kb 
DNA ladder, New England Biolabs, UK). PCR (as described in section 2.1.2) was then 
performed using the amplified fragment as the primer and ∆D2-pBS VWFEcoRI-BamHI as the 
template DNA. This resulted in the insertion of the D3 or D4 insert between the D1 and D’ 
domains (Figure 2.3). This vector was used to transform competent bacterial cells. 
Following sequencing, the VWF fragment was subcloned into pcDNA3.1 FL-VWF (Figure 
2.4). Figure 2.5 illustrates the final domain schematic of the two mutant constructs. 
 
 
 
 
Figure 2.3 Mutagenesis to insert D3 or D4 into ∆D2-pBS VWF. (A-C) PCR was 
performed using the amplified fragment as the primer and ∆D2-pBS VWFEcoRI-BamHI as the 
template DNA. This resulted in the insertion of the D3 or D4 insert between the D1 and D’ 
domains.  
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Figure 2.4 Subcloning EcoRI-BamHI fragment from ∆D2-pBSVWF into 
pcDNA3.1FL-VWF.     
 
 
 
 
 
 
 
 
Figure 2.5 Schematic of the domain structure of the D2 domain replacement 
mutants. (A) wild-type (wt) FL-VWF (B) D3→D2 VWF (C) D4→D2 VWF.  
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2.3 CELL CULTURE 
2.3.1 General tissue culture 
All general tissue culture was performed according to standard laboratory procedures. It 
was performed in a separate laboratory specifically designated for tissue culture in class II 
flow cabinets (FASTER BHG 2004, JENCONS-PLS). Cells were grown in humidified 
incubators (BIOHIT, Biological Instrumentation Service, UK) in 5% CO2 at 37ºC.  An 
inverted microscope CK2 (Olympus, Japan) was used to view cultured cells. 
 
2.3.2 Cell passage 
HEK293 and HEK293T cells (ThermoScientific, USA) were grown in T175 tissue culture 
flasks (Nunc®, Sigma, USA) with 25mls of growth media. Growth media comprised 
Minimal Essential Medium (Sigma, USA) supplemented with 10% (v/v) fetal bovine serum 
(Biosera, France), 5mM penicillin/streptomycin (Invitrogen, UK), 5mM L-glutamine 
(Invitrogen, UK) and 1x non-essential amino acids (Sigma, USA) before use. When cells 
reached reached 80-100% confluency they were split into more flasks. Autoclaved 
phosphate buffered saline (PBS) was used to wash the cells gently 2x, then 1ml 0.25% 
trypsin-EDTA (Sigma, USA) was used to detach the cells from the flask’s surface. Once 
the cells were detached, growth media was added to inactivate the trypsin, and then the 
cells were seeded appropriately.  
 
2.3.3 Transient transfection  
Transient transfection is used to produce recombinant protein in a short time period. The 
transfected DNA is not integrated into the cell genome and therefore it is lost from cells 
after repeated rounds of DNA replication and cell division. HEK293T cells express high 
levels of SV40 large tumour (T) antigen, which allows episomal replication of SV-40 origin-
containing plasmids (such as pcDNA 3.1). HEK293T cells at ~80-100% confluency were 
transfected with wt-VWF and VWF mutants. 2µg/ml of DNA and polyethylenimine (PEI), in 
the ratio of 2.25:1 (PEI: DNA), were diluted individually in autoclaved 150mM NaCl. The 
PEI solution was added drop-wise to the DNA solution and incubated for 20 minutes at 
room temperature. Growth media was removed from the cells and Optimem conditioned 
medium (Invitrogen, UK) was added. The DNA:PEI solution was then applied to the cells 
and they were incubated for 2 days at 37ºC, 5%C02. The conditioned media was collected.  
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If required, it was purified by ion-exchange chromatography and Heparin-Sepharose 
chromatography (section 2.4.3). 
 
For one set of experiments, the transient transfections were carried out in alkalinised cells 
(section 4.6.2). HEK293T cells were transiently transfected as described above. After 24 
hours, 15µM monensin (Sigma, USA) or 5µM ammonium chloride were added to the cell 
culture media. Monensin is an ionophore which causes intracellular alkalinisation, although 
it also disrupts carbohydrate processing in the Golgi. The media and cell lysates were 
harvested 48 hours later. 
 
HEK293 cells were used for studying intracellular storage of VWF. The mechanism of 
transient transfection was the same as that described above for HEK293T cells. 
 
2.3.4 Cell lysis 
In order to examine the expression and secretion of recombinant proteins, following 
harvesting of media from 6 well plates, cells were lysed by addition of 1ml of cold (4ºC) 
CHAPS buffer (30mM Tris-HCl, 150mM NaCl, 0.5%(w/v) CHAPS, pH7.5) to each well. 
After 3 minutes incubation, the lysate was collected and centrifuged for 4 minutes at 
13000rpm to remove cellular debris. In an attempt to release the high molecular weight 
multimers from the cell for analysis the lysis technique was modified. Protease inhibitor 
cocktail (Sigma, USA) was added to the CHAPS buffer 1/100. After 3 minutes incubation, 
the lysate was collected and left on ice for 40 minutes, room temperature for a further 5 
minutes and then centrifuged as before. 
 
2.4 GENERAL PROTEIN TECHNIQUES  
2.4.1 SDS polyacrylamide gel electrophoresis  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) separates 
proteins on the basis of molecular weight. SDS is an anionic detergent which denatures 
proteins to their primary structure and confers a negative charge on them. 4x SDS loading 
buffer (200mM Tris-HCl, 50%(v/v) glycerol, 8%(w/v) SDS, 0.4%(w/v) bromophenol blue, 
pH6.8) was added to samples to be analysed under non-reducing conditions.  For samples 
to be analysed under reducing conditions, 7% v/v β-mercaptoethanol was added to the 4x 
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SDS loading buffer before use. All samples were run in parallel with a pre-stained 
molecular weight marker (Novex, Invitrogen, UK). Samples were heated for 15 minutes at 
90ºC and then loaded onto a 4-12% Bis-Tris NuPage precast polyacrylamide gel 
(Invitrogen, UK). Electrophoresis was carried at 200V for approximately 40 minutes. 
 
2.4.1.1 Coomassie staining of SDS-PAGE gels 
Coomassie staining was used to detect proteins in gels non-specifically (with a detection 
limit of 7ng protein). Following SDS-PAGE, the gels were washed three times with ddH20 
for 5 minutes, and then incubated with 10mls SimplyBlue™ SafeStain (Invitrogen, UK) on 
a shaker at room temperature for 1 hour. Gels were de-stained by washing with ddH2O on 
a shaker at room temperature for an hour.  
 
2.4.1.2 Western blot 
Western blot was used to detect specific proteins in gels. After SDS-PAGE, proteins were 
transferred to nitrocellulose membranes (Amersham Pharmacia, UK) using transfer buffer 
(25 mM Tris-HCl, 192 mM glycine, 20%(v/v) methanol, pH8.3) and a Trans-Blot 
Electrophoretic Transfer Cell (Bio-Rad, USA). Transfer was carried out for 60 minutes at 
400A. After transfer, membranes were incubated in blocking buffer containing 2.5%(w/v) 
non-fat milk powder in PBS-T (Phosphate Buffered Saline, 0.1% v/v Tween 20) for either 1 
hour at room temperature on a shaker or at 4ºC overnight. Membranes were then 
incubated with the relevant horse radish peroxidase (HRP) conjugated antibody diluted in 
PBS-T for 1 hour on a shaker at room temperature. Antibodies used and their PBS-T 
dilution are listed in Table 2.1. Membranes were then washed extensively in PBS-T, 3x for 
5 minutes each on a shaker. Protein was detected with an Immobilion ECL 
chemiluminescence kit (Merck Millipore, USA). Briefly, equal amounts of solutions A and B 
were mixed together and applied to the membrane for 5 minutes. The membrane was then 
exposed to Hyper-Film (Amersham Pharmacia, UK) and developed. 
 
Antibody Concentration 
Anti-hVWF-HRP (Dako, Denmark) 
Anti-His(C-Term)-HRP (Invitrogen, UK) 
1 in 5000 
1 in 5000 
 
Table 2.1 Antibodies used for Western blotting. 
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2.4.2 Purification of VWF from HaemateP® 
2.4.2.1 Gel filtration 
Gel filtration separates proteins on the basis of size. It was used to isolate high molecular 
weight plasma-derived (pd) VWF from the commercial pdVWF-FVIII concentrate Haemate 
P® (CSL Behring, Australia). 500-1000IU of Haemate P® powder were resuspended in 
10ml of ddH2O and centrifuged at 4000g for 5 minutes. The solution was loaded on to a 
Sephacryl S-400 HR gel filtration column (Amersham Pharmacia, UK) (60mm × 26mm, 
360ml volume) which had been pre-equilibrated with two column volumes of Buffer A 
(20mM Tris-HCl, 100mM NaCl, pH7.4) at a flow rate of 0.5ml/min. A flow rate of 1ml/min 
was used for elution and 5ml fractions were collected. VWF concentration was determined 
using the VWF ELISA (section 2.4.4.2) and multimer composition (section 2.4.4.1) and 
static collagen binding activity was analysed (section 2.4.4.3). 
 
 
2.4.3 Purification of recombinant VWF 
2.4.3.1 Ion-exchange chromatography 
Ion-exchange chromatography separates proteins on the basis of charge. A SK-16 
chromatography column (Amersham Pharmacia, UK) was packed with 30ml Fractogel-
EMD-TMAE+ (Merck Millipore, Billerica, USA) according to manufacturer’s instructions. 
The column was equilibrated with five column volumes of buffer A (20mM Tris-HCl, 
100mM NaCl, pH7.4). The expression media containing recombinant VWF was first 
passed through a 0.4µm filter and then loaded at a flow rate of 1ml/min. The column was 
then washed until the UV absorbance at 280nm of the wash-through had returned to 
baseline. The recombinant VWF was then eluted using buffer B (20mM Tris, 500mM NaCl, 
pH7.4). Samples requiring further purification by Heparin-Sepharose affinity 
chromatography were dialysed into buffer A using SnakeSkin® Pleated Dialysis Tubing 
3500MWCO (ThermoScientific, USA), and samples requiring no further purification were 
dialysed into 20mM Tris, pH7.4. 
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2.4.3.2 Heparin-Sepharose affinity chromatography 
Heparin-Sepharose affinity chromatography, which separates proteins on the basis of their 
affinity for heparin, was used to further purify ion-exchanged recombinant VWF. A 
Heparin-Sepharose 6 fast flow column (GEHealthcare, UK) was equilibrated with two 
column volumes of buffer A (20mM Tris-HCl, 100mM NaCl, pH7.4).  The gel filtered 
fractions were loaded at a flow rate of 0.5ml/min, and then the column was washed until 
the UV absorbance at 280nm had returned to baseline. VWF was eluted using 500mM 
NaCl in 20mM Tris, pH 7.4, and then dialysed into 20mM Tris, pH 7.4. 
 
2.4.4 VWF analysis 
2.4.4.1 VWF multimer analysis  
High resolution agarose gels may be used to analyse the multimer pattern of VWF. 
1.4%(w/v) high gelling temperature agarose (Seakem®, Lonza, USA) was dissolved in 
100ml of gel buffer (200mM Tris, 100mM glycine, 0.1% SDS, pH 9.0) and cast using a Bio-
Rad mini-gel casting system (1.5mm diameter glass plates). Gels were stored at 4°C for a 
minimum of 24 hours and a maximum of 7 days. Samples were mixed with sample buffer 
(10mM Tris, 8M urea, 1mM EDTA, 2%(w/v) SDS, 0.01%(w/v) bromophenol blue, pH 8.0) 
and incubated for 30 minutes at 60°C. The gels were positioned in a Bio-Rad mini-gel 
electrophoresis tank with cold (4ºC) running buffer (100mM Tris, 150mM glycine, 
0.1%(w/v) SDS, pH 8.4) and the tank was surrounded by ice. 10µl of sample was applied 
to each well and electrophoresis was performed at 60V for 20 minutes and then at 35V 
until the tracking dye reached the end of the gel. Western blot with polyclonal anti-hVWF-
HRP was then performed (section 2.4.1.2).  
 
2.4.4.2 VWF ELISA 
VWF antigen (VWF:Ag) concentration was measured by enzyme-linked immunosorbent 
assay (ELISA). 96 well microtitre MaxiSorp plates (Nunc®, Sigma, USA) were coated with 
polyclonal anti-hVWF antibodies (Dako, Denmark) diluted 1/500 in 50mM sodium 
bicarbonate buffer (pH9.6), 100l per well. The plates were incubated either overnight at 
4°C or for 60-90 minutes at room temperature. Wells were then washed 3x with PBS-T 
and blocked with 2.5% BSA (Sigma, USA) in PBS-T for 1 hour at room temperature (100l 
per well). Serial dilutions of the VWF test samples were applied in duplicate, alongside 
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serial dilutions (1/10 to 1/640) of a standard reference plasma (VWF 10µg/ml) 
(Technoclone, Austria). After incubation at room temperature for 1 hour, the wells were 
washed 3x with PBS-T. 100l of anti-hVWF-HRP (Dako, Denmark), diluted 1/1000 in PBS-
T, was then added to each of the wells and allowed to incubate for 45 minutes at room 
temperature. The wells were again washed 3x with PBST. 180µl substrate (Sigma colour 
fast OPD tablets) was added to each of the wells and the reaction was stopped with 50µl 
2M sulphuric acid. Absorbance was recorded at 492nm (UV-1601 spectrophotometer, 
Shimadzu).  The concentration of VWF in each sample was determined using a standard 
curve generated using the reference plasma. 
 
2.4.4.3 Collagen binding assay  
The collagen binding assay is a sensitive measure of high molecular weight VWF because 
the highest molecular weight multimers bind collagen with the greatest affinity. Human 
type III collagen (Sigma, USA) was diluted to a final concentration of 100µg/ml in 50mM 
carbonate buffer (pH 9.6). 100l were applied to each well of MaxiSorp plates (Nunc®, 
Sigma, USA). The plates were incubated overnight at room temperature. After incubation 
the plates were washed 3x with PBS-T and then blocked with 2-2.5% BSA in PBS-T for 2 
hours at room temperature. After blocking, the wells were washed 3x as before. Serial 
dilutions of the test sample were applied to the wells in duplicate, alongside serial dilutions 
of standard reference plasma (VWF 10µg/ml) (Technoclone, Austria). After incubation for 
90 minutes at room temperature, wells were washed 3x with PBS-T, and anti-hVWF-HRP 
antibody (Dako) applied to the wells (1/1000 in PBST) for 45 minutes. After a final wash 
step, substrate solution (Sigma colour fast OPD) was added and the reaction was stopped 
with 50µl 2M sulphuric acid. Absorbance was recorded at 492nm (UV-1601 
spectrophotometer, Shimadzu). The ratio of collagen binding to VWF antigen 
(VWF:CB/VWF:Ag) was calculated by performing a VWF ELISA in parallel (section 
2.4.4.2).  
 
2.4.4.4 Free thiol assay 
The free thiol content of VWF was assessed using a plate based ELISA. Maleimide-PEO2-
Biotin (MPB) reacts with the thiol group on a cysteine residue to form a stable carbon-
sulphur bond. 310µl of wt or mutant VWF (diluted to 0.46µg/ml in PBS) were incubated 
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with a final concentration of 100µM EZ-link® Maleimide-PEO2-Biotin (ThermoScientific, 
USA) for 10 minutes at room temperature. The reaction was quenched with 200µM 
reduced glutathione (GSH, 1µl of 100mM stock solution in ddH20). The samples were then 
diluted with PBS to a final concentration of 0.25µg/ml VWF. 100µl of the sample was 
applied in triplicate to MaxiSorp plates (Nunc®, Sigma, USA) that had previously been 
prepared as for a VWF ELISA. Briefly, the plates had been coated with polyclonal anti-
hVWF antibody (Dako, Denmark), blocked with 2.5% BSA in PBS-T and washed.  After 
incubation with the MPB labelled VWF samples at room temperature for 1 hour, the plates 
were washed 3 times with PBS-T. MPB was detected by incubation for 45 minutes with 
streptavidin peroxidase polymer ultrasensitive (Sigma, USA) diluted 1 in 500, and parallel 
samples were detected with polyclonal anti-hVWF-HRP (Dako, Denmark) diluted 1 in 
1000, to ensure equal concentrations of VWF were analysed. Bound antibody was 
measured with Sigma colour fast OPD as previously described (section 2.4.4.2). The free 
thiol content was expressed as a ratio of bound MPB to bound VWF (ratio of average 
absorbance).  
 
2.4.4.5 EndoglycosidaseH digestion of cell lysates 
Endoglycosidase H (EndoH) cleaves asparagine-linked mannose-rich oligosaccharides 
from glycoproteins. The post-translational glycosylation of proteins starts in the ER and 
continues after translocation to the Golgi. EndoH is able to cleave all these 
oligosaccharides until the enzyme Golgi-alpha-mannosidase II removes 2 mannose 
subunits; all later oligosaccharide structures are resistant to EndoH. EndoH was therefore 
used to differentiate whether VWF in the cells lysates was retained within the ER (and was 
cleavable by EndoH) or whether it was within the Golgi (and resistant to EndoH).  
 
1µl EndoH (New England Biolabs, UK) was added to 26µl of lysate sample and 3µl of G5 
NEB buffer. For each lysate, a control was run in parallel using 1µl ddH20 instead of 
EndoH. These were incubated at 37ºC overnight and then run on a reducing SDS-PAGE 
gel followed by Western blot (section 2.4.1). 
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2.5 QUANTIFICATION OF ∆D4-C6 VWF 
The standard ELISA for quantifying VWF uses rabbit polyclonal anti-hVWF (Dako, 
Denmark). This has been shown to bind to multiple epitopes throughout VWF229. Therefore 
it may not bind to ∆D4-C6 VWF as well as it does to FL-VWF, which would result in 
underestimating the concentration of ΔD4-C6 by this technique. Alternatively the 
conformational change resulting from deletion of D4-C6 might increase antibody binding. It 
was therefore important to confirm the accuracy of the standard ELISA quantification for 
this fragment. 
 
Following quantification of wt VWF and ∆D4-C6 VWF using a standard VWF ELISA, 15µl 
of an equal concentration of each recombinant VWF was loaded onto a polyacrylamide gel 
(4-12% Bis-Tris, Invitrogen, UK) and SDS-PAGE electrophoresis and Coomassie stain 
were performed (section 2.4.1). The intensity of the VWF bands was analysed using 
ImageJ software (MacMaster Biophotonics). This detected an inaccuracy in the standard 
VWF ELISA for quantification of ΔD4-C6 (discussed in section 6.5). 
 
2.6 STATIC VWF SELF-ASSOCIATION ASSAY 
The ability of VWF to self-associate under static conditions was examined by ELISA, in a 
method similar to that used by Urlichts et al203. First, biotin was conjugated to amines on 
purified pdVWF using three different kits, according to manufacturer’s instructions. Briefly, 
for each: 
 EZ-link® Sulfo-NHS-SS-biotin (ThermoScientific, USA) has a long spacer arm. An 
appropriate volume of 10mM Sulfo-NHS-SS-Biotin in ddH2O was added to purified 
pdVWF in PBS to create a ≥20 fold molar excess of biotin. The volume of 10mM 
Sulfo-NHS-SS-Biotin added was calculated according to manufacturer’s 
instructions. It was incubated at room temperature for 30 minutes, and then the 
non-reacted Sulfo-NHS-SS-Biotin was removed by overnight dialysis in 20mM Tris, 
pH7.4 at 4°C using D-Tube™ Midi Dialyzer MWCO 6-8kDa (Novagen, Germany).  
 For Lightning-Link™ Biotin Type A (Innova Biosciences, UK), 10%(v/v) of LL-
Modifier reagent was added to pdVWF in PBS. This mixture was applied directly to 
the vial of Lightning-Link™ mix. After overnight incubation at room temperature 
10%(v/v) of LL-quencher reagent was added.  
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 For Amersham ECL Protein Biotinylation (GEHealthcare, UK), 1mg/ml pdVWF in 
40mM bicarbonate buffer was incubated with 40µl of biotinylation reagent per mg of 
VWF protein for 1 hour at room temperature. It was then applied to an equilibrated 
Sephadex G25 column. 5x 1ml fractions were eluted in PBS and fractions 2 and 3 
were saved.   
Following the biotinylation procedures, the success of biotinylation was assessed by 
ELISA using streptavidin peroxidase polymer ultrasensitive (Sigma, USA) diluted 1 in 500 
for detection. The concentration of biotinylated VWF (b-VWF) was measured by VWF 
ELISA (section 2.4.4.2). The multimeric pattern (section 2.4.4.1) and static collagen 
binding activity (section 2.4.4.3) were also examined post-biotinylation (see section 5.2 for 
results).  
 
The ability of pdVWF to self-associate under static conditions was then examined by 
ELISA. Purified pdVWF was bound directly to a 96 well microtitre MaxiSorp plate (Nunc®, 
Sigma, USA) at a concentration of 5µg/ml in 50mM bicarbonate buffer (pH9.6), 100µl per 
well, and incubated at 4ºC overnight. The plate was then washed 3x with PBS-T and 
blocked with 3% BSA in PBS-T for 1 hour at room temperature. Serial dilutions of b-VWF 
(400-3.125nM) were added to the VWF coated wells in duplicate, and incubated for 1 hour 
at 37ºC. The molar concentration of VWF was calculated based on a monomeric weight of 
250kDa. After washing 3x with PBS-T, the wells were incubated with streptavidin 
peroxidase polymer ultrasensitive (Sigma, USA) diluted 1 in 500 for 45 minutes at room 
temperature. Bound streptavidin peroxidase was measured with Sigma colour fast OPD as 
previously described (section 2.4.4.2). Binding curves were fitted to the one-site binding 
model using GraphPad Prism 4.0 software, to determine KD. 
 
In order to determine the role of thiol exchange in VWF self-association, the free thiols on 
b-VWF were blocked with N-ethylmaleimide (NEM), which forms an almost irreversible 
thiolether bond. 500mM NEM (Sigma, USA) in 70% EtOH was added to each serial 
dilution of b-VWF (400-3.125nM) to give a final concentration of 20mM NEM (that is, 9.2µl 
in 230µl sample). Following incubation for 15 minutes at room temperature in the dark, 
100µl were applied to each well. Each sample was applied in duplicate. As a control an 
equivalent volume of 70% EtOH (9.2µl to 230µl) was added to serial dilutions of b-VWF 
and applied to the wells in parallel. The ELISA was otherwise carried out as described 
above.  
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2.7 PERFUSION ASSAYS  
2.7.1 Preparation of blood for perfusion assays 
Blood was collected from healthy donors into tubes with 10%(v/v) ACD anticoagulant 
(ACD: 85mM sodium citrate, 111mM glucose and 71mM citric acid, pH4.5). The whole 
blood was processed as described below to remove VWF and other plasma proteins which 
would otherwise interfere with the flow assay. All the centrifugation steps were performed 
at room temperature without a break. Any solutions were pre-warmed to room 
temperature. A full blood count analyser (Sysmex XE-2100 haematology analyser, Japan) 
in the clinical pathology laboratory at Hammersmith Hospital was used to verify that the 
haematocrit and platelet count were within 5% of the original value after processing. 
 
2.7.1.1 Preparation of RBC and platelets together 
Red blood cells (RBCs) and platelets were ideally processed together as this reduced 
platelet activation (as detected by platelet binding on control runs, see sections 4.5.7 and 
4.5.8). Apyrase grade VI (Sigma, USA), prostaglandin E1 (PGE1, Sigma, USA) and EDTA 
were added to the whole blood to prevent platelet activation at final concentrations of 
2U/ml, 10µM, and 5mM respectively. The blood was then centrifuged at 2100g for 13 
minutes. The supernatant (platelet-poor plasma) was discarded. The pellet containing 
RBC and platelets was gently re-suspended in HEPES-Tyrodes pH6.5 (HT: 10mM 
HEPES, 140mM NaCl, 2.7mM KCl, 0.4mM NaH2PO4, 10mM NaHCO3, 5mM dextrose) and 
made up to the original volume, and apyrase and EDTA were added (final concentrations 
1U/ml and 5mM respectively). It was centrifuged as before and then this wash cycle of 
supernatant removal, re-suspension of the pellet and centrifugation was performed again. 
A third wash cycle was performed, but without the addition of apyrase. The final pellet was 
then re-suspended to its original volume to reproduce a normal haematocrit and platelet 
count, with HT pH7.4. This was supplemented with 3.5mg/ml BSA and 2.5µM PGE1 (final 
concentrations). The platelets were labelled with 1nM DiOC6 (Invitrogen, UK) to render 
them fluorescent.  
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2.7.1.2 Preparation of RBC and platelets separately 
Blood and platelets were prepared separately for experiments in which platelets were 
perfused over VWF bound directly to the slide because for these experiments only 2% the 
normal platelet count was desired. Final concentrations of 2u/ml apyrase grade VI (Sigma, 
USA), 10µM PGE1 (Sigma, USA), and 5mM EDTA were added to whole blood to prevent 
platelet activation, and the blood was centrifuged at 120g for 15 minutes.  
 The top phase containing platelet rich plasma (PRP) was placed into a separate 
tube and final concentrations of 10%(v/v) ACD, 1U/ml apyrase grade VI (Sigma, 
USA) and 5mM EDTA were added (Sigma, USA). This was then centrifuged for 15 
min at 1200g to isolate platelets. The platelet poor plasma in the supernatant was 
discarded and the pellet containing platelets was washed by re-suspending in 10ml 
of HT pH6.5 supplemented with 3.5mg/ml BSA, 1U/ml apyrase and 2.5µM PGE1. It 
was centrifuged at 1200g for 12 minutes. The platelet pellet was then re-suspended 
in 1ml of HT pH7.5 supplemented with 3.5mg/ml BSA.  
 The initial RBC pellet was re-suspended in 0.9% NaCl and centrifuged at 1200g for 
12 minutes. This wash step was repeated 3 further times. The RBCs were then re-
suspended to the original blood volume in HT pH7.4 supplemented with a final 
concentration of 3.5mg/ml BSA.  
Platelets were then added to the RBCs at a concentration of 2% of original (that is, 20µl of 
1ml platelet suspension added per 10mls of RBC final suspension). PGE1, at a final 
concentration of 2.5µM, was added to the final volume of RBCs and platelets to inhibit 
platelet activation. The platelets were rendered fluorescent with 1nM DiOC6 (Invitrogen, 
UK).    
 
 
2.7.1.3 Preparation of whole blood 
After collection of blood in ACD, 10µM PGE1 and 5mM EDTA were added to prevent 
platelet activation. In some assays, to exclude an effect of the citrate anticoagulant, blood 
was collected into 10%(v/v) 40µM PPACK (Calbiochem®, MerkMillipore), a selective 
thrombin inhibitor, as used in Savage et al198. The platelets were rendered fluorescent with 
10nM DiOC6 (Invitrogen, UK).    
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2.7.2 Preparation of flow slides 
Parallel perfusion Ibidi® flow slides were used in all cases. The uncoated (hydrophobic 
plastic) μ-Slide V0.1 was used unless otherwise stated. Two other types of slide were used 
in some experiments: plastic IbiTreated μ-Slide V0.1, as these have a physical surface 
modification that makes the plastic surface hydrophilic; and a sticky-Slide 10.1 Luer over a 
glass coverslip, to provide a glass surface.  
 
To investigate the binding of platelets directly to VWF, purified VWF constructs were 
diluted to 30µg/ml in bicarbonate buffer (pH9.6) to saturate the slide and incubated for 1 
hour. The channels were then washed carefully 3x with PBS (using 10x channel volume) 
and blocked for 15 minutes with 1.5% BSA in PBS. The channels were then washed a 
further 3x with PBS before use in the perfusion assays. As a control, in order to assess the 
coating of VWF to the plate, VWF was stripped off after the initial incubation by adding 
40µl multimer sample buffer (10mM Tris, 8M urea, 1mM EDTA, 2%(w/v) SDS, 0.01%(w/v) 
bromophenol blue, pH 8.0) to each channel and incubated for 20 minutes at 60°C. The 
solution was aspirated from the channels and resolved using SDS-PAGE under reducing 
conditions followed by Western blot and detection with anti-hVWF-HRP.  The density of 
VWF bands was compared using ImageJ software (MacMaster Biophotonics, freely 
available from http://rsbweb.nih.gov/ij/).  
 
To investigate VWF mediated platelet adhesion to collagen, the flow slides were coated 
with type III collagen (Sigma, USA). The collagen was diluted with 25mM acetic acid to a 
final concentration of 100µg/ml, and incubated overnight at 4ºC. The slides were washed, 
blocked with 1% BSA in PBS, and washed again as described above, before use in a 
perfusion assay.  
 
2.7.3 Flow chamber and digital image processing 
The prepared flow slide was placed on an inverted epifluorescent microscope (Olympus-
CKX41). Whole blood, processed blood, or buffer was perfused through the slides using 
an Aladdin-1000 syringe pump (World Precision Instruments) which generated a 
continuous laminar flow. Specific wall shear rates were achieved by adjusting the flow rate 
according to conversion tables provided by the manufacturer. All experiments were 
recorded in real time using a QImaging camera (Rollera XR) and QCapture pro software 
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(QImaging, Canada). The digitalised images were collected, processed and analysed 
using VirtualDub software (www.virtualdub.org) and ImageJ software (MacMaster 
Biophotonics, www.rsbweb.nih.gov/ij/).  
 
2.7.4 Measurement of platelet binding to VWF 
To investigate the ability of VWF to support GPIbα dependent platelet tethering, a 
suspension of RBCs supplemented with platelets (section 2.7.1.2) was perfused for 3 
minutes over VWF immobilised directly onto the flow slide (section 2.7.2).  Platelet 
attachment was analysed at a range of shear rates (400-1500s-1). Every 30-60s a short 
movie (1s, with frames every 0.05s) was taken in a typical field of view, and at the 3 
minute endpoint the movie was taken in 3 fields of view. The experiment was repeated in 
duplicate on three separate occasions. The accumulated platelets at each time point were 
assessed by stacking 3 sequential frames and performing a minimal Z-projection (to 
remove translocating platelets) using ImageJ software. The nucleus counter function 
located in the ImageJ ‘particle analysis’ plug-in was then used to quantify the surface 
coverage (%) of visible platelets. 
 
2.7.5 Measurement of VWF-mediated platelet binding to collagen 
To investigate VWF-mediated platelet binding to collagen, plasma-free blood (section 
2.7.1.1) was perfused over collagen-coated slides (section 2.7.2), with or without the 
addition of recombinant VWF at a final concentration of 5µg/ml. Shear rate was typically 
1500s-1, but shear rates within the range 800-10000s-1 were also used. Short movies (1s, 
with frames every 0.05s) were recorded every minute for 5 minutes in a typical field of 
view, and at the 5 minute endpoint the movie was taken in 3 fields of view. Each 
experiment was repeated in duplicate on 3 separate occasions. The accumulated platelets 
at each time point were assessed as described above (section 2.7.4). Briefly, at each time 
point 3 sequential frames were stacked (to remove translocating platelets) and the surface 
coverage (%) of visible platelets was measured using ImageJ.  
 
In order to assess the binding of VWF to collagen under flow, similar experiments were 
performed using buffer rather than plasma-free blood. HT buffer pH7.4 was supplemented 
with 7% (v/v) Ficoll-Paque™ Plus (Amersham Biosciences, Sweden) and recombinant 
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VWF at final concentration of 5µg/ml. This was perfused over collagen-coated slides 
(section 2.7.2) at 1500s-1 for 5 minutes. The flow-through was collected. The channels 
were washed gently 3x with PBS. VWF bound to collagen was subsequently recovered by 
adding 40µl multimer sample buffer to each channel and incubating for 20 minutes at 
60°C. The solution was aspirated and analysed using a reducing SDS-PAGE gel followed 
by Western blot and detection with anti-hVWF-HRP.   
 
2.7.6 Use of NEM to block free thiols 
The effect of free thiols on VWF-mediated platelet binding to collagen was studied in the 
perfusion assay using purified pdVWF (section 2.4.2) treated with NEM (an alkene which 
reacts with thiols to form a C-S bond which is almost irreversible).  
 
Initially, 500mM NEM (Sigma, USA) in 70% ethanol was added to plasma-free blood just 
prior to perfusion to give a final concentration of 5-50mM NEM. Controls were run in which 
an equivalent volume of 70% ethanol was added. Additionally, purified pdVWF was pre-
treated with NEM (excess removed by dialysis) prior to perfusion. For this, purified pdVWF 
was incubated with 20mM NEM (Sigma, USA), or an equivalent volume of 70% ethanol, 
for 20 minutes at room temperature in the dark. Some samples were quenched with 40mM 
reduced glutathione (GSH) for 2 minutes (500mM stock in ddH20). All the samples were 
then dialysed overnight at 4°C into 20mM Tris pH7.4, using D-Tube™ Midi Dialyzer 
MWCO 6-8kDa (Novagen, Germany). The samples were re-quantified using the VWF 
ELISA (section 2.4.4.2) and their multimer pattern (section 2.4.4.1) and static collagen 
binding activity (section 2.4.4.3) were analysed. 
 
2.8 STATISTICAL ANALYSIS 
Analysis of data was performed using the Prism software package (GraphPad Prism 
version 4.0 Software for Science, USA). Data sets were analysed for Gaussian distribution 
using D’Agostino and Pearson omnibus normality test. The individual data sets were all 
normally distributed and were therefore expressed as mean, with standard error of mean 
(SEM). Time course perfusion experiments were analysed using area under the curve 
(AUC). Individual data sets were compared using paired t-tests. P values ≤0.05 were 
considered significant. 
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CHAPTER 3: THE IMPORTANCE OF FREE THIOLS AND C DOMAINS 
IN THE SYNTHESIS OF VWF 
 
3.1 INTRODUCTION 
Both pd and recombinant VWF have been shown to contain free thiols208,210,215 (section 
1.5.2). Free thiols have been identified in pd VWF by mass spectroscopy208 and most of 
these free thiols are located within the  C domains of VWF. They include some or all of: 
C889 and C898 in D3 and C2448, C2451, C2490, C2491, C2453, C2528 and C2533 in 
the C domains. C2453 has also been identified as the most abundant unpaired cysteine in 
recombinant VWF155. Whilst the crystal structures of the VWF C domains have not been 
resolved, the crystal structures of two typical C domains, in crossveinless2 and 
collagenIIA, have been determined14,15. Based on sequence homology, a model of the 
VWF C domains has been predicted152,155 (section 1.3.3). Five of the possible free thiols lie 
in the C3 domain and are all predicted on modelling to be disulphide-bonded (2431-2453, 
2448-2490, 2451-2468, 2473-2491)152,155. Two of the cysteines located within C4 are also 
predicted to be disulphide-bonded (2528-2570 and 2499-2533)152. Furthermore, the two 
cysteines in the D3 domain were shown to be disulphide-bonded by direct observation of 
the phenylthiohydrantoin of cysteine during Edman degradation (889-1031 and 898-993)34. 
This poses the conundrum that cysteines predicted by homology to be paired, have been 
shown to be unpaired in a proportion of monomers. Curiously, some of the presumably 
unpaired partners were not detected in Choi’s analysis208. It is not known whether these 
cysteines are genuinely paired or not. If they are, questions arise as to whether they are 
initially paired and then become unpaired, and if so how and where this happens. It is also 
not known currently what role, if any, these free thiols play in the function of VWF.  
 
Extracellular thiol-disulphide exchange is increasingly being recognised as an important 
regulator of protein function. The majority of allosteric disulphides have a –RHStaple 
configuration, such as that predicted for C2451A-C2468A (section 1.5.3). It has been 
suggested that these free thiols may play a role in the lateral self-association of VWF. The 
self-association of VWF was first demonstrated by Savage et al198. It has subsequently 
been described under both static and shear conditions203,199, and on both collagen230 and 
EC surfaces81,84 (section 1.5.1). It has been hypothesised that self-association is important 
in regulating VWF function, increasing its multimeric size and consequently its platelet 
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binding ability. It has been proposed that lateral self-association occurs via new disulphide 
bonds forming between VWF multimers which unravel under shear104,208. In support of this 
hypothesis, the number of free thiols has been shown to be reduced after VWF is exposed 
to shear208 (section 1.5.3). 
 
Ganderton et al155 investigated which free thiols may result in lateral self-association by 
disrupting some of these predicted pairings. The authors examined the expression pattern 
of the VWF fragment, C3C4 (2429-2495), with and without cysteine mutations (section 
1.5.3). The authors concluded that lateral self-association involves reduction of the intra-
domain Cys2431-Cys2453 bond by a reductase during or after secretion, after which 
C2431 links to either C2431 or C2451 on an adjacent monomer and that reduction of the 
C2451A-C2468A bond is a rate limiting step. However, these experiments used a small 
fragment of VWF, and examined the oligomer pattern of the secreted protein in the media. 
It is not known whether these reactions take place in full-length VWF, during secretion or 
whilst circulating in plasma. In this study I aimed to determine further the role of these 
specific cysteine residues in the structure of VWF and in providing free thiols for self-
association. 
 
3.1.1 Hypothesis 
• Some or all of the cysteines identified to be possibly free are important for the 
lateral self-association of VWF. 
 
3.1.2 Aims 
• To determine the role of specific cysteine residues in providing free thiols for self-
association. 
• To determine whether these cysteines become unpaired following VWF secretion or 
whether they are simply not paired during VWF synthesis. 
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3.2 NATURALLY OCCURING MUTATIONS 
Using the ISTH-SSC VWF Online Database (http://www.vwf.group.shef.ac.uk/), an initial 
search was performed to look for known naturally occurring mutations of any of the 
cysteines found by Choi et al208 to be possibly free. The search was then extended to the 
proposed binding partners of all these free cysteines (based on modelling using 
homologous C domains152,155), and finally to all of the other cysteines in the C domains.   
 
No naturally occurring mutations have been reported of either the cysteines which Choi et 
al208 found to be free in the D3 domain (C889 and C898) or of their proposed binding 
partners (C1031 and C993 respectively)34,152.  
 
Within the C domains, a naturally occurring mutation in one of the cysteines reported by 
Choi et al208 to be free, C2533X, has been reported to the database as causing VWD (type 
unclassified; VWFAg 10%, VWF:CB 5%, VWF:Ricof 4%). However as a stop codon it 
causes a marked conformational change, beyond that of a specific cysteine mutation, and 
no expression work has been published. Neither are there any reported naturally occurring 
mutations of any of the proposed pairing partners of these free cysteines. 
 
The search for naturally occurring cysteine mutations was extended throughout the six C 
domains (Table 3.1). Only nine mutations have been reported, and only one has been 
further investigated by expression work (C2304Y). Expression of recombinant C2304Y 
VWF resulted in marked intracellular retention, although co-transfection with wt led to 
secretion with virtually normal multimers231. C2304Y affects the first cysteine of the CGLC 
motif in C1, and as such is discussed further in Chapter 4 (section 4.3).  
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Domain Mutation VWD type Other information Reference 
C1 C2257S Type 1 Heterozygous mutation associated with 
abnormal multimer pattern. 
Goodeve et al232 
C1 C2304Y Type 1 Heterozygous mutation associated with 
abnormal multimer pattern. Expression of 
recombinant mutant VWF cDNA led to 
marked intracellular retention and loss of 
HMWMs. Cotransfection with wt led to 
virtually normal multimers. 
Goodeve et al232 
Eikenboom  
et al
231
 
C2 C2340R Type1 Heterozygous mutation, normal multimer 
pattern. 
James et al233 
C2 C2362F Type 1 or 3 Heterozygous mutation associated with 
abnormal multimer pattern. 
Type 3 in patient homozygous for mutation. 
Goodeve et al232 
Eikenboom  
et al231 
C3 C2477 (S/Y) Type 1 Heterozygous mutation associated with 
abnormal multimers. 
Goodeve et al232 
C4 C2533X Unclassified No further details. Unpublished 
C4 C2557Sfsx8 Type 3 Homozygous mutation.  Corrales et al
234 
C6 C2671Y Type 3 Compound heterozygote for VWF deletion. Eikenboom  
et al231  
C6 C2693Y Type 1 Heterozygous mutation associated with 
abnormal multimer pattern. 
Goodeve et al232 
 
Table 3.1 Naturally occurring cysteine mutations within the C domains. A search of 
the ISTH-SCC VWF Online Database (http://www.vwf.group.shef.ac.uk/) revealed the 
above mutations had been reported as causing von Willebrand Disease (VWD).  Only 
C2304Y has had further expression work performed. 
 
3.3 RECOMBINANT WT VWF CONTAINS FREE THIOLS 
Other groups have shown that both pdVWF104,208,209 and recombinant wt VWF155,210 
contain free thiols. As I planned to use recombinant VWF to examine the functional 
importance of these nine cysteines found to be possibly free in pdVWF, I first looked to 
see if both pdVWF and recombinant VWF had a similar proportion of free thiols. This was 
studied using a free thiol assay (section 2.4.4.4). Briefly, an equal concentration of pdVWF 
(from reference plasma) and wt VWF (from conditioned media of HEK293T cells) was 
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incubated with MPB, a thiol-reactive agent. After incubation, the VWF was loaded onto a 
microtitre plate which had been coated with polyclonal anti-hVWF and blocked with BSA. 
The VWF was detected with either streptavidin peroxidase or polyclonal anti-hVWF-HRP 
antibody. The free thiol content was expressed as a ratio of bound MPB to bound VWF. 
Recombinant wt VWF was found to have a similar proportion of free thiols as pdVWF 
(p=0.54). 
 
 
Figure 3.1 Free thiols in pd VWF and wt VWF. A free thiol assay, based on ELISA 
technique, was used to analyse the proportion of free thiols on VWF. Graph showing the 
ratio of bound MPB to bound VWF for pd VWF (from reference plasma) and recombinant 
wt VWF (p=0.54). (Values shown here are mean ±SEM of three separate experiments 
performed in duplicate.) 
 
 
3.4 RECOMBINANT CYSTEINE TO ALANINE POINT MUTATIONS  
Cysteine to alanine point mutants were made in expression vectors, as described in the 
sections below. In all cases, large scale DNA preparations were then made and used for 
small scale transient transfection of mammalian HEK293T or HEK293 cells (section 2.3.3). 
HEK 293T cells were used for all transfections except for those looking at the location of 
intracellular retention of the mutants (sections 3.4.5 and 3.5.3). After 3 days the media and 
lysate were harvested. The concentration of each VWF variant in the conditioned media 
and cell lysate was then assayed using the VWF ELISA (section 2.4.4.2). 
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3.4.1 Expression of the original nine individual point mutations: C889A, C898A, 
C2448A, C2451A, C2490A, C2491A, C2453A, C2528A, C2533A  
Single cysteine to alanine point mutants were constructed at the nine cysteine residues 
which were found by Choi et al208 to be possibly free: C889, C898, C2448, C2451, C2490, 
C2491, C2453, C2528, C2533.  The two mutants in D3 (C889A and C898A) were initially 
made in vector pGEM-VWFXhoI-KpnI, and the remaining C domain mutants were made in the 
pcDNA3.1 A2-CK vector. The mutants were then subcloned into pcDNA3.1 FL-VWF.   
 
Wt VWF and the nine recombinant C→A VWF mutants were expressed on a small scale in 
HEK293T cells. The concentration of each VWF variant in the conditioned media and cell 
lysate was then assayed using the VWF ELISA. All the mutants were retained 
intracellularly, with no or minimal secretion detectable (Figure 3.2).  
 
 
 
 
 
 
Figure 3.2 Expression of wt VWF and the original nine individual C→A point 
mutants, based on the cysteines found to be free in plasma by Choi et al208. The 
concentration of VWF in media and lysate, determined by VWF ELISA, is shown. All nine 
individual C→A point mutants were retained intracellularly. (Values shown here are mean 
±SEM of three separate transfections performed in duplicate.) 
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3.4.2 Further recombinant cysteine to alanine point mutants: C2431A, C2468A and 
the double mutant C2431A-C2453A 
Three additional mutants were made based on the new understanding that the C-terminus 
is comprised of six C domains, the predicted disulphide-pairings within these domains, the 
predictions of important functional –RHStaple allosteric disulphide-bonds, and the 
expression of these mutants in a small VWF fragment155,19. Two single cysteine to alanine 
point mutants were constructed at C2431 and C2468 (predicted to be paired to C2453 and 
C2451 respectively) and a double mutant C2431A-C2453A was also constructed. Of note, 
the C2451A-C2468A double mutant was not made as this had not secreted when 
expressed in a small fragment of VWF155. The single mutants were made initially in 
pcDNA3.1 A2-CK, and the double mutant in pcDNA3.1 A2-CK C2453A. The mutants were 
then sub-cloned into pcDNA3.1 FL-VWF.  
 
Following transient transfection of HEK293T cells, both of the additional individual 
mutants, C2431A and C2468A, as well as the double mutant, C2431A-C2453A, were 
retained intracellularly with no or minimal secretion detectable (Figure 3.3).  
 
 
 
Figure 3.3 Expression of wt VWF and additional C→A mutants. The concentration of 
VWF in media and lysate, determined by VWF ELISA, is shown. Both individual C→A 
point mutants are retained intracellularly. The double C→A point mutant is also retained 
intracellularly. (Values shown here are mean ±SEM of three separate transfections 
performed in duplicate.) 
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3.4.3 Expression of some C→A mutants in fragments of VWF 
In order to examine whether the loss of a cysteine residue resulted in intracellular retention 
due to abnormal local folding or a more generalised structural change, for example with 
multimerisation, some of the C→A mutants were then expressed in smaller fragments of 
VWF.  During construction of the full length mutants, the C domain C→A mutants had 
been first constructed in the expression vector pcDNA3.1 A2-CK. Some of the mutants 
were additionally made in the expression vector pcDNA3.1 A3-CK (Figure 3.4). In order to 
investigate whether the C→A mutations resulted in retention due to abnormal dimerisation, 
a stop codon was inserted just before the start of the CK domain in pcDNA3.1 A2-CK, 
creating pcDNA3.1 A2-C6 (Figure 3.4). In general the cysteines that were investigated the 
most intensely (that is, in the most number of constructs) were those which had been 
predicted to be of particular functional importance, and shown to secrete when expressed 
in the very small VWF fragment C3C4(2429-2495): C2431, C2451, C2453, and 
C2468155,213. 
 
Transient transfection of HEK293T cells, harvesting, and analysis using the VWF ELISA 
was performed as previously described.  The wt VWF fragments secreted in all cases and 
were detected by the polyclonal anti-hVWF antibody, despite the loss of epitopes229. In 
general, the fragments were expressed at higher levels than FL-VWF, consistent with the 
hypothesis that cells can produce a smaller protein more rapidly than a larger one235. The 
wt monomeric fragment A2-C6 however had lower secretion levels when compared to the 
dimer A2-CK (media:lysate ratio p<0.05). Monomers might be secreted at lower levels 
than dimers and higher order oligomers due to the different conformation resulting in 
greater retention by the cell’s quality control mechanisms, perhaps due to exposed 
hydrophobic patches or free thiols235-237. However, for each particular VWF fragment, the 
expression levels of the recombinant mutants can be accurately compared to that of the  
wt. In comparison to the equivalent wt VWF fragment, all the C→A point mutants 
(individual and double) failed to secrete in the dimeric VWF fragments A2-CK, A3-CK and 
the monomeric fragment A2-C6 (p<0.05) (Figure 3.5). 
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Figure 3.4 Schematic of the VWF fragments expressed.  
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Figure 3.5 Expression of C→A mutants in VWF fragments (A2-CK, A3-CK, A2-C6). 
The concentration of VWF in media and lysate, as determined by the VWF ELISA, is 
shown. (A) The individual and double C→A point mutations were all retained intracellularly 
when expressed in the A2-CK VWF fragment. (B) In the A2-C6 monomeric fragment of 
VWF, C2468A is secreted at much lower levels than wt and is mainly retained 
intracellularly (media:lysate ratio p<0.05). (C) The individual and double C→A point 
mutations were all retained intracellularly when expressed in the A3-CK fragment of VWF. 
(Values shown here are mean ±SEM of three separate transfections performed in 
duplicate.) 
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3.4.4 Mutation of cysteine to serine 
Cysteine to alanine is a standard innocuous substitution. However, alanine is a small 
hydrophobic amino acid, whereas cysteine is a small polar amino acid. One of the 
cysteines (C2448) was therefore additionally mutated to serine (polar), in order to see if 
the failure of secretion was the result of changing the polarity of the amino acid backbone. 
The mutation was made in the expression vector pcDNA3.1 A2-CK.   
 
Transient transfection of this VWF fragment showed that C2448S was retained 
intracellularly (Figure 3.6). 
 
 
Figure 3.6 Expression of C to S mutant in the A2-CK fragment. The concentration of 
VWF in media and lysate, determined by VWF ELISA, is shown. Secretion could not be 
rescued by mutating the cysteine (polar) to serine (polar) rather than to alanine 
(hydrophobic). (Values shown here are mean ±SEM of three separate transfections 
performed in duplicate.) 
 
 
3.4.5 Localisation of C→A mutants retained intracellularly 
In order to investigate where these mutants were retained within the cell, the composition 
of VWF in the cell lysate of HEK293 cells was studied. This technique has previously been 
used by Wang et al238. Initially recombinant VWF was expressed in HEK293T cells, 
however both wt and the C→A mutants only showed a pro-VWF band, with no mature 
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VWF as had previously been described for wt lysates in HEK293 cells238 (data not shown). 
The experiment was therefore repeated with HEK293 cells. It was found that by harvesting 
6 days after transfection (rather than the standard 3), differences seen between wt and the 
mutants were accentuated.  
 
Briefly, the FL-VWF DNA preparations were used for small scale transient transfection of 
HEK293 cells. The media and cell lysates were harvested after 6 days. Analysis using the 
VWF ELISA demonstrated that all of the FL-VWF C→A mutants were retained 
intracellularly in HEK293 cells, as for HEK293T cells (data not shown). The wt and mutant 
cell lysates were then loaded onto a reducing SDS-PAGE gel at a concentration of 
0.1µg/ml, and VWF was detected by Western blot with polyclonal anti-hVWF (section 
2.4.1.2). The wt media was used as a size control. The density of the bands was analysed 
using ImageJ.  
 
The wt VWF was retained mainly as mature VWF, whereas the mutants were retained 
mainly as pro-VWF (Figure 3.7). The reducing gel for wt-VWF and one of the mutants is 
illustrated (Figure 3.7, A). The ratio of pro-VWF to mature VWF present can be quantified 
by analysing the density of the appropriate band with ImageJ, and then this can be 
expressed as a ratio (Figure 3.7, B). As furin cleaves the propeptide from VWF after 
multimerisation in the trans-Golgi, the uniformly low ratios suggest that the C→A mutants 
are retained either in the ER or in the early Golgi. 
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Figure 3.7 Cell lysates of C→A mutants in FL-VWF. The cell lysates from HEK293 cells 
were examined by SDS-PAGE and Western blotting. The density of the bands was 
determined using ImageJ. (A) Reducing gel shows that the wt VWF retained within the cell 
is mainly mature processed VWF (green box), whereas the C→A mutant shown is retained 
intracellularly mainly as pro-VWF (red box). This appearance was typical of the C→A 
mutants. (B) Graph showing the ratio of mature VWF to pro-VWF for all the mutants, as 
determined by the density of the appropriate sized band.  (Values shown here are mean 
±SEM of three separate transfections.) 
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EndoH cleaves asparagine-linked mannose-rich oligosaccharides from glycoproteins 
(section 2.4.4.5). It was therefore used to differentiate whether the mutants were retained 
within the ER (and were cleavable by EndoH) or whether they were within the Golgi 
(where glycans are processed and become resistant to EndoH). The cell lysates were 
incubated at 37ºC overnight, with and without EndoH present and then run on a reducing 
SDS-PAGE gel followed by Western blot and detection with polyclonal anti-hVWF. The 
detectable pro-VWF band migrated further through the gel following treatment with EndoH, 
suggesting that EndoH de-glycosylated VWF and reduced its size (Figure 3.8). This 
suggests that all the C→A mutants were retained as pro-VWF within the ER. 
 
 
 
 
 
 
 
Figure 3.8 EndoH deglycosylates pro-VWF. SDS-PAGE and Western blot were used to 
look at the effect of EndoH incubation on the VWF in cell lysates. Reducing gel shows wt 
VWF media as a size control, wt lysate containing a pro-VWF band and darker mature 
VWF band (as shown in Figure 3.7, A) and that the C→A mutants are retained mainly as 
pro-VWF which is reduced in size by EndoH. (The gels shown here are representative 
examples of experiments performed in at least duplicate.) 
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3.4.6 Co-expression of C→A mutants with wt VWF 
In order to examine whether the secretion of the cysteine mutants could be rescued by 
processing alongside normal VWF monomers, each of the individual C→A point mutants 
and the double mutant were co-expressed with wt VWF. The DNA preparations of FL-VWF 
wt and mutants were used for small scale transient transfection of HEK293T cells. The 
standard protocol was used, except that 50% of the DNA preparation used for transfection 
was wt-VWF and 50% was the mutant VWF.  
 
Co-expression of wt VWF with the C→A mutant VWF rescued secretion in all cases, but to 
varying degrees (Figure 3.9). However, this does not distinguish whether the processing of 
wt VWF alongside the C→A mutant VWF was able to rescue the secretion of mutant VWF, 
or whether it was simply wt VWF alone being secreted. 
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Figure 3.9 Co-expression of wt VWF with the C→A mutants. The concentration of 
VWF in the media (A) and lysate (B) is shown, as determined by the VWF ELISA. Wt VWF 
rescued secretion levels to varying degrees. (Values shown here are mean ±SEM of three 
separate transfections performed in duplicate.) 
 
 
In order to ascertain whether the improved secretion levels following co-transfection were 
simply a result of wt VWF alone being secreted, or whether the C→A mutant VWF was 
also being secreted, we repeated the co-transfection experiments using ∆A1A3 VWF 
(Δ1239-1480, 1673-1876) that lacks both the A1 and A3 domains (construct kindly 
supplied by Dr Agata Nowak). The smaller size of VWF ΔA1A3 allowed identification of 
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both co-transfected VWFs by their difference in size (the full length C→A mutants would 
migrate less through the gel than the smaller ∆A1A3 VWF) (Figure 3.10, A).  Prior to the 
co-expression study, small scale transient transfection of HEK293T cells with pcDNA3.1 
∆A1A3 VWF alone was performed in order to verify its expression profile using the 
standard VWF ELISA. It may have been underquantified compared to wt VWF, as the 
polyclonal anti-hVWF antibody used recognises several epitopes located within the VWF A 
domains229. While comparison of the media:lysate ratios showed that it was not secreted 
as efficiently as wt VWF (paired media:lysate ratio p<0.05, Figure 3.10, B), it was 
considered that it was secreted well enough to be used in the subsequent experiment.  
 
 
 
  
 
 
Figure 3.10 ∆A1A3. (A) Diagram illustrating the domain structure of ∆A1A3 (∆1239-1480, 
1673-1876). (B) Graph to show the concentration of VWF in the media and lysate, 
determined by VWF ELISA. ∆A1A3 was secreted less efficiently than wt (paired t-test of 
media:lysate ratio p<0.05). (Values shown here are mean ±SEM of three separate 
transfections performed in duplicate.) 
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The full length C→A mutants were then co-expressed with ∆A1A3 VWF, using the protocol 
previously described for co-expression of these mutants with wt.  30µl of the conditioned 
media of each co-transfection was loaded onto a reducing gel, and SDS-PAGE 
electrophoresis and Western blot with polyclonal anti-hVWF antibodies was performed. As 
can be seen, ∆A1A3 VWF migrated further through the gel than FL-VWF (Figure 3.11, A). 
This allowed the relative secretion of the C→A VWF mutants and ∆A1A3 VWF to be 
analysed using ImageJ (Figure 3.11, B). For most of the co-transfections, it was mainly 
∆A1A3 alone that was secreted. However, full length C889A, C898A, C2490A, C2491A 
(and to a lesser degree C2533A) were secreted alongside ∆A1A3 VWF to a significant 
extent (ratio of C→A mutant:ΔA1A3  >0.1).  
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Figure 3.11 Co-transfection of C→A point mutants with ΔA1A3. SDS-PAGE and 
Western blot were performed to examine the relative secretion of full-length C→A mutant 
and ∆A1A3 into the conditioned media following co-transfection. (A) Reducing gel of co-
transfection media. The expression media of wt FL-VWF and ΔA1A3 alone are shown as 
size controls. ∆A1A3 VWF (green box) migrated further through the gel than full-length 
VWF (wt or C→A mutants, red box). (B) Graph to show the relative secretion of C→A 
mutant to ∆A1A3 in the conditioned media, as quantified by band density using ImageJ. 
For most of the co-transfections, it was mainly ∆A1A3 alone that was secreted. However, 
full length C889A, C898A, C2490A, C2491A (and to a lesser degree C2533A) were 
secreted alongside ∆A1A3 VWF to a significant extent (ratio of C→A mutant:ΔA1A3  >0.1). 
(Values shown here are mean ±SEM of three separate transfections and the gel is a 
representative example.) 
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For the 5 C→A mutants (C889A, C898A, C2490A, C2491A, and C2533A) in which 
significant VWF could be detected in the media when co-expressed with ΔA1A3 (ratio 
C→A:ΔA1A3 >0.1), the multimeric pattern was then studied. The conditioned media from 
the co-expression of these five C→A mutants with wt VWF was loaded and run on a 
multimer gel (section 2.4.4.1), and a Western blot was performed with polyclonal anti-
hVWF antibody. The multimeric pattern of the VWF from the media of each co-transfection 
was similar to that from the media of wt alone (Figure 3.12). 
 
 
 
 
 
 
 
Figure 3.12 Multimer gel of recombinant VWF from media of co-transfection of wt 
and C→A VWF mutations.  The multimeric pattern of the VWF from each of the co-
transfections is similar to that of wt alone. (This is a representative example of a gel, 
performed in duplicate.) 
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3.5 RECOMBINANT C DOMAIN DELETION MUTANTS 
The cysteine to alanine point mutants had been constructed with the aim of investigating 
the importance of these cysteines in the synthesis of VWF and in self-association. 
Because none of these mutants secreted, I was not able to study their function, in 
particular their hypothesised role in the lateral self-association of VWF. Most of these free 
thiols are contained within the C domains, C3 and C4. I therefore made a series of C 
domain deletion mutants, with the aim of obtaining recombinant mutant VWF to test the 
importance of these domains in functional assays. 
 
The C domain deletion mutants were made in expression vectors, as described in the 
sections below. In all cases, large scale DNA preparations were then made and used for 
small scale transient transfection of mammalian HEK293T or HEK293 cells (section 2.3.3). 
HEK293T cells were used for all transfections except for those looking at the location of 
intracellular retention of the mutants (sections 3.4.5 and 3.5.3). After 3 days the media and 
lysate were harvested. The concentration of each VWF variant in the conditioned media 
and cell lysate was then assayed using the VWF ELISA (section 2.4.4.2). 
 
3.5.1 Expression of the C domain deletion mutants 
C domain deletion mutants were constructed in the pcDNA3.1 A2-CK vector using PCR to 
remove the required residues (section 2.2.2). Of note, the first two C domain deletion 
mutants to be made were based on the original domain boundaries described by Titani11 
and Sadler127 and were ∆2400-2662 and ∆2400-2515. During the course of this PhD, new 
sequence homology alignments, expression work and electron microscopy led to the re-
annotation of the C terminus as six C domains152. Thus the original domain deletion 
mutants which corresponded to deletion of Sadler’s domains C1C2 and C1 were 
respectively renamed:  ∆C3-C6- (∆2400-2662) and ∆C3C4- (∆2400-2515). Based on the 
newly proposed domain boundaries, the other C domain deletion mutants were 
subsequently made in pcDNA3.1 A2-CK: ∆D4-C6 (∆1875-2720), ∆C1-C6 (∆2255-2720), 
∆C1C2 (∆2255-2428), and ∆C3 (∆2431-2494). Briefly, to make ∆C3-C6- (∆2400-2662) 
reverse and forward primers starting either side of the region to be deleted that is, 2399 
and 2663 respectively) were designed. The PCR product was purified, phosphorylated 
with PNK and ligated. The same technique was used to make the other C domain deletion 
mutants in pcDNA3.1 A2-CK. The VWF fragment containing the deletion was then sub-
cloned into pcDNA 3.1 FL-VWF.  
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Whilst the standard VWF ELISA, which uses polyclonal anti-hVWF, may slightly under-
quantitate the deletion mutants due to loss of epitopes229, it can be seen from the levels 
detected in the lysate that these deletion mutants were still readily detected (Figure 3.13). 
Most of the deletion mutants were retained intracellularly (Figure 3.13). Whilst ∆C1-C6 
secreted at higher levels than the smaller deletion mutants its media:lysate ratio (mean 
0.2) remained grossly abnormal compared to wt (mean 1.2, p<0.05). Whilst the levels of 
∆D4-C6 detected in the harvested media were lower than those for wt, the media:lysate 
ratios were comparable (p=0.43). This enabled ∆D4-C6 to be investigated further and this 
is discussed in Chapter 6. 
 
 
 
 
Figure 3.13 Expression of VWF C domain deletion mutants. The concentration of VWF 
in media and lysate, as determined by the VWF ELISA, is shown. The majority of domain 
deletion mutants were retained intracellularly, however ∆D4-C6 was secreted with 
comparable efficiency to wt (mean media:lysate ratios 1.0 and 1.2 respectively, paired t-
test p=0.43). (Values shown here are mean ±SEM of three separate transfections 
performed in duplicate.) 
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3.5.2 Expression of C domain deletion mutants in VWF fragments 
The domain deletion mutants which had been retained intracellularly (∆C1-C6, ∆C1C2, 
∆C3, ∆C3-C6- and ∆C3C4-) were then expressed in smaller fragments of VWF. This was 
to determine whether the mutation resulted in intracellular retention due to abnormal local 
folding or due to a more general effect, such as interfering with multimerisation. During 
construction of the full length mutants, all the C domain deletion mutants had been first 
constructed in pcDNA3.1 A2-CK, which is an expression vector. In addition some of these 
deletion mutants were then made in smaller fragments of VWF. They were cloned directly 
into pcDNA3.1 A3-CK, pcDNA3.1 D4-CK and pcDNA3.1 C1-CK (Figure 3.14). As 
previously described (section 3.4.3), a stop codon was inserted just prior to the CK domain 
(at residue 2724) in some of the vectors allowing expression of these fragments as 
monomers (Figure 3.14).   
 
 
 
 
 
Figure 3.14 Illustration of expressed wt VWF fragments. 
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The wt VWF fragments secreted in all cases albeit some fragments expressed, or were 
detected by the polyclonal anti-VWF antibody, more readily than others, as already 
discussed (section 3.4.3). In comparison to the equivalent wt VWF fragment most of the 
domain deletion mutants failed to secrete in the dimeric VWF fragments A2-CK, A3-CK, 
D4-CK and C1-CK and the monomeric fragment A2-C6 (Figure 3.15 and 3.16). This was 
similar to the results obtained with the C→A mutants (section 3.4.3). However 
exceptionally, whilst ∆C3 did not secrete in A2-CK or the monomer A2-C6, it secreted in 
the smaller VWF fragments A3-CK, D4-CK and C1-CK (Figures 3.16). As the expression 
and detection levels of the wt VWF fragments varied, this expression pattern for ∆C3 was 
verified by expressing the full range of wt and ΔC3 VWF fragments (FL-VWF to C1-CK) 
simultaneously (Figure 3.17). This confirmed that although ∆C3 is retained intracellularly in 
FL-VWF and A2-CK, in smaller VWF fragments (A3-CK or smaller) it is secreted and 
expressed at comparable levels to wt (paired t-test of media-lysate ratio, p>0.05 in all 
these fragments). 
 
 
 
 
Figure 3.15 Expression of VWF C domain deletion mutants within VWF fragments. 
The concentration of VWF in media and lysate, determined by the VWF ELISA, is shown. 
(A) Both ∆C3 and ∆C3C4- were retained intracellularly when expressed in A2-CK VWF 
fragment. (B) Both ∆C3 and ∆C3C4- were retained intracellularly when expressed in the 
monomeric VWF fragment A2-C6. (Values shown here are mean ±SEM of three separate 
transfections performed in duplicate.) 
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Figure 3.16 Expression of C domain deletion mutants within smaller VWF fragments. 
The concentration of VWF in media and lysate determined by VWF ELISA is shown. (A) 
∆C3 expressed at comparable levels to wt in VWF fragment A3-CK (paired t-test of 
media:lysate ratio p=0.33), however ∆C3C4- was again retained intracellularly. (B) and (C) 
∆C3 was again expressed at comparable levels to wt in the smaller VWF fragments D4-CK 
and C1-CK (paired t-test of media:lysate ratio p=0.52 and p=0.24 respectively), whereas 
∆C3C4- was retained intracellularly. (Values shown here are mean ±SEM of three 
separate transfections performed in duplicate.) 
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Figure 3.17 Expression of ΔC3 in different fragments of VWF. Wt and ΔC3 VWF were 
expressed simultaneously in a range of VWF fragments (FL-VWF to C1-CK) to compare 
secretion levels. The concentration of VWF in media and lysate was determined by VWF 
ELISA and the ratio of VWF in the media to lysate is shown. ∆C3 is retained intracellularly 
in FL-VWF and A2-CK, but in fragments of A3-CK or smaller it is secreted and expressed 
at comparable levels to wt (paired t-test of media:lysate ratio, p>0.05 in all these 
fragments). (Values shown here are mean ±SEM of three separate transfections 
performed in duplicate.)  
 
 
3.5.3 Localisation of C domain deletion mutants retained intracellularly 
In order to investigate where the full-length domain deletion mutants were retained within 
the cell, the composition of VWF in the cell lysate of HEK293 cells was studied (section 
3.4.5). Briefly, FL-VWF DNA preparations were used for small scale transient transfection 
of HEK293 cells. After 6 days, the media and cell lysates were harvested and the 
concentration of each VWF variant was assayed using the VWF ELISA. As expected from 
the transfections with HEK293T cells, all of the FL-VWF C domain deletion mutants, other 
than ∆D4-C6, were very poorly secreted and the majority was retained intracellularly (data 
not shown). The conditioned media and mutant cell lysates were then loaded onto a 
reducing SDS-PAGE gel at a concentration of 0.05µg/ml (or neat media if the detectable 
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VWF was less than this), and VWF was detected by Western blot with polyclonal anti-
hVWF-HRP antibody.  
 
The amount of mature VWF to pro-VWF present in the lysate was quantified by analysing 
the gels with ImageJ, and then this was expressed as a ratio (Figure 3.18, A). The 
intracellular wt and ∆D4-C6 VWF were present mainly as mature VWF, although ∆D4-C6 
had a higher proportion of propeptide present. The other domain deletion mutants were 
mainly retained as pro-VWF (Figure 3.18). As furin cleaves the propeptide from VWF after 
multimerisation in the trans-Golgi, this suggests that the C domain deletion mutants are 
retained either in the ER or in the early Golgi.  
 
As previously (section 3.4.5), EndoH was used to differentiate whether the mutants were 
retained within the ER (and were cleavable by EndoH) or whether they were within the 
Golgi (and resistant to EndoH). The cell lysates were incubated at 37ºC overnight, with 
and without EndoH present, and then run on a reducing SDS-PAGE gel, followed by 
Western blot and detection with polyclonal anti-hVWF-HRP antibody. The detectable pro-
VWF band migrated further through the gel following treatment with EndoH, suggesting 
that EndoH de-glycoslylated the mutant VWF and reduced its size (Figure 3.18, B). This 
suggests that ∆C1-C6, ∆C3, ∆C3-C6-, and ∆C3C4- were retained as pro-VWF within the 
ER. While a band is detected in the media for all of the deletion mutants other than ΔC3, 
this is because the gels were loaded with 0.05µg/ml VWF for both media and lysate 
samples (or neat media if the detectable VWF was less than this) in order to detect a band 
in the media to use as a size control.  
 
 
 
 
 
 
 107 
 
 
 
 
Figure 3.18 Cell lysates of domain deletion mutants expressed in FL-VWF. SDS-
PAGE and Western blotting were performed on conditioned media and cell lysates of 
HEK293 cells. The density of the bands was analysed by ImageJ. (A) Graph showing the 
ratio of mature VWF to pro-VWF in the lysates for all the mutants, based on the density of 
the appropriate band as analysed by ImageJ. The intracellular wt and ∆D4-C6 VWF were 
present mainly as mature VWF, although ∆D4-C6 had a higher proportion of propeptide 
present. The other domain deletion mutants were mainly retained as pro-VWF (B) 
Reducing gel showing three lanes for each recombinant VWF. The first lane (red M) is 
VWF from the conditioned media as a size control; the second and third lanes are VWF in 
the cell lysates, without and with EndoH treatment respectively.  ∆C1-C6, ∆C1C2, ∆C3, 
∆C3-C6- and ∆C3C4- are retained mainly as pro-VWF, which is reduced in size following 
treatment with Endo H, suggesting that they are retained within the ER. (Values shown 
here are mean ±SEM of three separate transfections and gels are representative of 3 
experiments.) 
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3.5.4 Co-expression of C domain deletion mutants with wt VWF 
In order to determine whether the secretion of the retained C domain deletion mutants 
could be rescued by processing alongside normal VWF monomers, ∆C1-C6, ∆C1C2, ∆C3, 
∆C3-C6-, and ∆C3C4- were co-expressed with wt VWF. The protocol for co-transfection of 
the FL-VWF preparations was as previously described (section 3.4.6). Similarly to with the 
C→A mutants (Figure 3.9), co-expression of wt VWF with the full length C domain deletion 
mutant rescued secretion in all cases, but to varying degrees (Figure 3.19). ∆C3 and 
∆C1C2 had the most increased secretion levels following co-transfection. However, this 
does not distinguish whether the processing of wt VWF alongside the C domain deletion 
mutant was able to rescue the secretion of mutant VWF, or whether it was simply wt VWF 
alone being secreted. 
 
 
Figure 3.19 Co-expression of C domain deletion mutants with wt VWF. The C domain 
deletion mutants were expressed in HEK293T cells either alone or co-expressed with wt 
FL-VWF. The concentration of VWF in media and lysate, determined by the VWF ELISA, 
is shown. Co-expression of wt VWF with the C domain deletion mutant rescued secretion 
in all cases, but to varying degrees. ∆C3 and ∆C1C2 had the most increased VWF 
secretion levels following co-transfection and their media:lysate ratios were comparable to 
wt (p=0.33 and 0.48 respectively). (Values shown here are mean ±SEM of three separate 
transfections performed in duplicate.)  
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In order to distinguish whether the C domain deletion mutants were secreted together with 
wt VWF, SDS-PAGE and Western blot were performed on the conditioned media of co-
transfections. The C domain deletion mutants were smaller in size than wt FL-VWF 
(between 63 and 465 amino acids). For the larger C domain deletions (∆C1-C6, ∆C3-C6-, 
and ∆C1C2 with 465, 262 and 173 amino acids deleted respectively) it was considered 
that this size difference from wt VWF could be detected on a gel. However, for the smaller 
deletions (∆C3 and ∆C3C4- with 63 and 115 amino acids deleted respectively) it was 
considered more likely to be able to distinguish these on a gel from ∆A1A3 VWF (444 
amino acids deleted) than from wt VWF. Therefore ∆C3 and ∆C3C4- were co-expressed 
with ∆A1A3 in HEK293T cells using the same method described above.  
 
The conditioned media and cell lysates from the co-expressions were then loaded onto a 
reducing SDS-PAGE gel at a concentration of 0.1µg/ml (or neat media if the detectable 
VWF was less than this), and VWF was detected by Western blot with polyclonal anti-
hVWF-HRP antibody. In these co-expression studies only the wt (Figure 3.20, A) or ∆A1A3 
(Figure 3.20, B) could be seen clearly on the gel, suggesting that whilst expression levels 
of these C domain deletion mutants could be rescued by co-expression with wt VWF, it 
was mainly the wt VWF that was secreted.  
 
 
 
 
Figure 3.20 Reducing gel of co-expression media. SDS-PAGE and Western blot were 
performed to examine the relative secretion of the C domain deletion mutants into the 
conditioned media following co-transfection with either wt FL-VWF or ∆A1A3 VWF. (A) 
Reducing gel of FL-wt alone and with ΔC1-C6, ΔC1C2 or ΔC3-C6-. (B) Reducing gel of 
ΔA1A3 alone and with ΔC3 or ΔC3C4-. None of the deletion mutants were secreted at 
detectable levels with wt or ΔA1A3. (The gel shown here is representative of gels from 
duplicate experiments.)  
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3.6 WHERE ARE DISULPHIDE BONDS FORMED AND BROKEN? 
 
Ganderton et al155 expressed wt VWF and 5 of the C→A mutants (C2431A, C2451A, 
C2453A, C2468A and C2431-C2453A) in the small monomeric C3C4 VWF fragment, and 
they all secreted, even forming different patterns of higher order oligomers. However in my 
studies, using fragments A3-CK (dimers) and A3-C6 (monomers), these C→A mutants 
were retained intracellularly. I was therefore interested to determine whether these smaller 
wt VWF fragments formed higher order oligomers in the media, as described for wt 
C3C4155.  
 
Conditioned media of wt A2-CK and wt A2-C6, which had been expressed in HEK293T 
cells during the previously described expression studies, were loaded onto a non-reducing 
gel in equal concentrations. SDS-PAGE and Western blot with polyclonal anti-VWF-HRP 
antibody was performed. The wt-VWF fragments were secreted predominantly as dimers 
and monomers respectively and did not show significant higher order oligomers (Figure 
3.21). This is in contrast to the results reported for the smaller C3C4 fragment155. This 
pattern was the same for wt A2-CK and A2-C6 expressed in HEK293 cells (data not 
shown).   
 
Interestingly both of the lysates showed higher order oligomers, most clearly seen for A2-
C6 (Figure 3.21).  The wt A2-CK and wt A2-C6 lysates were then reduced with β-
mercaptoethanol, loaded onto a gel, and SDS-PAGE and Western blot performed. The 
higher order oligomers resolved to monomers, indicating that they are disulphide-bonded 
(Figure 3.22, A). The lysates were then incubated with or without EndoH overnight at 37ºC 
(section 2.4.4.5) before being run on a non-reducing gel. EndoH was able to de-
glycosylate all the oligomers, indicating that the higher order oligomers are formed and 
retained within the ER (Figure 3.22, B). As these higher order oligomers are not secreted 
in significant amounts, it appears that they result from non-native disulphide bonds forming 
between subunits, and that either the disulphide bonds will be reduced and eventually a 
correctly folded monomer/dimer released from the cell, or that the abnormal disulphide-
bonded aggregates will eventually be degraded235,239,240. 
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Figure 3.21 A2-CK and A2-C6 fragments form higher order oligomers in cell lysates. 
SDS-PAGE and Western blot was used to examine higher order oligomer formation in the 
media and cell lysates of HEK293T cells. Non-reducing gel of wt media and lysates in A2-
CK and A2-C6 with reduced (R) wt A2-CK media as a size control. The wt VWF A2-CK 
and A2-C6 fragments were secreted predominantly as dimers and monomers respectively, 
although both of their lysates showed higher order oligomers. The bands in the lysates are 
slightly smaller in size than the equivalent band in the media, possibly due to incomplete 
carbohydrate processing. The reduced wt A2-CK size control migrates less far through the 
gel than the non-reduced monomer as its conformation is more open. (The gel is 
representative of 3 separate experiments.)  
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Figure 3.22 The higher order oligomers in cell lysates are disulphide-bonded and 
cleaved by EndoH. SDS-PAGE and Western blot was used to examine higher order 
oligomer formation in the media and cell lysates from transfections in HEK293T cells. The 
media and lysate of wt A2-CK and wt A2-C6 was either reduced (R) or non-reduced (NR). 
(A) The higher order oligomers visible in the lysates of A2-CK and A2-C6 resolve to 
monomers on being reduced, indicating that they are disulphide-bonded. (B) The higher 
order oligomers are cleaved by EndoH, suggesting they are all formed and retained within 
the ER. (The gels shown are representative of at least duplicate experiments.) 
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For interest, the lysates of the cysteine mutants proposed to be of functional importance 
by Ganderton et al155 (C2431A, C2451A, C2453A and C2468A and C2431A-C2453A), 
and that had been expressed in the A2-CK fragment in HEK293T cells (and retained 
intracellularly), were then loaded onto a non-reducing gel and SDS-PAGE and Western 
blot performed. The lysates of all the mutants (except perhaps C2431A) showed 
enhanced higher order oligomers compared to wt. (Figure 3.23). In addition, the media 
and lysates of ∆C3 in A3-CK and A3-C6 (which secreted) were run on a non-reducing gel 
and compared to wt. Interestingly, although C3 contains the majority of the cysteines 
hypothesised to be important in lateral self-association, the oligomeric pattern of the media 
and lysates is similar to wt (Figure 3.24).  
 
 
 
 
 
Figure 3.23 C→A mutant A2-CK fragments form higher order oligomers in cell 
lysates. SDS-PAGE under non-reducing conditions and Western blot was used to 
examine higher order oligomer formation in the media and cell lysates of wt and C→A 
mutants in A2-CK fragment, from transfections in HEK293T cells.  Reduced (R) wt A2-CK 
media as a size control. The lysates for the C→A mutants (except perhaps C2431A) show 
enhanced higher order oligomers compared to wt. (The gels shown are representative of 
at least duplicate experiments.)  
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Figure 3.24 Media and lysates of ΔC3 in A2-CK and A2-C6 VWF fragments form 
similar pattern of oligomers to wt. SDS-PAGE under non-reducing conditions and 
Western blot was used to examine higher order oligomer formation in the media and cell 
lysates from transfections in HEK293T cells. Reduced (R) wt A3-CK media was used as a 
size control. The media and lysates of wt and ΔC3 in A3-CK and A3-C6 show a similar 
pattern. (The gel shown is representative of at least duplicate experiments.)  
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3.7 DISCUSSION 
VWF contains a number of free thiols which have been located to some or all of nine 
cysteine residues: C889, C898, C2448, C2490, C2491, C2451, C2453, C2528 and C2533 
in both pd and recombinant VWF155,208. After VWF was exposed to shear in a cone-plate 
viscometer, these free thiols were no-longer detected, but the VWF showed increased 
platelet binding208. In separate experiments, it has been reported that VWF can laterally 
self-associate198.  It has thus been postulated that the loss of free thiols results from their 
participation in new disulphide bonds between VWF multimers, causing the lateral self-
association of VWF. This increases the overall size of VWF and thus increases platelet 
capture. It is therefore curious that recently proposed models of the VWF C domains, 
based on sequence homology with typical C domains in other proteins, have predicted that 
in fact all these cysteines should be paired in the mature molecule152,155.  Nonetheless, 
structural and expression work using small fragments of VWF has subsequently provided 
further evidence that two of the above cysteines, C2431 and C2451, may participate in 
lateral self-association155. This project therefore aimed to explore the origin and fate of 
cysteines and their thiol groups in the function of full-length VWF. 
 
A search of the Sheffield VWF database to look for known naturally occurring mutations of 
any of these cysteines, or their predicted binding partners152,155 was uninformative. It 
revealed one mutation of the nine candidate free thiols (C2533X) associated with VWD.  
However this is a stop codon and so does not assist in understanding the function of the 
cysteine residues. 
 
3.7.1 Cysteine point mutations 
To investigate the importance of cysteines in the synthesis and structure of VWF, eleven 
individual cysteine to alanine point mutations were made; comprising the nine potential 
free thiol sites identified by Choi et al208 and two additional sites predicted to be disulphide 
partners with two of them (C2431A and C2468A)152,155. One double point mutant (C2431A-
C2453A) was also made to avoid leaving unpaired cysteines and this has also been 
predicted to be a key functional disulphide pair155. The other disulphide pair which has 
been proposed as having key functional importance (C2451A-C2468A) was not made as a 
double mutant, as this failed to secrete when made in a small VWF fragment (C3C4)155. 
When expressed in HEK293T cells, all C→A mutants (including the double mutant) 
showed almost total intracellular retention (Figures 3.2 and 3.3). This suggests that the 
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proteins were misfolded and targeted for degradation and confirms the preliminary 
conclusion from the homology analyses that these cysteines have an important structural 
role in the assembly of VWF into its native configuration. Cells have multiple quality control 
mechanisms, particularly in the ER, for ensuring only correctly folded proteins are secreted 
from the cell. The molecular chaperones and associated systems in the ER (which include 
thiol isomerases such as PDI) recognise abnormalities such as exposed hydrophobic 
amino acids, free thiols, defective glycosylation and protein aggregation235-237,240,241. This 
results in ER retention until either the protein is re-folded into its native conformation, or 
until it is targeted for degradation235,242. Even relatively minor changes in conformation may 
result in ER retention. The process of folding is dynamic, that is, there are structural 
fluctuations243. An abnormality which causes decreased stability of the native 
conformation, will result in increased fluctuations of conformations and increased time 
spent in a non-native conformation within the ER, increasing the likelihood of retention. 
The entropy of the folded protein has been shown to be an important determinant of the 
efficiency of secretion, the higher the entropy the more efficient the secretion244,245. 
Proteins that are terminally misfolded are retro-translocated to the cytosol where they are 
degraded by proteasomes (ER-associated degradation, ERAD). Pulse chase labelling, 
combined with the use of proteasome inhibitors to block degradation, has shown that 30-
75% of newly synthesised proteins are degraded within 20 minutes246,247. 
 
In order to investigate whether the cysteine mutations resulted in intracellular retention due 
to localised mis-folding or due to a more generalised conformational change, such as with 
multimerisation, some of the mutants were expressed in VWF fragments. The cysteines 
which were investigated the most intensely by this method were the ones which Ganderton 
et al155 had proposed to be of key functional importance. The C→A mutants failed to 
secrete in either A2-CK or A3-CK dimeric fragments or in the monomeric A2-C6 fragment 
(Figure 3.5). This suggests that these cysteines form disulphide bonds which are crucial 
for the folding of the domain itself and without them the misfolded or incomplete molecule 
is retained and targeted for degradation. Cysteine to alanine is a standard innocuous 
substitution, but it changes the polarity of the amino acid backbone. A further cysteine 
mutant was therefore made, mutating the cysteine to serine (polar). However this also 
failed to secrete, suggesting that it is the cysteine itself which is essential for secretion, 
and therefore probably the ability to form disulphide bonds. Interestingly, this is in contrast 
to work published during the course of this PhD in which C2431A, C2451A, C2453A, 
C2468A and C2431A-C2453A were expressed in a considerably smaller VWF fragment, 
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monomeric C3C4 (2429-2495), and in which they apparently all secreted with some 
forming higher order oligomers155. However, the secreted VWF was only analysed by 
Western blot of the conditioned media. It is therefore impossible to know how well the 
mutants were secreted. Western blot is extremely sensitive, as demonstrated by the 
detection of a band in the media for most of the C domain deletion mutants (Figure 3.18, 
B). Without comparing the media and lysate samples it is therefore not possible to tell how 
efficiently the mutants secreted. Perhaps the mutants secreted poorly, or perhaps they 
secreted well but the C3C4 fragment may simply be small enough to either escape the 
cell’s mechanisms for recognition of abnormal protein, or to be produced in such large 
quantities that some of it inevitably escapes and is secreted248-250. 
 
Co-expression studies were performed to investigate whether wt VWF could rescue the 
secretion of mutant VWF. Wt and mutant monomers might pair as dimers, perhaps 
preventing exposure of either free thiols forming abnormal conjugates or hydrophobic 
patches, and allow secretion. Co-expression of wt with the C→A mutants produced some 
secretion in all cases, but to varying degrees (Figure 3.9). Co-expression with a shortened 
∆A1-A3 fragment showed that in the majority of cases it was only the wt-VWF protein that 
was secreted. However C889A, C898A, C2490A, C2491A and C2533A were secreted in 
small amounts alongside wt VWF (Figure 3.11). There was no correlation between the 
level of VWF in the media with either co-secretion of wt and mutant VWF monomers or 
with secretion of wt VWF monomers alone. As the majority of C→A co-expressions 
showed reduced VWF concentration in the media compared to wt alone, it suggests a 
dominant negative effect of the mutant, which is typical of VWD. Multimer gel analysis of 
secreted VWF from these five mutants demonstrated normal multimeric pattern, 
suggesting that these mutant monomers can be incorporated with normal monomers to 
form grossly normal multimeric structures (Figure 3.12). 
 
Disulphide bond formation is believed to occur primarily in the ER where there are a 
number of proteins with PDI activity and correct protein folding is ensured by complex 
quality control mechanisms, as previously described235,251,252. I therefore explored the point 
in processing at which the mutant protein was being retained within the cell. Reducing gels 
of cell lysates showed that all the C→A mutants were retained mainly as pro-VWF (that is, 
containing the un-cleaved propeptide), as opposed to wt VWF in the lysate which was 
mainly processed (Figure 3.7). Furthermore, EndoH was able to cleave the majority of the 
retained mutant protein, confirming that it was retained within the ER (Figure 3.8). These 
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data demonstrate that the mutant proteins containing C→A mutations are recognised as 
mis-folded early in processing. The failure to form a disulphide bond may prevent the 
domain from reaching its favourable conformation, or the free thiol might be directly 
recognised by a chaperone thiol oxidoreductase, resulting in ER retention. One 
explanation for the finding of free thiols in pd and recombinant VWF, is that the cysteines 
form critical disulphide bonds during the assembly and folding of the VWF C domains; 
possibly in a sequential fashion so that the formation of later disulphide bonds is 
dependent on the formation of preceding ones. However, once the protein in correctly 
folded, some disulphide bonds may be broken without loss of tertiary structure.  The 
subsequent breaking of disulphide bonds may be mediated by changes in the pH, shear 
forces during secretion, or the presence of isomerases (platelet PDI or intrinsic isomerase 
activity of VWF). 
 
3.7.2 C domain deletion mutations 
Theoretically, even though disrupting individual or paired cysteines within a domain results 
in retention, it might be possible to remove an intact C domain and for the mutant to 
secrete. If C domain deletion mutants secreted it would result in protein that could be 
tested in functional assays, including perfusion assays to examine self-association. A 
series of C domain deletion mutants were therefore made. As previously discussed, during 
the course of this PhD the understanding of the structure of the C-terminus has improved 
and consequently the annotation has changed from two to six C domains152 (section 
1.3.3). Thus the original domain deletion mutants which corresponded to deletion of 
Sadler’s domains C1C2 and C1 were respectively renamed:  ∆C3-C6- (∆2400-2662) and 
∆C3C4- (∆2400-2515). Failure of these to secrete (Figure 3.13) may have been a result of 
the incorrect boundaries and so further C domain deletion mutants were subsequently 
made based on the new domain boundaries: ∆D4-C6 (∆1875-2720), ∆C1-C6 (∆2255-
2720), ∆C1C2 (∆2255-2428), and ∆C3 (∆2431-2494). When expressed in HEK293T cells 
all of these mutants, other than ∆D4-C6, failed to secrete (Figure 3.13). Whilst these are 
apparently drastic mutations, this was surprising given that it is possible to delete either of 
the A1 or A3 domains whilst retaining normal expression levels (see Chapter 5, Figure 
5.12), and even deletion of both A1 and A3 (∆A1A3) still permits reasonable secretion 
(Figure 3.10). It is also intriguing that it is actually the biggest deletion (∆D4-C6) which 
secretes with an efficiency comparable to wt. It might be argued that ∆D4-C6 results in a 
small enough protein to escape the cells mechanisms for recognition of an abnormal 
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protein and therefore ER retention and subsequent degradation. This argument is 
consistent with the results that ∆C1-C6, the next biggest deletion, is partly secreted. 
However, ∆C1-C6 is only secreted at v low levels whereas ∆D4-C6 is expressed at 
comparable levels to wt and its multimer pattern appears normal (Chapter 6, Figure 6.3). 
An alternative possible explanation is that in the full-length dimer, the C domains need to 
be intact to allow correct folding and secretion (perhaps because of the dimeric ‘stem and 
bouquet’ structure of the C terminus during packaging in WPBs56) (section 1.2.5), but that 
if the D4 domain (part of the ‘raceme’) is removed along with all of the C domains the 
protein can be folded and packaged correctly. In order to investigate this hypothesis the 
deletion mutants were expressed in VWF fragments, some of which were monomeric.  
 
The retained deletion mutants were expressed in VWF fragments, in a similar manner to 
the C→A mutants. ∆C3 and ∆C3C4- were not secreted in either dimeric A2-CK or 
monomeric A2-C6, suggesting that the mechanism of retention is not due to failure of 
packaging into the dimeric ‘stem and bouquet’ in WPBs. However, intriguingly ∆C3 was 
secreted in A3-CK and smaller VWF fragments (Figure 3.17). This pattern is in contrast to 
both the other deletion mutant tested (C3C4-) (Figure 3.16) and the C→A mutants tested 
(C2431A, C2491A, C2431A-C2453A) (Figure 3.5). It is possible than ∆C3, as the smallest 
deletion mutant of a single intact C domain, is the least disruptive domain deletion and that 
when it is expressed in a small enough fragment it escapes the cells recognition 
mechanisms for mis-folded proteins. However, the change in size between A2-CK and A3-
CK is less than 200 amino acids and makes this explanation seem unlikely. Alternatively, 
when the A2 domain is present the removal of C3 from the ‘stem’ prevents correct folding, 
but the additional removal of the A2 domain changes the conformation or stability allowing 
secretion. 
 
In order to perhaps shed light on the mechanism/cause of intracellular retention, the 
location of where these C domain deletion mutants were retained was explored. Reducing 
gels of cell lysates showed that the C domain deletion mutants were retained mainly as 
pro-VWF (that is, containing the un-cleaved propeptide), as opposed to wt VWF in the 
lysate which was mainly processed (Figure 3.18, A). Furthermore, EndoH was able to 
cleave the majority of the retained mutant protein, confirming that it was retained within the 
ER (Figure 3.18, B). These data demonstrate that the retained C domain deletion mutant 
proteins, similar to the C→A mutants, are recognised as misfolded early in processing and 
fail to exit the ER. However in contrast to some of the C→A mutants, although co-
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expression with wt rescued secretion levels (Figure 3.19), it was due to secretion of wt 
alone (Figure 3.20). Thus none of the C domain deletion monomers could be incorporated 
with normal monomers into multimers. The cause of ER retention of the C domain deletion 
mutants is not clear. Possible explanations include exposure of hydrophobic amino acids 
on neighbouring domains, loss of glycoproteins, or a decrease in the conformational 
stability of the protein. 
 
3.7.3 Where are disulphide bonds formed and broken? 
The study by Ganderton et al155 showed that the wt C3C4 fragment secreted into the 
media and was detected as higher order disulphide-bonded oligomers. However, a wt 
C3C4 fragment expressed by Zhou et al152 appeared in media only as a monomeric band.  
Interestingly, the larger wt fragment (C1-C6) expressed by Ganderton et al155 did not form 
significant higher order multimers. Similarly, we found no evidence of significant higher 
order multimers secreted in the media by wt A2-CK, A2-C6, A3-CK or A3-C6 (Figures 3.21 
and 3.24). Regarding the mechanism proposed for lateral self-association by Ganderton et 
al155  (section 1.5.3, Figure 1.8), it is difficult to extrapolate the ability of a small fragment to 
be secreted as higher order oligomers (or to form them in the conditioned media after 
secretion) to the behaviour of full-length dimers in the plasma, in particular when larger 
VWF fragments do not behave in a similar manner when expressed. 
 
Interestingly, we did find that there were higher order oligomers in the cell lysates of wt A2-
CK and A2-C6 fragments, which were disulphide-bonded (Figure 3.22, A) and formed and 
retained within the ER (Figure 3.22, B). The lysates of the retained C→A mutants also 
contained higher order oligomers, that appeared enhanced compared to those of wt 
(Figure 3.23). The ΔC3 mutant (which lacks all 4 of the cysteines in Ganderton’s proposed 
model of self-association) showed a similar oligomeric pattern to wt fragments in both the 
media and lysate (Figure 3.24). Whilst interesting, interpretation of these data is limited. It 
is unclear how these higher order oligomers in our cell lysates relate to those C3C4 
oligomers previously reported in media155, because although it does demonstrate that 
VWF monomers can disulphide-bond to each other laterally, it indicates that this occurs 
within the ER and is recognised as abnormal by the quality control mechanisms in the ER. 
For wt VWF fragments it is not known whether the higher order oligomers seen in the cell 
lysate will be reduced and eventually released from the cell when correctly folded, or 
whether they will be targeted for degradation235,239,240. Whilst it appears that there are 
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similar but enhanced higher order disulphide-bonded oligomers in cell lysates of the C→A 
VWF fragments compared to wt, which are not secreted and must therefore be recognised 
as abnormal, retained within the ER and eventually degraded, this cannot be compared 
directly with oligomeric patterns seen in the media of smaller fragments. 
 
 
 
Pairing of the cysteines, which have been found to be possibly free in a proportion of 
monomers, appears to be essential for the normal synthesis of VWF. These cysteines 
form critical disulphide bonds during the assembly and folding of the VWF C domains; 
possibly in a sequential fashion so that the formation of later disulphide bonds is 
dependent on the formation of preceding ones due to sequential conformational changes. 
Furthermore, the C-domains must be intact for normal synthesis and secretion of VWF. 
Deletion of an intact C-domain may result in ER retention due to exposure of hydrophobic 
amino acids on neighbouring domains, loss of glycoproteins, or perhaps by decreasing the 
conformational stability of the protein. However, once the protein is correctly folded, some 
disulphide bonds may be broken without loss of tertiary structure.  Where these disulphide 
bonds are subsequently broken has not yet been elucidated. It might be mediated by 
changes in the pH, shear forces during secretion, or the presence of isomerases (platelet 
PDI or intrinsic isomerase activity of VWF). As all of the cysteine point mutants and 
domain deletion mutants (other than ΔD4-C6) were retained intracellularly, I was unable to 
explore the role of these free thiols in VWF using functional assays. The function of ΔD4-
C6 VWF will be discussed in Chapter 6. 
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CHAPTER 4: POTENTIAL THIOL ISOMERASE ACTIVITY OF 
CONSERVED CXXC MOTIFS IN D3, D4 AND C1 DOMAINS 
 
4.1 INTRODUCTION 
Thiol isomerase proteins catalyse thiol-disulphide interchange reactions. They share a 
common CXXC motif in their active site(s). The ability of the active site to be an efficient 
isomerase, oxidant or reductant depends on the reduction potential of the active site 
disulphide bond and the acid dissociation constant of the nucleophilic active site thiol. The 
reduction potential of the active sites is modulated by variations in the -XX- residues216, the 
conformational flexibility of the active site motif217, and the electrostatic charges of nearby 
amino acids (such as positively charged histidines)218 (section 1.6.1). 
 
The ER contains thiol isomerase enzymes and with its neutral pH is considered the 
optimal environment for disulphide bond formation. VWF dimerises in the ER through 
disulphide bond formation, thought to be catalysed by resident thiol isomerase enzymes. 
However VWF multimerises in the Golgi which, unlike the ER, lacks a high concentration 
of thiol isomerases and is relatively acidic which generally prevents disulphide 
rearrangement. To overcome these conditions, VWF appears to use its own propeptide to 
promote formation of the disulphide bonds at the N-terminus of dimers, to form multimers. 
The propeptide contains two CGLC motifs at positions 159 and 521. Whilst the isomerase 
activity of the propeptide has not been shown directly using a PDI activity assay219, there is 
significant indirect evidence of the thiol isomerase activity of these motifs28,219,220,222-224 
(section 1.6.2). Similarly, the CGLC motif in the D1 domain of submaxillary porcine mucin 
appears to catalyse oligomerisation253. 
 
Thiol isomerases have recently been implicated in regulating another aspect of VWF 
function. It has been reported that under shear conditions VWF laterally self-associates by 
the formation of new disulphide bonds between multimers, resulting in an increase in size 
and an increase in platelet binding (section 1.5). Thus self-association is potentially an 
important mechanism for regulating VWF function. Recent work has focused on which 
cysteines may be involved in providing the free thiols for thiol-disulphide exchange155,208, 
however how it might be catalysed remains unknown. It has been postulated that while 
shear stress alone may be sufficient for this thiol-disulphide exchange104, it may be 
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catalysed by a thiol isomerase: perhaps PDI on the surface of the platelets or a thiol 
isomerase intrinsic to VWF itself.  
 
Analysis of the VWF primary amino acid sequence shows that VWF contains 16 CXXC 
sites (whereas CXXC motifs are otherwise relatively rare, only present in 3.7% 
proteins225). Three of these sites are similar to the CGLC motifs in D1 and D2 (994CGLC in 
D3, 2085CGIC in D4 and 2304CGLC in C1) and are conserved across domains and species 
(section 4.2). Yet the potential thiol isomerase activity and function of these conserved 
CG(L/I)C motifs in D3, D4 and C1 have not been reported. These motifs might either be 
important for the intracellular synthesis of VWF or play a role extracellularly, for example in 
catalysing the thiol-disulphide exchange of lateral self-association. 
 
4.1.2 Hypothesis 
The conserved CG(L/I)C motifs in D3, D4 and C1 (994CGLC, 2085CGIC and 2304CGLC 
respectively) possess thiol isomerase activity and play a role either in the intracellular 
synthesis and processing of VWF or in its extracellular function, for example in catalysing 
the thiol-disulphide exchange of self-association. 
 
4.1.3 Aims 
To examine whether the conserved CG(L/I)C motifs in D3, D4 and C1 (994CGLC, 2085CGIC 
and 2304CGLC respectively) possess thiol isomerase activity by expressing recombinant 
mutants and studying their structure and function. 
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4.2 IN SILICO ANALYSIS 
Using the UniProt database (http://www.uniprot.org/uniprot/), in silico analysis of the amino 
acid sequence for human VWF (P04275) shows that there are 16 CXXC motifs clustered 
in the D and C domains. Of these, the vicinal cysteines in the D1 and D2 domains 
(159CGLC and 521CGLC) are the only ones for which apparent thiol isomerase activity has 
been demonstrated219 (section 1.6.2). There are three other chemically similar CG(L/I)C 
motifs within VWF and these were studied initially, rather than the other CXXC motifs, as it 
is known that the -XX- residues are important for determining thiol isomerase activity 
(section 1.6.1). ClustalX 2.0 software was used to align the VWF amino acid sequences of 
human (PO4275), mouse (Q8C1Z8), pig (Q28833), canine (Q28295), and bovine 
(F5XVA9) VWF D and C domains. For human VWF, this shows that the CGLC motifs in 
D1 and D2 are conserved across the D3 and D4 domains: D3 contains the same motif 
sequence 993CGLC; D4 a very similar sequence, 2085CGIC, displaced by 2 amino acids 
(Figure 4.1). These motifs are also conserved across species (Figure 4.3, A and B).  
 
The C1 domain contains a similar motif, 2304CGLC, but the overall domain sequence and 
structure of the C domain is different to that of the D domains and the C domains cannot 
therefore be aligned against the D domains. However, the C1 domain was aligned against 
the other VWF C domains on the UniProt site. Of note, the UniProt site describes VWF as 
having 3 classical C domains with 3 ‘linker’ regions. However, as discussed previously 
(section 1.3.3), recent analyses have resulted in an improved understanding that these 
‘linker’ regions share many of the characteristics of C domains and are probably C 
domains as well152,155. I performed the in silico analysis of the 3 C domains on the UniProt 
site at the start of my PhD, prior to publication of the more recent models and aligned them 
against the classical C domain of collagen IIA. In order to make this consistent with the 
new annotation of the C-terminus of VWF I have named the 3 UniProt C domains (C1-C3) 
C1, C3 and C5 respectively. VWF C1 was the only domain to contain a CGLC motif (also 
true when the ‘linker regions’ were analysed152,155) (Figure 4.2) but this motif is conserved 
across species (Figure 4.4).  
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                      *        20         *        40         *        60         *        80         *       100         *       120          
VWF_humanD1   : RCSLFGSDFVNTFDGSMYSFAGYCSYLLAGGCQKRSFSIIGDFQNGK-------RVSLSVYLGEFFD--IHLFVNGTVTQGD--QRVSMPYASKGLYLETE--AGYYKLSGEAYGFVARIDGS  
VWF_humanD2  : ECLVTGQSHFKSFDNRYFTFSGICQYLLARDCQDHSFSIVIETVQCADDRDAVCTRSVTVRLPGLHNSLVKLKHGAGVAMDG--QDIQLPLLKGDLRIQHT--VTASVRLSYGEDLQMDWDGR  
VWF_humanD3  : TCSTIGMAHYLTFDGLKYLFPGECQYVLVQDYCGSNPGTFRILVGNK---------GCSHPSVKCKKRVTILVEGGEIELFDGEVNVKRPMKDETHFEVVE--SGRYIILLLGKALSVVWDRH  
VWF_humanD4  : VCTGSSTRHIVTFDGQNFKLTGSCSYVLFQNKEQDLEVILHNGACSPG------AGQGCMKSIEVKHSALSVELHSDMEVTVNGRLVSVPYVGGNMEVNVYGAIMHEVRFNHLGHIFTFTPQN  
                                                                                                                     
                   *       140         *       160         *       180         *       200         *       220        
VWF_humanD1  : GNFQVLLSD-RYFNKTCGLCGNFNIFAEDDFMTQEGTLTSDPYDFANSWALSSGEQWCERASPPSSSCNISSGEMQKGLWEQCQLLKSTSVFARCHPL : 207 
VWF_humanD2  : GRLLVKLSP-VYAGKTCGLCGNYNGNQGDDFLTPSGLAEPRVEDFGNAWKLHGDCQDLQKQ--HSDPCALNP-RMTRFSEEACAVLTSP-TFEACHRA : 212 
VWF_humanD3  : LSISVVLKQ-TYQEKVCGLCGNFDGIQNNDLTSSNLQVEEDPVDFGNSWKVSSQCADTRKVPLDSSPATCHNNIMKQTMVDSSCRILTSDVFQDCNKL : 209 
VWF_humanD4  : NEFQLQLSPKTFASKTYGLCGICDENGANDFMLRDGTVTTDWKTLVQEWTVQRPGQTCQPILEEQCLVPDSS---------HCQVLLLP-LFAECHKV : 205 
         CGLC 
 
Figure 4.1 Sequence alignment of human VWF D domains (D1-4). D domain sequences of human VWF (UniProt database, P04275) were 
aligned using ClustalX 2.0. Overall the domains share approximately 30% sequence homology (9.2% identical). There is a conserved CGLC 
motif across the D1, D2 and D3 domains. D4 contains a similar CGLC motif, displaced by 2 amino acids.       
  
 
 
 
                       *        20         *        40         *        60         *        80         
VWF_C1        : TQCIGEDGVQHQFLEAWVPDHQPCQICTCLS--GRKVN-----CTTQPCPTAKAPTCGLCEVARLRQNADQCCPEYECVCD-- : 74 
VWF_C3        : KVCVH-RSTIYPVG-QFWEE--GCDVCTCTDMEDAVMGLRVAQCSQKPCED----SCRSGFTYVL--HEGECCGR--CL---- : 67 
VWF_C5        : EACML-NGTVIGPGKTVMID--VCTTCRCMVQVGVISGFKL-ECRKTTCN-----PCPLGYKEEN--NTGECCGR--CL---- : 66 
Collagen IIA  : GSCVQ-DGQRYNDKDVWKPE--PCRICVCDT--GTVL------CDDIICE--DVKDCLS---PEI--PFGECCPI--CP---- : 59 
                 C                    C  C C              C    C       CGLC           CC    C           
 
Figure 4.2 Sequence alignment of human VWF C domains (C1, C3 and C5) and human collagen IIA VWF C type domain. The C domain 
sequences of human VWF (UniProt database, P04275) were aligned to the classical C domain of human collagen IIA (P02458) using ClustalX 
2.0. The VWF C1 domain has an extra cysteine residue which forms the second vicinal cysteine of the CGLC motif (highlighted by red box). 
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VWF_hD1:RCSLFGSDFVNTFDGSMYSFAGYCSYLLAGGCQKRSFSIIGDFQNGK-------RVSLSVYLGEFFD--IHLFVNGTVTQGD—QRVSMPYASKGLYLETE-AGYYKLSGEAYGFVARIDGS  
VWF_mD1:RCSLFGDDFINTFDETMYSFAGGCSYLLAGDCQKRSFSILGNFQDGK-------RMSLSVYLGEFFD--IHLFANGTVMQGD--QSISMPYASQGLYLELEAGYYKLSSETFGFAARIDGN 
VWF_cD1:RCSLFGGDFINTFDESMYSFAGDCSYLLAGDCQEHSVSLIGGFQNGK-------RVSLSVYLGEFFD--IHLFVNGTMLQGT--QSISMPYASNGLYLEAEAGYYKLSSEAYGFVARIDGN  
VWF_pD1:ECLVTGQSHFKSFDNRHFTFSGVCQYLLARDCQDHTFSVIIETVQCADDPDAVCTRSVTVRLPSPHNSLVKLKHGGGVAMDG--WDVQIPFLQGDLRIQHTVMASVHLSYGEDLQIDWDGR  
VWF_bD1:RCSLFGADFINTFDESMYSFSGDCSYLLAGDCKTHSFSIVGDFQGGR-------RMGLSVYLGEFFD--IHVFVNGTVLQGG--QHVSMPYATRGLYLETEVGHHKLSSESYGFVARIDGS  
                                                                                                                             
VWF_hD1:GNFQVLLSD-RYFNKTCGLCGNFNIFAEDDFMTQEGTLTSDPYDFANSWALSSGEQWCERASPPSSSCNISSGEMQKGLWEQCQLLKSTSVFARCHPL:207 
VWF_mD1:GNFQVLMSD-RHFNKTCGLCGDFNIFAEDDFRTQEGTLTSDPYDFANSWALSSEEQRCKRASPPSRNCESSSGDMHQAMWEQCQLLKTASVFARCHPL:207 
VWF_cD1:GNFQVLLSD-RYFNKTCGLCGNFNIFAEDDFRTQEGTLTSDPYDFANSWALSSGEQRCKRVSPPSSPCNVSSDEVQQVLWEQCQLLKSASVFARCHPL:207 
VWF_pD1:GRLLVKLSP-VYAGRTCGLCGNYNGNQGDDFLTPAGLVEPLVEHFGNAWKLHGDCEDLRKQ--PTDPCSFNP-RLTRFAEEACAILTSP-KFQACHDA:212 
VWF_bD1:GNFQILLSD-RHFNKTCGLCGDFNIFAEDDFRTQEGTLTSDPYDFANSWALSSEEQRCPRVSPPSSSCNVSS-ELQKGLWEKCQLLKTASVFARCHAL:206 
             CGLC 
 
VWF_hD2:ECLVTGQSHFKSFDNRYFTFSGICQYLLARDCQDHSFSIVIETVQCADDRDAVCTRSVTVRLPGLHNSLVKLKHGAGVAMDG--QDIQLPLLKGDLRIQHTVTASVRLSYGEDLQMDWDGR  
VWF_mD2:ECLVTGQSHFKSFDNRYFTFSGICQYLLARDCEDHTFSIVIETMQCADDPDAVCTRSVSVRLSALHNSLVKLKHGGAVGIDG--QDVQLPFLQGDLRIQHTVMASVRLSYAEDLQMDWDGR  
VWF_cD2:ECLVTGQSHFKSFDNRYFTFSGVCHYLLAQDCQDHTFSVVIETVQCADDLDAVCTRSVTVRLPGHHNSLVKLKHGGGVSMDG--QDIQIPLLQGDLRIQHTVMASVRLSYGEDLQMDWDGR   
VWF_pD2:SCSALGLAHYLTFDGLKYLFPGECQYVLVQDYCGSNPGTFRILLGNE---------GCGYPSLKCRKRVTILVDGGEIELFDGEVMVKKPLKDETHFEVVESGRFITVLLGSGLSVVWDRH  
VWF_bD2:ECLITGQSHFKSFDDRHFTFSGVCQYLLAQDCQDHSFSVVIETVQCADDPDAVCTRSVTVRLPSPHHGLLKLKHGGGVALDG--QDVQIPLLQGDLRIQHTVTASLQLNFGEDLQIDWDGR  
                                                                                                                                   
VWF_hD2:GRLLVKLSP-VYAGKTCGLCGNYNGNQGDDFLTPSGLAEPRVEDFGNAWKLHGDCQDLQKQ--HSDPCALNP-RMTRFSEEACAVLTSP-TFEACHRA:212 
VWF_mD2:GRLLVKLSP-VYSGKTCGLCGNYNGNKGDDFLTPAGLVEPLVVDFGNAWKLQGDCSDLRRQ--HSDPCSLNP-RLTRFAEEACALLTSS-KFEACHHA:212 
VWF_cD2:GRLLVTLSP-AYAGKTCGLCGNYNGNRGDDFVTPAGLAEPLVEDFGNAWKLLGACENLQKQ--HRDPCSLNP-RQARFAEEACALLTSS-KFEPCHRA:212 
VWF_pD2:LGISVFLKQ-TYQEQVCGLCGNFDGVQNNDLTGSSLQVEEDPVDFGNSWKVSPQCADTRKVPLDTSPATCHNNVMKQTMVDSSCRILTSDIFQDCNKL:209 
VWF_bD2:GRLLLKLSP-VYAGRTCGLCGNYNGNQRDDFLTPAGLVEPLVEHFGNSWKLRADCEDLQEQ--PSDPCSLNP-RLTKFADQACAILTSP-KFEACHSA:212 
                        CGLC 
 
 
Figure 4.3 (A) Sequence alignment of VWF D1 and D2 domains across species. VWF D domain sequences from UniProt database were 
aligned using ClustalX 2.0 for the following species: human (h) P04275, mouse (m) Q28295, canine (c), pig (p) QQ28833, and bovine (b) 
F5XVA9. The CG(L/I)C motif in the individual D domains is conserved across species. 
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VWF_hD3:TCSTIGMAHYLTFDGLKYLFPGECQYVLVQDYCGSNPGTFRILVGNK---------GCSHPSVKCKKRVTILVEGGEIELFDGEVNVKRPMKDETHFEVVESGRYIILLLGKALSVVWDRH  
VWF_mD3:TRSAIGMAHYLTFDGLKYLFPGECQYVLVYDYCGSNPGTFQILVGNE---------GCSYPSVKCRKRVTILVDGGELELFDGEVNVKRPLRDESHFEVVESGRYVILLLGQALSVVWDHH  
VWF_cD3:TCSAIGMAHYLTFDGLKYLFPGECQYVLVQDYCGSNPGTFRILVGNE---------GCSYPSVKCKKRVTILVEGGEIELFDGEVNVKKPMKDETHFEVVESGQYVILLLGKALSVVWDHR  
VWF_pD3:VCTGSSTRHIVTFDGQNFKLMGNCSYVLFHNKEQDLEVILHNGACGAG----ARQACMKSIEVKHNGLSVELHRDMEVVVNGRQVSVPYVGGNMEVGIYGTIMYEVRFNHLGHILTFTPQN  
VWF_bD3:SCSALGLAHYFTFDGLKYLFPGECQYVLVQDHCGSNPGTFRVLVGNE---------GCSVPSLKCRKRITILVEGGEIELFD--------------------------------------- 
 
VWF_hD3:LSISVVLKQ-TYQEKVCGLCGNFDGIQNNDLTSSNLQVEEDPVDFGNSWKVSSQCADTRKVPLDSSPATCHNNIMKQTMVDSSCRILTSDVFQDCNKL:209 
VWF_mD3:LSISVVLKH-TYQEQVCGLCGNFDGIQNNDSTTSSLQVEEDPVNFGNSWKVSSQCADTRKLSLDVSPATCHNNIMKQTMVDSACRILTSDVFQGCNRL:209 
VWF_cD3:LSISVTLKR-TYQEQVCGLCGNFDGIQNNDFTSSSLQIEEDPVDFGNSWKVNPQCADTKKVPLDSSPAVCHNNIMKQTMVDSSCRILTSDIFQDCNRL:209 
VWF_pD3:NEFQLQLSPKTFASKMYGLCGICDENGANDFMLRDGTVTTDWKTMVQEWAVQQPGQMCQPVPKEQCPVSGGY---------QCQVLLSA-LFAECHKV:205 
VWF_bD3:--------------------------------------------------------------------------------------------------:73 
             CGLC 
 
VWF_hD4:VCTGSSTRHIVTFDGQNFKLTGSCSYVLFQNKEQDLEVILHNGACSPG----ARQGCMKSIEVKHSALSVELHSDMEVTVNGRLVSVPYVGGNMEVNVYGAIMHEVRFNHLGHIFTFTPQN  
VWF_mD4:VCTGSSTRHIVTFDGQNFKLTGSCSYVIFQNKEQDLEVLLHNGACSPG----AKQACMKSIEIKHAGVSAELHSNMEMAVDGRLVLAPYVGENMEVSIYGAIMYEVRFTHLGHILTYTPQN  
VWF_cD4:VCMGSSTRHIVTFDGQNFKLTGSCSYVLFQNKEQDLEVILHNGACSPG----AKETCMKSIEVKHDGLSVELHSDMQMTVNGRLVSIPYVGGDMEVNVYGTIMYEVRFNHLGHIFTFTPQN  
                                                                                                                    
VWF_hD4:NEFQLQLSPKTFASKTYGLCGICDENGANDFMLRDGTVTTDWKTLVQEWTVQRPGQTCQPILEEQCLVPDSS---------HCQVLLLP-LFAECHKV  205 
VWF_mD4:NEFQLQLSPKTFASKMHGLCGICDENGANDFTLRDGTVTTDWKRLVQEWTVQQPGYTCQAVPEEQCPVSDSS---------HCQVLLSA-SFAECHKV  205 
VWF_cD4:NEFQLQLSPRTFASKTYGLCGICDENGANDFILRDGTVTTDWKALIQEWTVQQLGKTCQPVPEEQCPVSSSS---------HCQVLLSE-LFAECHKV  205  
                           CGIC    
 
Figure 4.3 (B) Sequence alignment of VWF D3 and D4 domains across species. VWF D domain sequences from UniProt database were 
aligned using ClustalX 2.0 for the following species: human (h) P04275, mouse (m) Q28295, canine (c), pig (p) QQ28833, and bovine (b) 
F5XVA9. The CG(L/I)C motif in the individual D domains is conserved across species. 
 
 
VWF_hC1 : TQCIGEDGVQHQFLEAWVPDHQPCQICTCLSGRKVNCTTQPCPTAKAPTCGLCEVARLRQNADQCCPEYECVCD: 74 
VWF_pC1   : TQCVDDDGIRHQFLETWVPDHQPCQICTCLSGRRVNCTLQPCPTARAPACGLCEVARLRQEAHQCCPEYECVCD: 74 
VWF_mC1  : TQCVGEDGVRHQFLETWVPDHQPCQICMCLSGRKINCTAQPCPTARAPTCGPCEVARLKQSTNLCCPEYECVCD: 74 
VWF_c1  : TQCISEDGVRHQFLETWVPAHQPCQICTCLSGRKVNCTLQPCPTARAPTCGPCEVARLRQNAEQCCPEYECVCD: 74 
                                                                CGXC  
Figure 4.4 Sequence alignment of VWF C1 domains across species. VWF C1 domain sequences from UniProt database were aligned 
using ClustalX 2.0 for the following species: human (h) P04275, mouse (m) Q28295, canine (c), pig (p) QQ28833, and bovine (b) F5XVA9. 
The CGXC motif in C1 domain is conserved across species. 
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4.3 NATURALLY OCCURRING MUTATIONS 
A search was performed on the ISTH-SCC VWF Online Database 
(http://www.vwf.group.shef.ac.uk/) to look for known naturally occurring mutations within 
the CG(L/I)C motifs identified in the D and C domains (Table 4.1). One mutation, G160W, 
has been reported which affects D1-CGLC. The mutation of one of the –XX- residues of 
the motif may affect the pKa and thiol isomerase activity of the CXXC motif. Interestingly 
this leads to loss of HMWMs (as expected) but also to marked intracellular retention. Co-
transfection with wt led to virtually normal multimers, which is perhaps not surprising as it 
is known that expression of the propeptide in trans can rescue multimerisation221. Two 
other mutations, C996E and C2304Y, have been reported which affect one of the 
cysteines in the D3 and C1 CGLC motifs respectively. Recombinant C2304Y 
demonstrated similar results to G160W. No expression work has been carried out on 
C996E and so it remains only a putative causative mutation. 
 
Domain Mutation Type of VWD Other information Reference 
D1 G160W Type 1 Mild-moderate bleeding 
Expression of recombinant mutant VWF cDNA led 
to marked intracellular retention and loss of 
HMWMs. Cotransfection with wt led to virtually 
normal multimers. 
Eikenboom  
et al
231
 
D3 C996E Type 1 Putative causative mutation found in family study. 
No expression work carried out. 
James et 
al
233
 
C1 C2304Y Type1 Mild-moderate bleeding. 
Recombinant mutant VWF demonstrated similar 
results to G160W. 
Eikenboom  
et al
231
 
 
Table 4.1 Naturally occurring mutations affecting the conserved CG(L/I)C motifs. 
Von Willebrand disease (VWD) causing mutations reported to the ISTH-SCC VWF Online 
Database (http://www.vwf.group.shef.ac.uk/). 
 
4.4 RECOMBINANT FULL LENGTH MUTANTS: D2 REPLACEMENT 
In order to determine the thiol isomerase activity and functional role of the conserved 
CG(L/I)C motifs, 2 complementary types of mutants were constructed. D2 domain 
replacement mutants were made in which the D2 domain (known to have thiol isomerase 
activity necessary for multimerisation) was replaced by either the D3 or D4 domain,  and 
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these are discussed further in this section. Glycine insertion mutants were also made, in 
which a glycine is inserted into each CG(L/I)C motif as this has been previously shown to 
disrupt thiol isomerase activity219, and these are discussed in section 4.5.  
 
All mutants were cloned into expression vectors, as detailed in the individual sections. In 
all cases, large scale DNA preparations were then made and used for transient 
transfection of mammalian HEK293T or HEK293 cells (section 2.3.3). HEK 293T cells 
were used for all transfections except for those looking at the location of intracellular 
retention of the mutants. The media and lysates were harvested after 3 days (unless 
otherwise stated) and the concentration of each VWF variant in the conditioned media and 
cell lysate was assayed using the VWF ELISA (section 2.4.4.2). 
 
4.4.1 Expression of full length VWF D2 replacement mutants: D3→D2, D4→D2 
The propeptide is crucial for multimerisation220,221. It has been proposed that this is 
because the CGLC motifs in D1 and D2 possess intrinsic isomerase activity219,222,224 
(section 1.6.2). Therefore the D2 domain was replaced by either the D3 or D4 domain to 
investigate whether they possess intrinsic isomerase activity that can replace that of the 
D2 domain. The construction of these mutants is described in detail in section 2.2.5. 
Briefly, reverse and forward primers starting either side of the D2 domain (that is, end of 
D1 and start of D’ respectively) were designed, and PCR was used to remove the D2 
domain (residues 387-598) from the pBS VWFEcoRI-BamHI vector, creating the vector ∆D2-
pBS VWFEcoRI-BamHI. In order to amplify the D3 or D4 domain, new primers were then 
designed which flanked both the D3 (or D4) domain to be inserted and the surrounding 
region of the vector (that is, forward primer last 20 base pairs of D1 and first 20 of D3 or 
D4, reverse primer last 20 base pairs of D3 or D4 and first 20 of D’). To amplify the D3 
domain by standard PCR techniques, these primers were used with the vector pGEM 
VWFXhoI-KpnI as template. To amplify the D4 domains, these primers were used with the 
vector pcDNA3.1 D’-CK as template DNA. The amplified domain (with flanking regions) 
was purified and quantified. PCR was then performed using this amplified fragment as the 
primer and ∆D2-pBS VWFEcoRI-BamHI as the template DNA. This resulted in the insertion of 
D3 (or D4) between the D1 and D’ domains (Figures 2.1, 2.2 and 2.3). Following 
sequencing, the VWF fragments containing the mutations were subcloned into pcDNA3.1 
FL-VWF (Figure 2.4).  
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Wt VWF and the D2 replacement mutants (D3→D2 and D4→D2) were transiently 
expressed in HEK293T cells on a small scale. This allowed investigation of whether the 
mutations played a role in effective secretion. Both the D3→D2 and D4→D2 mutants were 
retained intracellularly, with minimal secretion detectable (Figure 4.5). Of note, different 
lysis techniques (section 2.3.4) were attempted in an effort to optimise the multimers 
released from the cell lysate for analysis on multimer gel. However, neither the wt or 
mutant lysates showed higher molecular weight multimers, and so this analysis did not 
further our understanding of the intracellular processing and was not pursued. 
 
 
 
 
Figure 4.5. Expression of full length D2 replacement mutants. The concentration of 
VWF in media and lysate, determined by the VWF ELISA, is shown. Both D3→D2 and 
D4→D2 mutants were retained intracellularly. (Values shown here are mean ±SEM of 3 
separate transfections performed in duplicate.) 
 
 
4.4.2 Localisation of D2 replacement mutants retained intracellularly 
In order to investigate where the full-length D2 domain replacement mutants were retained 
within the cell, the composition of VWF in the cell lysate of HEK293 cells was studied, as 
described in section 3.4.5. Briefly, the FL-VWF DNA preparations were used to transiently 
transfect HEK293 cells, media and cell lysates were harvested after 6 days, and the 
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concentration of VWF was assayed using the VWF ELISA. As expected from the 
transfections with HEK293T cells, both of the FL-VWF D2 replacement mutants were very 
poorly secreted and the majority was retained intracellularly (data not shown). The cell 
lysates were then loaded onto a reducing SDS-PAGE gel and VWF was detected by 
Western blot with polyclonal anti-hVWF-HRP antibody.  
 
ImageJ was used to quantify the amount of mature VWF to pro-VWF present, and then 
this was expressed as a ratio (Figure 4.6, A). The wt VWF was retained mainly as mature 
VWF. The D2 replacement mutants were mainly retained as pro-VWF (Figure 4.6). As 
furin cleaves the propeptide from VWF after multimerisation in the trans-Golgi, this 
suggests that the D2 replacement mutants are retained either in the ER or in the early 
Golgi. As previously described (sections 2.4.4.5 and 3.4.5) EndoH was therefore used to 
differentiate whether the mutants were retained within the ER (and were cleavable by 
EndoH) or whether they were within the Golgi (and resistant to EndoH). The cell lysates 
were incubated at 37ºC overnight, with and without EndoH present and then run on a 
reducing SDS-PAGE gel, followed by Western blot and detection with polyclonal anti-
hVWF-HRP. The detectable pro-VWF band migrated further through the gel following 
treatment with EndoH, suggesting that EndoH de-glycoslylated the mutant VWF and 
reduced its size (Figure 4.6, B). This suggests that D3→D2 and D4→D2 were retained as 
pro-VWF within the ER. 
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Figure 4.6 Cell lysates of D2 domain replacement mutants expressed in FL-VWF. 
SDS-PAGE under reducing conditions and Western blot with polyclonal anti-hVWF-HRP 
were performed on cell lysates of HEK293 cells. (A) Graph showing the ratio of mature 
VWF to pro-VWF for all the mutants, based on the density of the appropriate band as 
analysed by ImageJ. (B) Cell lysates, without and with EndoH treatment. The first lane is 
VWF from the conditioned media as a size control. (Values shown are mean ±SEM of 3 
separate transfections performed in duplicate and the gel is a representative example.) 
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4.5 RECOMBINANT FULL LENGTH MUTANTS: GLYCINE INSERTION 
4.5.1 Expression of glycine insertion mutants: GlyD2, GlyD3, GlyD4 and GlyC1 
In order to investigate the possible thiol isomerase activity of the conserved CG(L/I)C 
motifs, glycine insertion mutants were made in which a glycine is inserted into each CXXC 
motif to form CXGXC.  This has previously been shown to disrupt thiol isomerase 
activity219 whilst being a small enough mutation to minimise the risk of causing a gross 
conformational change. Briefly, a glycine was inserted into 993CGLC, 2085CGIC and 
2304CGLC motifs to create the mutants GlyD3, GlyD4 and GlyC1 respectively. A glycine 
was inserted into the 521CGLC to make GlyD2 as a control, as had previously been 
reported219. The mutants were initially made in vectors pBS VWFEcoRI-BamHI (for GlyD2 and 
GlyD3) and pcDNA3.1 A2-CK (for GlyD4 and GlyC1). The fragments of VWF pcDNA 
containing the mutations were subcloned into pcDNA3.1 vector FL-VWF. 
 
The GlyD4 and GlyC1 mutants were expressed and secreted in the conditioned media at 
similar levels to wt VWF, although the GlyD2 and GlyD3 mutants were mainly retained 
within the cell (Figure 4.7).  
 
 
 
Figure 4.7 Expression levels of the glycine insertion mutants. The concentration of 
VWF in media and lysate of HEK293T cells, determined by the VWF ELISA, is shown. 
GlyD4 and GlyC1 were secreted at comparable levels to wt (media:lysate ratio p=0.08 and 
p=0.18 respectively). However GlyD2 and GlyD3 were mainly retained intracellularly. 
(Values shown are mean ±SEM of 3 separate transfections performed in duplicate.) 
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4.5.2 Multimer analysis of glycine insertion mutants 
The multimeric composition of expressed recombinant VWF was analysed by agarose gel 
electrophoresis followed by Western blot. The multimeric composition of the mutants was 
compared to that of recombinant wt VWF and pdVWF. Unconcentrated samples were 
used for all the recombinant VWF samples shown. GlyD2 demonstrated a dimeric band, a 
faint tetrameric band and few higher order bands. No secreted multimers were visible on 
the gel for GlyD3. The GlyD4 and GlyC1 mutants showed a similar multimeric pattern to wt 
VWF, although the GlyD4 multimers migrated slightly less through the gel suggesting that 
these dimers have a more open conformation (Figure 4.8).  
 
 
 
 
Figure 4.8 Multimer gel of wt VWF and glycine insertion mutants. GlyD2 secretes 
mainly as dimers, with a fainter tetrameric band. GlyD3 cannot be detected on a multimer 
gel. GlyD4 and GlyC1 have a similar multimeric pattern to wt, although GlyD4 multimers 
migrate slightly less than wt and GlyC1 suggesting that these dimers have a more open 
conformation. (RP is reference plasma.) (This gel is representative of 3 experiments.) 
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4.5.3 Localisation of GlyD2 and GlyD3 mutants retained intracellularly  
In order to investigate where GlyD2 and GlyD3 were retained within the cell, the 
composition of VWF in the cell lysate of HEK293 cells was studied, as described earlier 
(sections 3.4.5 and 4.4.2). As expected from the studies using HEK293T cells, GlyD2 and 
GlyD3 were very poorly secreted and the majority was retained intracellularly in HEK293 
cells, whereas GlyD4 and GlyC1 were secreted at similar levels to wt (data not shown). 
The conditioned media and cell lysates were then loaded onto a reducing SDS-PAGE and 
Western blot performed.   
 
As described previously (section 4.4.2), the amount of mature VWF and pro-VWF present 
was quantified by analysing the gels with ImageJ (Figure 4.9). The wt VWF was present 
mainly as mature VWF. The D2 replacement mutants were mainly retained as pro-VWF 
(Figure 4.9, A). The detectable pro-VWF band for GlyD3 migrated further through the gel 
following treatment with EndoH, showing that EndoH de-glycoslylated GlyD3 and reduced 
its size, suggesting that it is retained within the ER (Figure 4.9, B). Interestingly, GlyD2 
does not show a clear shift following treatment with EndoH. This suggests that while much 
of it is retained as pro-VWF, it may leave the ER and be arrested during processing in the 
Golgi. 
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Figure 4.9 Cell lysates of glycine insertion mutants expressed in FL-VWF. SDS-
PAGE under reducing conditions and Western blot were performed on the cell lysates of 
HEK293 cells. The density of the bands was analysed by ImageJ. (A) Graph showing the 
ratio of mature VWF to pro-VWF for all the mutants, based on the density of the 
appropriate band as analysed by Image J. Intracellular wt VWF was divided fairly equally 
between pro-VWF and mature VWF, as were GlyD4 and GlyC1. However, GlyD2 and 
GlyD3 that were mainly retained intracellularly, were retained as pro-VWF. (B) Reducing 
gel showing wt media as a size control, and VWF from the lysates of transfections with wt, 
GlyD2 and GlyD3 before and after treatment with EndoH. GlyD3 pro-VWF is cleaved by 
EndoH, suggesting it is retained within the ER. However, GlyD2 pro-VWF is not 
convincingly cleaved by EndoH. (The gels shown are representative of 3 experiments.)  
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4.5.4 Collagen binding of GlyD4 and GlyC1 
The collagen binding function of VWF is highly sensitive to VWF multimeric size because 
individual A3 domains have only low affinity. Therefore an alteration in collagen binding 
may simply reflect an effect on multimerisation rather than a direct change in binding 
affinity.  The effect of mutations on binding to type III collagen was assessed by an ELISA 
based binding assay (section 2.4.4.3) and calculated as a ratio of collagen binding to VWF 
antigen (VWF:CB/VWF:Ag). The normal observed ratio is >0.7 for pdVWF. Recombinant 
wt VWF had a VWF:CB/VWF:Ag ratio of 0.5. This difference in collagen binding is due to 
differences in multimeric pattern, with pdVWF having more high molecular weight 
multimers. GlyD4 and GlyC1 both demonstrated normal ratios (Table 4.2). 
 
 
Mutant pd VWF wt GlyD4 GlyC1 
VWF:CBA/VWF:Ag 0.75 0.49 0.4 0.42 
 
 
Table 4.2 VWF:CB/VWF:Ag ratios for GlyD4 and GlyC1. A static ELISA based collagen 
binding assay was used to measure the collagen binding activity of recombinant VWF. It 
was expressed as a ratio of collagen binding to VWF antigen (VWF:CBA/VWF:Ag). GlyD4 
and GlyC1 showed a similar collagen binding activity to wt (p=0.44 and 0.38 respectively). 
(The values represent the mean ratio of 3 experiments.) 
 
4.5.5 Free thiol assay of GlyD4 and GlyC1 
GlyD4 and GlyC1 both expressed at comparable levels to wt, suggesting that these 
CG(L/I)C motifs were not essential for intracellular processing and secretion. A free thiol 
assay was used to investigate whether GlyD4 and GlyC1 have a similar proportion of free 
thiols to wt (section 2.4.5.4). A recombinant VWF variant which has an extra cysteine per 
monomer, Y1584C, was used as a calibrant (expression vector kindly supplied by Dr Tom 
McKinnon). Briefly, equal concentrations of pdVWF (from reference plasma) and 
recombinant wt, GlyD4, GlyC1 and Y1584C (from conditioned media of HEK293T cells) 
were incubated with MPB. After incubation, the VWF was loaded onto a microtitre plate 
which had been coated with polyclonal anti-hVWF and blocked with BSA. The VWF was 
detected with either streptavidin peroxidase or polyclonal anti-hVWF-HRP. The free thiol 
content was expressed as a ratio of bound MPB to bound VWF. Recombinant wt protein 
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demonstrated a mean free thiol ratio of 0.5. GlyD4 and GlyC1 both had significantly 
increased mean free thiol ratios (1.0, p<0.05) (Figure 4.10). This increase was similar to 
that observed with Y1584C. No MPB binding was observed when VWF was prior treated 
with 20mM NEM.  
 
 
Figure 4.10 Free thiol assay of GlyD4 and GlyC1. A free thiol assay, based on ELISA 
technique, was used to analyse the proportion of free thiols on VWF. Graph shows the 
ratio of bound MPB to bound VWF. GlyD4 and GlyC1 both had a significantly increased 
free thiol content compared to wt (p<0.05), comparable to the VWF mutant Y1584C. When 
VWF was prior incubated with 20mM NEM, no MPB binding was observed. (Values shown 
here are mean ±SEM of 3 separate ELISAs performed in duplicate.) 
 
 
4.5.6 Purification of recombinant VWF 
The CG(L/I)C motifs in D4 and C1 did not appear to be critical for the intracellular 
synthesis and secretion of VWF, its static collagen binding or its multimerisation, although 
GlyD4 appeared to have dimers with a more open conformation than wt (section 4.5.2). 
GlyD4 and GlyC1 both demonstrated increased free thiol content. It is possible that while 
these CG(L/I)C motifs may not play a major role intracellularly, they may have significant 
thiol isomerase activity in the extracellular environment, and play an important role for 
example in catalysing thiol-disulphide exchange resulting in self-association under flow. In 
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order to test their extracellular function, a perfusion flow assay was optimised (section 2.7) 
for which a large amount of purified protein was required. 
 
Large scale transient transfections of HEK293T cells were performed. Approximately 
200mls of expression media was collected and filtered. The VWF was purified by ion 
exchange chromatography using a previously equilibrated Fractogel-EMD-TMAE+ column 
(section 2.4.3.1). The bound VWF was eluted using 500mM NaCl (Figure 4.11, A). The 
elution fraction was analysed by SDS-PAGE under reducing conditions, followed by both 
Coomassie stain and Western blot (Figure 4.12, A and B). The elution fraction contained a 
band of approximately 250kDa, corresponding to monomeric VWF, however other 
contaminating proteins were still present (Figure 4.12, A). For the majority of experiments, 
this level of purification was adequate. Samples requiring no further purification were 
dialysed into 20mM Tris, pH7.4. 
 
Samples requiring further purification (such as for direct binding to Ibidi flow slides) were 
subsequently purified by Heparin-Sepharose affinity chromatography (section 2.4.3.2). The 
bound VWF was eluted using 500mM NaCl, and then dialysed into 20mM Tris, pH7.4. The 
purity of the eluted material was analysed using SDS-PAGE, Coomassie and Western blot 
as before (Figure 4.12, A and B). The purified VWF was then quantified by VWF ELISA, 
and the multimeric pattern analysed by multimer gel (Figure 4.12, C) and static collagen 
binding assay. The typical VWF recovery after ion exchange chromatography was 80%, 
and this reduced to 50% after subsequent Heparin-Sepharose chromatography. The 
multimeric structure and collagen binding activity of VWF before and after purification was 
similar, although there was a tendency to lose the highest molecular weight multimers. 
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Figure 4.11 Purification of recombinant VWF. Representative chromatograms showing 
(A) purification of recombinant VWF from conditioned media by ion exchange 
chromatography and (B) further purification of the ion-exchanged sample using a Heparin-
Sepharose column. Some proteins do not bind to the columns (flow-through fractions). 
After loading, the columns were extensively washed with buffer (20mM Tris and 100mM 
NaCl, pH7.4) to remove the majority of contaminant proteins from the columns (wash 
fractions). Bound protein was eluted with 500mM NaCl.  
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Figure 4.12 Purification of recombinant VWF by ion-exchange and Heparin-
Sepharose affinity chromatography. Following purification of recombinant VWF by ion-
exchange chromatography (IE) and Heparin-Sepharose chromatography (HS) samples 
were analysed on (A) Coomassie gel, reducing conditions (B) Western blot with polyclonal 
anti-hVWF-HRP, reducing conditions and (C) multimer gel.  Samples correspond to: a, 
conditioned media; b, IE flow-through; c, IE elution; d, HS flow-through; e, HS elution. 
Purified and concentrated VWF can be seen as the 250kDa band in the final HS elution 
fraction on Coomassie. This corresponds to the band detected on Western blot. The 
multimeric pattern is retained following purification, with a slight shift towards lower 
molecular weight multimers. (RP is reference plasma.) (All gels are representative of 3 
experiments.) 
 
142 
4.5.7 Perfusion assays: GlyD4 and GlyC1 immobilised directly to flow slide 
In order to study the functional effect of pdVWF and recombinant VWF mutants on VWF-
mediated platelet binding to collagen in a physiological environment, a perfusion assay 
was optimised based on those previously published198,230. The initial perfusion assay was 
set up by Dr Tom McKinnon and Dr Agata Nowak. They optimised the collagen binding to 
the slide (type and concentration), determined the saturating concentration for direct 
binding of VWF to the slide, and verified the removal of VWF from whole blood by 4 wash 
steps during blood processing. I further optimised this assay by using different blood 
preparation techniques, based on others published198,230. I established that platelet 
activation, as detected by platelet binding to collagen in the absence of VWF at 1500s-1, 
was minimised by processing blood and platelets together. I tested different fluorescent 
dyes for labelling platelets: mepacrine, calcein and DiOC6. There was no significant 
difference between these, except in the presence of excess DiOC6 which resulted in 
increased background platelet activation. I therefore minimised the concentration of DiOC6 
used. The final protocol is described in methods (section 2.9).  
 
To investigate the ability of recombinant VWF to support GPIbα dependent platelet 
tethering under flow, a suspension of RBCs supplemented with platelets was perfused 
over VWF immobilised directly onto the flow slide (section 2.7).  Briefly, the recombinant 
VWF was purified using both ion-exchange and Heparin-Sepharose chromatography to 
ensure optimal surface coverage (without contaminating proteins). The purified VWF was 
bound to uncoated plastic Ibidi® μ-Slide V0.1 at a saturating concentration. After blocking 
with BSA and washing with PBS, the flow slides were connected to the perfusion chamber. 
Fresh blood was prepared by centrifuging RBCs and platelets separately, and platelets 
were then added to the RBCs at a concentration of 2% of original (section 2.7.1.2). 
Apyrase, PGE1 and EDTA were added during processing to prevent platelet activation, 
and platelets rendered fluorescent using 1nM DiOC6. This was perfused over the flow 
slides at a wall shear rate of 1500s-1. After 3 minutes, a short movie (1s) was taken in 3 
fields of view using a QImaging camera and QCapture pro software. The digitalised 
images were collected, processed and analysed using Virtual Dub and ImageJ software 
(section 2.7.4). A 3 minute end-point was chosen as this is similar to what has previously 
been published, is within a physiologically relevant time frame. 
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There was no significant difference in platelet binding to GlyD4 or GlyC1 at 1500s-1 
compared to wt (p=0.09 and p=0.54 respectively) (Figure 4.13). Of note, the amount of 
VWF bound to the slide using this technique was checked by stripping (section 2.7.2) and 
analysis by SDS-PAGE and Western blot and was similar for each mutant (Figure 4.14). 
 
 
 
 
Figure 4.13 Platelet binding to VWF immobilised direct to flow slide. Platelets in a 
suspension of RBCs were perfused at 1500s-1 over purified recombinant VWF bound 
directly to a flow slide. Platelet attachment was analysed after 3 minutes by taking a short 
movie (1s, frames every 0.05s) in 3 fields of view. The accumulated platelets were 
assessed by stacking 3 frames (to remove translocating platelets) and surface coverage 
(%) was measured using ImageJ. A control of carbonate buffer alone was used. There 
was no significant difference in the binding of platelets to wt or GlyD4 or GlyC1 (p=0.09 
and p=0.54 respectively). (Values shown are mean ±SEM of duplicate experiments 
repeated on 3 separate occasions.)   
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Figure 4.14 VWF bound directly to the slide. Recombinant VWF was bound directly to 
the standard hydrophobic plastic flow slides at 30µg/ml. The slides were washed, then 
stripped, and this was analysed by SDS-PAGE under reducing conditions and Western 
blot. Recombinant wt, GlyD4 and GlyC1 bound to the flow slides in comparable amounts. 
(Gel is representative of 2 experiments.) 
 
 
4.5.8 Perfusion assays: GlyD4 and GlyC1 perfused over collagen-coated slide 
To investigate the ability of the recombinant VWF mutants to support platelet tethering to 
collagen under flow, plasma-free blood was perfused over a collagen-coated flow slide, 
with or without the addition of recombinant VWF at a final concentration of 5µg/ml. Briefly, 
uncoated plastic Ibidi® μ-Slide V0.1 was coated with 100µg/ml human type III collagen, and 
blocked with BSA (section 2.7.5). Plasma-free blood was prepared by centrifuging RBCs 
and platelets together in order to minimise activation (section 2.7.1.1). Apyrase, PGE1, 
EDTA and DiOC6 were added as previously (section 4.5.7). Purified recombinant VWF was 
added to the plasma-free blood at a final concentration of 5µg/ml (lower limit of the normal 
range). The plasma-free blood was perfused over the flow slides at a range of wall shear 
rates (800-3000s-1). Short movies (1s) were recorded every minute for 5 minutes and the 
accumulated platelets at each time point were assessed as previously described (sections 
2.7.5 and 4.5.7). The end-point of 5 minutes was chosen as this was similar to previously 
published work, is a physiologically relevant time frame, and additionally platelet capture 
by pdVWF and recombinant wt VWF plateaued by 5 minutes.  
 
There was no difference in the VWF-mediated platelet binding to collagen after 5 minutes 
between wt and GlyD4 and GlyC1 at 800s-1, 1500s-1 or 3000s-1 (Figure 4.15). As a control, 
in order to check that the mutants and wt bound to collagen under flow with a similar 
affinity, the experiment was repeated using recombinant VWF in buffer rather than plasma-
free blood (section 2.7.2). After 5 minutes the perfusion was stopped, the slide was 
stripped, and then analysed by SDS-PAGE and Western blot. Recombinant wt VWF, 
GlyD4 and GlyC1 bound to collagen under flow conditions to a similar extent (Figure 4.16). 
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Figure 4.15 VWF-mediated platelet attachment to collagen. Perfusion of purified 
recombinant VWF proteins over human collagen type III for 5 minutes at 800sˉ¹, 1500sˉ¹, 
3000sˉ¹. Graph shows the percentage surface coverage by platelets at 5 minutes, 
following analysis of stacked frames from 3 different fields of view, using VirtualDub and 
ImageJ. There was no significant difference in the VWF-mediated binding of platelets to 
collagen between wt and either GlyD4 or GlyC1 at any shear rate tested (p>0.05) (Values 
shown are mean ±SEM of duplicate experiments repeated on 3 separate occasions.)  
 
 
 
 
 
 
 
Figure 4.16 Recombinant VWF bound to collagen under flow. Recombinant VWF 
(5µg/ml) in buffer was perfused over a collagen-coated flow slide at 1500s-1 for 5 minutes. 
The slides were washed, stripped, and analysed by SDS-PAGE under reducing conditions 
and Western blot. Wt, GlyD4 and GlyC1 bound to the collagen in comparable amounts. 
(Gel is representative of 2 experiments.)  
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Interestingly, although there was no statistically significant difference in the surface 
coverage of accumulated platelets at 5 minutes between wt and GlyD4 or GlyC1 at 800s-1, 
1500s-1 or 3000s-1, when the data were analysed over the whole 5 minute time course (at 
1 minute intervals) there was a slight difference in the rate of VWF-mediated platelet 
binding to collagen. The graphs demonstrate a trend for GlyC1 to mediate slower binding 
of platelets to collagen than either GlyD4 or wt (Figure 4.17). Using paired t-tests to 
compare the area under the curve (AUC), this was not significant at 800s-1 or 3000s-1 but it 
was significantly different at 1500s-1 (p=0.006).   
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Figure 4.17 Time course of VWF-mediated platelet binding to collagen over 5 
minutes. Purified recombinant VWF at 5µ/ml in plasma-free blood was perfused over type 
III human collagen (wt-black, GlyD4-red, GlyC1-blue). Graphs show the cumulative 
percentage surface coverage by platelets over a 5 minute time course at (A) 800s-1, (B) 
3000s-1, and (C) 1500s-1. At each time point, platelet surface coverage analysis was 
performed on stacked frames using ImageJ. The area under the curve (AUC) was 
calculated for each mutant over each time course and compared using the paired t-test. 
Although there appeared to be a trend for GlyC1 to mediate slower binding of platelets to 
collagen than wt, this was not significant at 800s-1 or 3000s-1. However at 1500s-1, GlyC1 
mediated slower platelet binding to VWF than wt (p=0.006). (Values shown are mean 
±SEM of duplicate experiments repeated on 3 separate occasions.)  
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Figure 4.17 
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4.6 D’D3 
4.6.1 Expression of D’D3: wt and GlyD3 
Although GlyD3 had not expressed in FL-VWF, it was not known whether this was 
because it possessed intrinsic isomerase activity which was essential for correct synthesis, 
or simply because the glycine insertion had caused a conformational change resulting in 
the protein being recognised as abnormal. In order to investigate this further GlyD3 was 
made in a small VWF fragment, D’D3 (764-1270). 
 
Firstly, D’D3 needed to be made in an expression vector. The method is detailed in section 
2.2.4. Briefly, primers were designed to remove VWF residues 1271-2813 from the 
template vector pcDNA3.1 D’-CK (764-2813) by PCR (reverse primer from 1270, forward 
primer from start of vector after 2813). Then primers were designed to mutate the TGA 
stop codon, prior to the 6xHis-tag, into tyrosine (TAC), resulting in pcDNA3.1 D’D3-His 
(764-1271). The 6xHis tag was added in order to allow detection and purification of this 
D’D3 fragment. Finally a glycine was inserted to create GlyD3 in D’D3-His.  
 
Following small scale transient transfection of HEK293T cells with D’D3 (wt and GlyD3), 
the media and cell lysate were harvested after 3 days. In order to examine the expression 
of this small fragment, the media and lysate were loaded onto polyacrylamide gels and 
SDS-PAGE and Western blot performed. Both anti-His-HRP and polyclonal anti-hVWF-
HRP antibodies were initially used for detection. Anti-His-HRP was much more sensitive 
and so was subsequently always used, unless stated otherwise. A non-reducing gel 
showed that wt D’D3 secreted as monomers, with mainly monomers in the lysate (ratio 
approximately 1:1 following analysis of band density with ImageJ) (Figure 4.18, A). GlyD3 
could not be detected in the media on Western blot, but was present in the lysate with 
marked higher order multimers (Figure 4.18, A). These higher order oligomers in the lysate 
of GlyD3 D’D3 were reduced to monomers by β-mercaptoethanol and were therefore 
disulphide-bonded (Figure 4.18, B). The higher order bands in the lysate migrated further 
through the gel following treatment with EndoH (section 4.5.3), showing that EndoH de-
glycosylated these bands and reduced their size, suggesting that these higher order 
oligomers are formed in the ER. This is consistent with the hypothesis that the CGLC motif 
in D3 plays a role in the prevention (or reduction) of non-native disulphide bonds in the ER. 
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Figure 4.18 Expression of wt and GlyD3 in D’D3 VWF fragment. SDS-PAGE and 
Western blot were performed on media (M) and cell lysates (L). (A) Non-reducing gel 
showing wt D’D3 secreted as monomers, and the lysate shows mainly monomers with   
faint higher order oligomer bands. GlyD3 cannot be detected in the media, but is present in 
the lysate with marked higher order oligomers. (B) Reducing gel shows that these higher 
order oligomers in the lysate are reduced to monomers by β-mercaptoethanol and are 
therefore disulphide-bonded. (Gel is representative of 3 experiments.) 
 
 
 
Figure 4.19 EndoH cleavage of oligomeric bands in GlyD3 lysate. The lysate of GlyD3 
was incubated with (+) and without (-) EndoH. The oligomers migrated further through the 
gel following treatment with EndoH, suggesting that EndoH de-glycosylated the oligomers 
and reduced their size. (Gel is representative of 3 separate experiments.) 
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4.6.2 Alkalinisation 
If the CGLC motif in D3 has thiol isomerase activity and plays a role in the prevention (or 
reduction) of non-native disulphide bonds in the ER (pH 7.2), it is possible that there might 
be a more pronounced effect of the mutation if the cells are alkalinised. In order to test 
this, HEK293T cells were again transiently transfected with D’D3 VWF (wt or GlyD3). After 
24 hours, 15µM monensin or 5µM ammonium chloride was added to the cell culture media 
(section 2.3.3). Monensin is an ionophore which causes intracellular alkalinisation, 
although it also disrupts carbohydrate processing in the Golgi. The pH of the cell media in 
these experiments was between 7.4 and 7.6 (compared to normal, 7.2-7.4). The media 
and cell lysates were harvested 48 hours later, loaded onto a non-reducing gel, and SDS-
PAGE and Western blot performed. Both monensin and ammonium chloride slightly 
increased the higher order multimers seen in wt lysate, and they greatly increased the 
higher order oligomers seen in the cell lysate of GlyD3 in D’D3 (Figure 4.20). This is 
consistent with the hypothesis that non-native disulphide bonds form between D’D3 
fragments in an intracellular alkaline environment, and that this is prevented (or reduced) 
by the thiol isomerase activity of the CGLC motif in D3.  
 
 
 
Figure 4.20 Expression of D’D3 VWF fragment (wt and GlyD3) following treatment 
with monensin or ammonium chloride. SDS-PAGE and Western blot were performed 
on media (M) and cell lysates (L). Both monensin and ammonium chloride slightly 
increased the higher order multimers seen in wt lysate and they greatly increased the 
higher order oligomers seen in the cell lysate of GlyD3 in D’D3. (Gel is representative of 2 
experiments.) 
151 
4.6.3 Co-transfections of wt D’D3 with GlyD3 D’D3 
In order to examine whether wt could rescue the secretion of GlyD3, the wt D’D3 was co-
expressed with GlyD3 D’D3. The standard protocol for small scale transient transfection of 
HEK293T cells was used, except that 50% of the DNA preparation used for transfection 
was wt D’D3-His and 50% was GlyD3 D’D3-His.  
 
A non-reducing gel showed that following co-transfection, monomeric D’D3 was secreted, 
but with more higher order oligomers seen in the lysate than with wt alone (Figure 4.21).  
 
 
Figure 4.21 Co-transfection of wt D’D3 and GlyD3 D’D3. SDS-PAGE and Western blot 
with anti-His-HRP were performed on media (M) and cell lysates (L). Non-reducing gel 
showing that, following co-transfection of wt with GlyD3, D’D3 was detected in the media 
as monomers but the lysate had additional higher order monomers (greater than wt alone). 
(Gel is representative of 3 experiments.) 
 
  
However, the experiment described above does not distinguish whether the processing of 
wt D’D3 with GlyD3 VWF was able to rescue the secretion of GlyD3, or whether it was 
simply wt D’D3 alone being secreted. Therefore another co-transfection was performed, 
using wt D’D3 (no His tag) and GlyD3 D’D3-His. The procedure was carried out as above, 
except Western blot on the media and lysate samples was performed with both anti-His-
HRP (Figure 4.22, A) and anti-hVWF-HRP (required long exposure) (Figure 4.22, B). 
GlyD3 D’D3-His was not secreted following co-transfection with wt D’D3 (Figure 4.22, A). 
The control shows that wt D’D3 was secreted into the media when transfected alone and it 
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can also be seen in the media of the first co-transfection (Figure 4.22, B). Whilst these 
bands are faint, this is compatible with the poor detection of D’D3 by polyclonal anti-
hVWF-HRP. 
 
A 
 
B 
 
 
Figure 4.22 Co-transfection of wt D’D3 and GlyD3 D’D3. HEK293T cells were 
transiently transfected with wt D’D3 (no His tag) and GlyD3 D’D3-His. Non-reducing SDS-
PAGE gels of media (M) and cell lysates (L). (A) Western blot with anti-His-HRP. GlyD3 
D’D3-His was not secreted following co-transfection with wt D’D3 (B) Western blot with 
polyclonal anti-hVWF-HRP. Wt D’D3 was secreted into the media when transfected alone 
and it can also be seen in the media of the first co-transfection. Whilst these bands are 
faint, this is compatible with the poor detection of D’D3 by polyclonal anti-hVWF-HRP. 
(Gels are representative of 2 experiments.) 
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4.7 DISCUSSION 
The importance of thiol-disulphide exchange in regulating protein structure and activation 
is being increasingly appreciated214.  These reactions are catalysed by thiol isomerases 
which are characterised by a CXXC motif in their active site. This project aimed to 
determine the role of CXXC motifs (within domains other than the propeptide) in 
determining VWF structure and function. 
 
In silico analysis demonstrated human VWF has 16 CXXC motifs. In addition to the two 
CGLC motifs of the propeptide which are thought to possess intrinsic isomerase activity, 
three other chemically similar CG(L/I)C motifs are found in the D3, D4 and C1 domains. It 
is known that the -XX- residues are important in determining thiol isomerase activity, and 
so I chose to initially study these 3 CG(L/I)C motifs, as opposed to the other 11. The motif 
is conserved across all 4 D domains (Figure 4.1) but the C1 domain is the only VWF C 
domain to contain a CGLC motif (Figure 4.2). These motifs are also conserved across 
species (Figures 4.3 and 4.4). The motifs in D3 and C1 are the same as in the propeptide, 
CGLC; the D4 motif is similar (CGIC), but is displaced by 2 amino acids. In general, 
sequences are conserved if they are important to the structure and function of a molecule. 
This suggests that these CG(L/I)C motifs in the D3, D4 and C1 domains have an important 
role, perhaps possessing thiol isomerase activity essential either intracellularly in VWF 
synthesis or extracellularly, for example in VWF self-association. This has not previously 
been reported. 
 
A search of the VWF Sheffield database revealed three documented naturally occurring 
mutations that cause VWD by disrupting the CGLC motif: G160W231, C2304Y231, and 
C996E233 (Table 4.1). However, these mutations give limited information. The importance 
of the thiol isomerase activity of the CGLC motif in D1 has already been reported, and 
expression studies which showed marked intracellular retention of G160W with loss of 
HMWMs suggest that the mutation disrupts this231, although one might have assumed that 
dimers would have been produced as was previously reported219,220. Whilst expression 
studies also showed marked intracellular retention of C2304Y231 (which disrupts the first 
cysteine of the CGLC motif in C1) and could suggest an important role for this motif, it 
could also simply be due to the significant change in the amino acid backbone produced 
by the insertion of tyrosine. C996E (which disrupts the second cysteine of the CGLC motif 
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in D3) is currently only a putative causative mutation as no expression studies have been 
carried out.  
 
The roles of the CG(L/I)C motifs in the D3, D4 and C1 domains were investigated by two 
complementary methods: replacing the D2 domain (known to have thiol isomerase activity 
necessary for multimerisation) with either the D3 or D4 domain; and by inserting a glycine 
to create CXGXC which is known to disrupt thiol isomerase function219. 
 
4.7.1 D2 replacement mutants 
When the D2 domain of VWF (with known thiol isomerase activity necessary for 
multimerisation) was replaced by either the D3 or D4 domain, the mutant was not secreted 
from the cell (Figure 4.5). Different lysis techniques were attempted in an effort to optimise 
the multimers released from the cell lysate, but none of these showed high molecular 
weight multimers in the cell lysates of either wt VWF or D3→D2 and D4→D2 mutants. 
 
As already discussed (section 3.7), disulphide-bond formation is thought to occur primarily 
in the ER where there are a number of proteins with PDI activity and correct protein folding 
is ensured by a complex quality control mechanism235,254. I therefore explored the point at 
which the mutant protein was being retained within the cell. Reducing gels of cell lysates 
showed that both D3→D2 and D4→D2 were retained mainly as pro-VWF (that is, 
containing the un-cleaved propeptide), as opposed to wt VWF in the lysate which was 
mainly processed (Figure 4.6, A). Furthermore, EndoH was able to cleave the majority of 
the retained mutant protein, confirming that it was retained within the ER (Figure 4.6, B). 
These data demonstrate that these mutant proteins are recognised as misfolded early in 
processing and fail to exit the ER. However, this does not distinguish whether this is as a 
result of thiol isomerase activity (although one may have expected dimers to still be 
secreted) or whether it was a result of the significant structural change. As D domains only 
share about 30% sequence homology, it is likely that the protein was simply recognised as 
being abnormally folded because of the change in amino acid backbone. It would have 
been possible to have made a series of D2 replacement mutants, with smaller portions of 
the amino acid sequence (centred on the CGLC motif) being replaced. However, it was 
considered to be more productive to study the glycine insertion mutants. 
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4.7.2 Glycine insertion mutants 
The insertion of a glycine has previously been shown to disrupt the thiol isomerase activity 
of the CGLC motifs in D1 and D2219. This technique was therefore used to investigate the 
conserved CG(L/I)C motifs in the D3, D4 and C1 domains. The mutants GlyD3, GlyD4 and 
GlyC1 were made, and in addition GlyD2 was made as a control.  
 
4.7.2.1 GlyD2 
When expressed in HEK293T cells, both GlyD2 and GlyD3 were mainly retained 
intracellularly (Figure 4.7). This was initially surprising for GlyD2, as it had previously been 
reported to cause only loss of multimerisation and to be secreted as dimers219. However, 
on closer examination of the literature, whilst secretion of a D’-CK construct (that is, 
lacking the propeptide) has been reported as resulting in dimers with similar secretion 
levels to a D1-CK construct (that is, full length VWF) in COS cells220, a similar study has 
not been done for the mutant GlyD2. GlyD2 was studied using a stable cell line, which 
selects the most efficiently secreting cells219, and no study examining expression and 
secretion levels has been reported. Our result is consistent with the expression studies of 
the clinical mutation affecting D1-CGLC (G160W) which showed loss of HMWMs but with 
significant intracellular retention231. It suggests that disruption of the CGLC motif (by 
inserting a glycine) has an additional effect, beyond disrupting only the thiol isomerase 
activity of the motif and preventing multimerisation but allowing dimers to be secreted at 
normal levels. The insertion of a glycine between a random CXXC motif is not necessarily 
a significant amino acid backbone change, as illustrated by the normal secretion levels of 
GlyD4 and GlyC1 (Figure 4.7). But perhaps the conformation of GlyD2 in the Golgi (when 
the propeptide must align with D3 to allow multimerisation to occur normally) is recognised 
by the cell as being abnormal and some of it is targeted for degradation prior to propeptide 
cleavage.  
 
The reducing gel of cell lysate from HEK293 cells transfected with GlyD2 shows that it is 
retained as pro-VWF, and therefore retained within the ER or early Golgi (Figure 4.9, A). 
Interestingly, following EndoH digestion there is not a convincing band shift (Figure 4.9, B). 
This suggests that whilst GlyD2 is retained as pro-VWF, it reaches the Golgi and is 
processed by the enzyme Golgi-alpha-mannosidase II making it resistant to cleavage by 
EndoH. This is consistent with the above hypothesis that the conformation of GlyD2 in the 
Golgi (when the propeptide must align with D3 to allow multimerisation to occur normally) 
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is recognised by the cell as being different than that of wt VWF and some of it is targeted 
for degradation prior to propeptide cleavage. Whilst most of the reported quality control 
mechanisms exist within the ER, the Golgi has also been reported to play a role255-257. 
 
4.7.1.2 GlyD3 
GlyD3 was also retained intracellularly (Figure 4.7). This suggests that loss of the D3-
CGLC motif causes a significant conformational change, and that the abnormally folded 
protein is retained within the cell. Whilst this might be because the glycine causes a 
significant change in the amino acid backbone, as discussed above this does not seem the 
most likely reason given the secretion of GlyD4 and GlyC1. The D3-CGLC motif may 
therefore possess thiol isomerase activity and play a role in multimerisation within the cell. 
In order to see at which point it was retained within the cell, the cell lysate was analysed 
the results show that GlyD3 was retained as pro-VWF which was cleaved by EndoH, thus 
suggesting it was retained within the ER (Figure 4.9, B).  
 
In order to investigate the potential intracellular intrinsic isomerase activity of D3-CGLC, an 
expression vector containing a smaller VWF fragment (D’D3) was made. A His-tag was 
added to enable detection of this fragment, and a glycine was inserted into the CGLC motif 
to make GlyD3-D’D3-His. D’D3-His (wt and GlyD3) were then expressed in HEK293T 
cells. The wt D’D3 fragment was detected on Western blot as an approximately 65kDa 
monomeric band of comparable density in both the media and lysate (Figure 4.18, A). 
Intriguingly, GlyD3 in D’D3 did not secrete, but the lysate showed marked higher order 
oligomers (not present in significant amount in wt lysate) which could be reduced by β-
mercaptoethanol (Figure 4.18, B) and cleaved by EndoH (Figure 4.19). This suggests that 
GlyD3 D’D3 makes disulphide-bonded higher order oligomers in the ER, which are not 
detected in a similar quantity in wt D’D3 lysate, and are not secreted presumably because 
they are recognised by the cell as being abnormal. These may be simply a result of the 
inserted glycine directly disrupting disulphide-bonds by altering the spacing of the 2 
cysteines and thus creating free thiols which form aberrant disulphide bonds. However, it 
is also consistent with the possibility that D3-CGLC possesses intrinsic thiol isomerase 
activity which is important for preventing (or reducing) non-native disulphide bond 
formation within the ER. An example of a similar role for a CGLC motif has previously 
been reported253. Mucins contain VWF D domains. Expression studies in which the CGLC 
motif in the D3 domain of submaxillary porcine mucin was mutated (cysteine to alanine) 
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revealed that this motif plays a role in preventing aberrant disulphide-bond formation in 
non-acidic compartments of the cell253.  
 
To explore the hypothesis that VWF D3-CGLC possesses thiol isomerase activity, 
important in preventing (or reducing) non-native disulphide-bonds in the ER, the 
expression studies were repeated but in the presence of monensin or ammonium chloride 
to alkalinise the cell. The ER is slightly alkaline (pH~7.2-7.4) and the activity of thiol 
isomerases is dependent on the pH, varying with the acid dissociation constant of the 
nucleophilic active-site thiol. When analysed on non-reducing gels, wt D’D3 fragment 
secreted as monomers in all conditions. In alkaline conditions some higher order oligomers 
could be seen in the lysate (Figure 4.20). Fascinatingly, the higher order oligomers in the 
lysate of GlyD3 D’D3 were increased in the presence of both monensin and ammonium 
chloride. This is again consistent with the hypothesis that D3-CGLC is important for 
preventing non-native disulphide bond formation in non-acidic compartments of the cell, as 
when this motif is disrupted there are greatly increased non-secreted higher order 
oligomers in the lysate which are enhanced by intracellular alkalinisation. 
 
Subsequently a series of co-transfection experiments were performed, expressing wt D’D3 
with GlyD3 D’D3. Wt D’D3 was unable to rescue the secretion of GlyD3 D’D3, although its 
own secretion was not suppressed (Figures 4.21 and 4.22). This suggests that if D3-CGLC 
possesses intrinsic thiol isomerase activity essential for synthesis and secretion, that the 
loss of this function (in GlyD3) cannot be compensated by in trans expression of an active 
motif (in wt). However, neither does it rule out the possibility that the D3-CGLC motif 
possesses intrinsic thiol isomerase activity, as perhaps the conformation is not suitable to 
act on another domain in trans. In order to elucidate whether D3-CGLC possesses intrinsic 
thiol isomerase activity it would ideally be directly tested in a thiol isomerase activity assay. 
 
4.7.2.3 GlyD4 and GlyD5 
GlyD4 and GlyC1 secreted when expressed in HEK293T cells, with expression levels that 
were comparable to wt (Figure 4.7). The static collagen binding activity (Table 4.2) of 
GlyD4 and GlyC1 were also comparable to wt-VWF. Interestingly, while the multimeric 
pattern of GlyD4 and GlyC1 were similar to wt-VWF, demonstrating that multimerisation 
was not directly affected, the GlyD4 multimers migrated slightly less than wt suggesting 
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that these dimers have a more open configuration (Figure 4.8). A free thiol assay, based 
on the ability of recombinant VWF to bind MPB, which binds directly to free thiols, was 
performed. Both GlyD4 and GlyC1 had significantly increased free thiols compared to wt 
VWF, and the increase was comparable to 1 free thiol per monomer (Figure 4.10). This 
could suggest that the mutants still play a role in thiol-disulphide exchange although it is 
possible that the increased proportion of free thiols is caused because the insertion of the 
glycine directly disrupted the disulphide bonds of the vicinal cysteines in a proportion of 
molecules. Ideally mass spectrometry of GlyD4 and GlyC1 would be performed to analyse 
which cysteines are free compared to wt VWF.  
Whilst GlyD4 and GlyC1 do not possess thiol isomerase activity which is essential for 
intracellular VWF assembly and secretion, these motifs may play a critical role in the 
plasma, for example in self-association.  In order to investigate this, their function was 
examined in a perfusion assay. Physiologically relevant flow rates of 800s-1-3000s-1 were 
used (section 1.4.1). A shear rate of 1500s-1 was used the most frequently as initial 
platelet capture to a collagen surface is wholly dependent on the GPIbα-VWF interaction at 
this shear rate, and it requires less recombinant protein per perfusion assay than higher 
shear rates. Recombinant protein was added to the plasma-free blood at a final 
concentration of 5µg/ml, which is the lower limit of the normal range in vivo, and again is 
physiologically relevant whilst requiring the minimal amount of recombinant protein.  
 
Initially, to investigate the ability of recombinant VWF to support GPIbα dependent platelet 
tethering under flow, a suspension of RBCs supplemented with platelets was perfused 
over VWF immobilised directly onto the Ibidi® flow slide at a wall shear rate of 1500s-1. 
There was no significant difference in platelet binding to GlyD4 or GlyC1 compared to wt, 
suggesting that altering the CG(L/I)C motif does not directly affect GPIbα binding (Figure 
4.13).  
 
To investigate the ability of the recombinant VWF mutants to support platelet tethering to 
collagen under flow, plasma-free blood was perfused over a collagen-coated flow slide, 
with or without the addition of recombinant VWF. When the percentage coverage of 
accumulated platelets was examined after 5 minutes, there was no significant difference 
between GlyD4 or GlyC1 compared to wt (Figure 4.15). However, these experiments were 
then re-examined over the 5 minute time course, at 1 minute intervals. Interestingly there 
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was a trend for GlyC1 to mediate collagen-platelet binding more slowly than wt VWF. 
Whilst this did not reach statistical significance at 800s-1 or 3000s-1, it was statistically 
significant at 1500s-1.  As previously discussed, GyC1 had comparable multimeric pattern, 
static collagen binding and platelet (GPIbα) binding to wt and GlyD4. One possible 
explanation for these perfusion results over collagen is that GlyC1 cannot self-associate as 
well as wt VWF and GlyD4, and therefore does not bind platelets as effectively; consistent 
with a role for C1-CGLC in extracellular self-association. However, if this was true it is 
surprising that it only reached statistical significance at the single shear rate of 1500s-1. 
These were the results of duplicate runs, repeated on 3 separate occasions, with different 
batches of collagen and purified recombinant proteins (produced and purified in parallel 
each time). The results at 1500s-1 reach statistical significance as they have the least 
variation. It might be that if the experiments were repeated more times that the trend seen 
at both the other shear rates would also reach statistical significance. However, even so it 
is not clear that this slightly slower mediation of VWF platelet-collagen binding would be of 
clinical relevance. VWF mutants, known to cause clinically significant bleeding disorders, 
show a much greater decrease in platelet binding in this assay (see Figure 5.16 for the 
VWF mutants G1324S and H1786A which both cause VWD). 
 
 
These VWF expression and functional assays have not found an important physiological 
role of the CG(L/I)C motifs in D4 and C1. The CGLC motif in D3 may possess intrinsic thiol 
isomerase activity, essential for prevention (or reduction) of non-native disulphide-bonds in 
the ER, and thus play an essential role in the intracellular synthesis of VWF. It would be 
interesting to test the thiol isomerase activity of all these motifs directly by expressing them 
in a small fragment (similar to as already done for D3-CGLC using D’D3), purifying and 
testing them in a thiol isomerase activity assay over a physiological pH range.  
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CHAPTER 5: VWF SELF-ASSOCIATION 
5.1 INTRODUCTION 
The hypothesis that VWF self-associates through thiol-disuphide exchange, and that this is 
important physiologically in increasing the size of VWF and increasing its platelet binding 
affinity, has gained momentum in recent years. As discussed in section 1.5.1, VWF self-
association was first reported by Savage et al198 who showed that fluid-phase VWF 
multimers could homotypically associate with VWF multimers immobilised onto a glass 
surface and onto VWF immobilised onto a collagen surface. It has subsequently been 
reported by other groups that VWF self-association occurs above critical shear stress 
thresholds in a cone-plate viscometer199, on a collagen surface200, on VWF strings 
released from HUVECS215 and under certain static conditions which cause a 
conformational change (VWF bound directly to a plate203 and in the presence of high-dose 
ristocetin201). However, the kinetics of these interactions differ considerably suggesting 
that they may not all represent the same underlying interaction. Extracellular thiol-
disulphide exchange is increasingly being recognised as a way to regulate protein function 
(section 1.5.3) and indeed it has been proposed that this is the mechanism by which self-
association of VWF occurs. PdVWF and recombinant VWF both contain free 
thiols104,155,208,210,215 which have been located to specific residues in the D3 and C 
domains155,208 (section 1.5.2). One of these thiols has been predicted to form a –RHStaple 
disulphide bond which is typically a functional  allosteric disulphide bond213. In a cone-plate 
viscometer, it was shown that under physiological and pathological shear these free thiols 
were utilised, that is, formed new disulphide bonds208,209. This resulted in the hypothesis 
that lateral self-association occurs under shear by the formation of new disulphide bonds 
between adjacent multimers.  
 
However, despite the hypothesis and surrounding evidence, it has not yet been directly 
demonstrated that the self-association of VWF under physiological conditions occurs via 
thiol-disulphide exchange.  Many of the assays used to report the self-association of VWF 
have not used physiological conditions, and have not directly explored the mechanism 
behind the apparent self-association. Therefore this work aimed to develop a 
physiologically relevant perfusion assay to examine the self-association of VWF when 
perfused over a collagen surface; and to explore the role of free thiols in the self-
association of VWF, both statically and under physiologically relevant flow conditions. 
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5.1.1 Hypothesis 
Following a conformational change, such as that produced by shear, VWF can laterally 
self-associate by thiol-disulphide exchange. 
 
5.1.2 Aims 
• To examine the role of free thiols in the self-association of VWF, under both static 
conditions and under flow. 
• To develop a physiologically relevant perfusion assay to examine the mechanisms 
of VWF self-association when perfused over a collagen surface and in particular the 
role of free thiols. 
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5.2 STATIC SELF-ASSOCIATION OF VWF 
5.2.1 Purification of plasma-derived VWF from Haemate P 
In order to use pd VWF in static and perfusion assays, it was purified from Haemate P. 
Haemate P is a commercial VWF-FVIII concentrate that has a multimer pattern resembling 
normal human plasma258,259. Haemate P, re-suspended in ddH2O, was gel filtered through 
a Sephacryl S-400 gel filtration column (section 2.4.2). 5ml fractions were collected (Figure 
5.1). VWF was the first protein to be eluted, at fraction B8 in the example shown.  
 
 
 
Figure 5.1 Purification of pdVWF from Haemate P by ion-exchange chromatography. 
Haemate P was gel filtered through a Sephacryl S-400 gel filtration column. The 
chromatogram shows the 5ml fractions collected (A1-C8). VWF was the first protein to be 
eluted, shown here at fraction B8. (Chromatogram is representative of 2 purifications by 
this method.) 
 
 
The multimeric pattern of the purified pdVWF in the eluted fractions was analysed by 
multimer gel, SDS-Page and Western blot (Figure 5.2). The multimeric pattern of purified 
pdWF is similar to reference plasma (RP) although it has a greater proportion of high 
molecular weight multimers, especially in the first eluted sample. The static collagen 
binding affinity was determined by an ELISA based binding assay (section 2.4.4.3) and 
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expressed as a ratio of collagen binding to VWF antigen (VWF:CBA/VWF:Ag). The normal 
observed ratio is >0.7 for pdVWF. The collagen binding activity of VWF is highly 
dependent on multimeric size, and this is reflected in the relatively high collagen binding 
ratio of the eluted fractions (Table 5.1).  
 
 
 
Figure 5.2 Multimer gel of Haemate P size fractions. Following gel filtration, the eluted 
fractions containing VWF were analysed on a multimer gel. Fractions B9-B11 
demonstrated a similar multimer pattern to reference plasma (RP) but with a greater 
proportion of high molecular weight multimers, especially in the earliest fraction. (Gel is 
representative of 2 experiments.) 
 
 
 
Sample RP B9 B10 B11 
VWF:CBA/VWF:Ag 0.75 1.2 1.0 1.0 
 
 
Table 5.1 VWF:CBA/VWF:Ag ratios of Haemate P size fractions. An ELISA based 
collagen binding assay was used to measure the collagen binding activity of pdVWF 
purified gel filtration. It was expressed as the ratio of collagen binding to VWF antigen 
(VWF:CBA/VWF:Ag). The eluted fractions have a high collagen binding activity which 
reflects the proportion of high molecular weight multimers. (RP is reference plasma.) (The 
values represent the mean ratio of 3 experiments.) 
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5.2.2 Biotinylation of pdVWF 
In order to study static self-association using a similar ELISA based technique to that 
previously reported203, biotin was conjugated to amines on purified pdVWF. PdVWF was 
initially biotinylated using the Lightening-Link™ Biotin Conjugation Kit Type A (Innova). 
However, following the results of the static self-association assay (discussed below, Figure 
5.4), pdVWF was subsequently biotinylated using 2 other types of biotin: Amersham ECL 
Protein Biotinylation (GEHealthcare); and the biotin used by Ulrichts et al203 which has a 
long spacer arm, EZ-link® Sulfo-NHS-SS-biotin (ThermoScientific). The effectiveness of 
biotinylation was assessed using an ELISA technique (biotinylated-VWF, b-VWF, bound 
directly to microtitre plate, blocked with BSA, and detected with streptavidin-peroxidase). 
The concentration of b-VWF was measured by VWF ELISA. The VWF multimer pattern 
and static collagen binding activity were also determined. Neither the multimer pattern 
(Figure 5.3) nor collagen binding activity (Table 5.2) were affected by biotinylation. 
 
 
 
 
 
Figure 5.3 Multimer analysis of pdVWF post-biotinylation. The example shown here is 
the B11 fraction before (B11) and after (b-B11) biotinylation with EZ-link® Sulfo-NHS-SS-
biotin (ThermoScientific). The multimer pattern remains the same following biotinylation. 
(RP is reference plasma.) (The gel is representative of 2 experiments.) 
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Sample RP B11 b-B11 
VWF:CBA/VWF:Ag 0.75 1.1 1.0 
 
Table 5.2 VWF:CBA/VWF:Ag ratios post biotinylation. An ELISA based collagen 
binding assay was used to measure the collagen binding activity of purified pdVWF before 
(B11) and after (b-B11) biotinylation with EZ-link® Sulfo-NHS-SS-biotin (ThermoScientific). 
It was expressed as the ratio of collagen binding to VWF antigen (VWF:CBA/VWF:Ag). 
Biotinylation did not affect the collagen binding affinity of VWF. (RP is reference plasma.) 
(The values represent the mean ratio of 3 experiments.) 
 
 
5.2.3 Static self-association of pdVWF determined by ELISA  
The ability of VWF to self-associate under static conditions was examined by ELISA, in a 
method similar to that used by Ulrichts et al203 (section 2.6). The method was optimised 
following initial ELISAs that showed only minimal binding of b-VWF (Innova) to VWF. 
Buffers, incubation times and temperatures were varied. However, the most dramatic 
effect was achieved by changing the type of biotin bound to VWF (Figure 5.4). Briefly, 
pdVWF was bound directly to a microtitre plate and incubated overnight at 4ºC. It was 
blocked with 3% BSA and washed. Serial dilutions of b-VWF (400-3.125nM) were added 
to the wells in duplicate, and incubated for 1 hour at 37ºC. The molar concentration of 
VWF was calculated based on a monomeric weight of 250kDa, and these concentrations 
covered a physiological (approximately 30nM) and supraphysiological range. After 
incubation with streptavidin-peroxidase, bound antibody was measured with OPD. Binding 
curves were fitted to the one-site binding model using GraphPad Prism 4.0 software, to 
determine KD. b-VWF (Innova) had a poor binding fit and the KD could not be accurately 
determined. b-VWF (ThermoScientific), as used previously203, had the best fit curve and 
lowest KD = 35±5nM; b-VWF (GE Healthcare)  KD=76±16nM. 
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Figure 5.4 Static self-association assay. Purified pdVWF was bound directly to a plate, 
and then incubated with b-VWF. Bound b-VWF was detected with streptavidin-peroxidase. 
Binding curves were fitted to the one-site binding model using GraphPad Prism 4.0 
software to determine KD. b-VWF (ThermoScientific) had the best fit curve with KD 35±5nM 
and b-VWF (GEHealthcare) had  KD 76±16nM. b-VWF (Innova) had a poor binding fit and 
the KD could not be accurately determined. (Values shown are mean ±SEM of 3 separate 
experiments.) 
 
 
 
In order to investigate the role of thiol-disuphide exchange in the self-association of VWF 
under static conditions, this ELISA technique using the EZ-link® Sulfo-NHS-SS-biotin 
(ThermoScientific) was utilised. The b-VWF was incubated with 20mM NEM for 20 minutes 
to block free thiols. NEM is an alkene which reacts with thiols to form a C-S bond which is 
almost irreversible. As the stock solution of NEM was made using 70% ethanol (EtOH), 
controls were run in which the equivalent volume of 70% EtOH alone was added to 
pdVWF. Neither EtOH nor NEM affected the binding of b-VWF to pdVWF and the 
dissociation constants were unchanged (Figure 5.5), suggesting that this binding is not 
dependent on free thiols. 
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Figure 5.5 Static self-association assay ± blocking free thiols with NEM. Purified 
pdVWF was bound directly to a plate, and then incubated with b-VWF (EZ-link® Sulfo-
NHS-SS-Biotin, ThermoScientific) with or without prior incubation with 20mM NEM. Bound 
b-VWF was detected with streptavidin-peroxidase. Binding curves were fitted to the one-
site binding model using GraphPad Prism 4.0 software to determine KD. b-VWF had the 
best fit curve with KD 35±5nM, b-VWF+EtOH control KD 68±11nM, and b-VWF+NEM KD 
60±8nM. These data are comparable. (Values shown are mean ±SEM of 3 separate 
experiments.)  
 
 
5.3 SHEAR INDUCED VWF SELF-ASSOCIATION AND FREE THIOLS 
5.3.1 Effect of NEM on VWF–mediated platelet binding to collagen 
In order to study the functional effect of pdVWF and recombinant VWF mutants on VWF-
mediated platelet binding to collagen in a physiological environment, a perfusion assay 
was optimised based on those previously published198,230, as described in section 4.5.7.  
 
The effect of free thiols on VWF-mediated platelet binding to collagen was studied in the 
perfusion assay using purified pdVWF treated with NEM to block the free thiols. Initially 
NEM was added to plasma-free blood just prior to perfusion. Briefly, an uncoated plastic 
Ibidi® μ-Slide V0.1 was coated with 100µg/ml human type III collagen and blocked with 
BSA (section 2.7.2). Fresh whole blood was processed, centrifuging RBCs and platelets 
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together to minimise activation (section 2.7.1.1). Apyrase, PGE1 and EDTA were added 
during processing to prevent platelet activation and platelets were rendered fluorescent 
with 1nM DiOC6. Purified pdVWF was added to the plasma-free blood at a final 
concentration of 5µg/ml (lower end of normal range) and NEM was added just prior to 
perfusion (final concentration 5-50mM). The stock solution of NEM was made in 70% 
EtOH, and therefore an equivalent volume of 70% EtOH was added to the pdVWF control. 
The plasma-free blood preparation was then perfused over collagen at a wall shear rate of 
1500s-1 for 5 minutes. At this shear rate platelet binding to collagen is dependent on VWF, 
and self-association of VWF has been reported198. Accumulated platelet surface coverage 
was measured as previously described (sections 2.7.5 and 4.5.8).  
 
NEM reduced accumulated platelet surface coverage at all concentrations, reducing the 
platelet binding with increasing concentration until at 50mM there was virtually no platelet 
binding to collagen (Figure 5.6). This was statistically significant at all concentrations, even 
though at 5mM there was only a small difference in mean coverage (mean 24.4% to 
22.3%, p<0.05). This reduction in platelet capture following blocking of free thiols may 
result from prevention of VWF self-association. However as the platelet-capture was 
reduced so significantly at 50mM NEM, it seems likely that at least one factor other than 
self-association has been affected by the NEM. NEM may have reduced the ability of VWF 
to bind to platelets or to collagen. Furthermore, as NEM was added directly to the plasma-
free blood it may have had a direct effect on platelets or collagen. It is noteworthy that 
while non-activated platelets cannot bind to collagen type III directly at a shear rate of 
1500s-1, once they are slowed down by VWF-GPIbα interaction then they may bind directly 
to collagen by the GPVI receptor.  
 
 
169 
 
Figure 5.6 Perfusion of pdVWF over collagen with NEM added just prior to flow. 
Plasma-free blood was perfused over collagen coated flow slides at 1500s-1 for 5 minutes. 
Purified pdVWF was added at 5µg/ml, and NEM was added just prior to perfusion (final 
concentration 5-50mM). An equivalent volume of 70% EtOH was added to the control 
pdVWF. Short movies (1s, frames every 0.05s) were recorded at 5 minute end-point using 
a QImaging camera and QCapture pro software. The accumulated platelets were 
assessed by stacking 3 frames (to remove translocating platelets) and percentage surface 
coverage measured using ImageJ. NEM reduced accumulated platelet surface coverage 
at 5 minutes at all concentrations, reducing platelet-binding with increasing concentration 
until at 50mM there was virtually no platelet-binding to collagen. This was statistically 
significant at all concentrations, even though at 5mM there was only a small difference in 
mean (mean 24.4% to 22.3%, p<0.05). (Values are mean ±SEM of duplicate experiments 
performed on 3 separate occasions.)  
 
 
 
5.3.2 Controls 
Further perfusion assays were undertaken to investigate whether there was a direct effect 
of NEM on platelet-VWF binding or platelet-collagen binding, or VWF-collagen binding.  
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5.3.2.1 Control: effect of NEM on platelet-VWF binding 
First, in order to investigate any effect of NEM on platelet-VWF binding, platelets ±NEM 
were perfused over pdVWF bound directly to a flow slide. The NEM was added just prior to 
flow in order to block any exposed free thiols on platelets. It may also have had sufficient 
time to block free thiols exposed on the surface-bound VWF. Briefly, pdVWF which had 
been purified by gel filtration was bound directly to a standard hydrophobic plastic Ibidi® µ-
SlideV0.1 at a saturating concentration. Platelets in a suspension of RBCs were perfused 
over the slides at 1500s-1 as previously described (sections 2.7.1.2 and 4.5.7.1). NEM 
(5mM-50mM) was added to the processed blood just prior to perfusion. After 3 minutes a 
short movie was taken in 3 fields of view and the surface coverage of the accumulated 
platelets was assessed as before.  Interestingly there was no effect on platelet-VWF 
binding (Figure 5.7).  
 
Figure 5.7 Perfusion of platelets ±NEM over pdVWF bound directly to slide. Platelets 
in a suspension of RBCs were perfused over purified pdVWF bound directly to standard 
flow slide at a wall shear rate of 1500s-1 for 3 minutes. NEM (5mM-50mM) was added just 
prior to perfusion. A short movie was taken in 3 fields of view using a QImaging camera 
and QCapture pro software. The accumulated platelets at each time point were assessed 
by stacking 3 frames (to remove translocating platelets) and quantified using ImageJ to 
measure surface coverage (%). NEM had no effect on platelet-VWF binding. (Values 
shown are mean ±SEM of duplicate experiments performed on 3 separate occasions.) 
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5.3.2.2 Control: effect of NEM on platelet-collagen binding 
In order to investigate whether NEM had a direct effect on platelet-collagen binding, 
plasma-free blood was perfused over collagen (with no added VWF) at 300s-1. At this 
shear rate non-activated platelets can bind to type III collagen directly. Briefly, a standard 
plastic Ibidi® μ-Slide V0.1 was coated with 100µg/ml human type III collagen. Fresh whole 
blood was processed, centrifuging RBCs and platelets together, as previously described 
(section 5.3.1). NEM was added just prior to perfusion (final concentration 5-50mM). An 
equivalent voume of 70% EtOH was added to the control (+0mM NEM). The plasma-free 
blood preparation was then perfused over the collagen at a wall shear rate of 300s-1 for 5 
minutes. Interestingly there was a significant reduction in the direct binding of platelets to 
collagen with increasing concentration of NEM (mean surface coverage with 0mM and 
5mM NEM was 11.8% and 7.1% respectively, p<0.05) (Figure 5.8).  
 
Figure 5.8 Perfusion of plasma-free blood ±NEM over collagen at 300s-1. Plasma-free 
blood was perfused over a collagen-coated flow slide at a wall shear rate of 300s-1 for 5 
minutes. NEM (5-50mM) was added just prior to perfusion. A short movie was taken in 3 
fields of view using a QImaging camera and QCapture pro software. The accumulated 
platelets at each point were assessed by stacking 3 frames (to remove translocating 
platelets) and quantified using ImageJ by measuring surface coverage (%). Accumulated 
surface coverage at 3 minute endpoint is shown. There was a reduction in the direct 
binding of platelets to collagen with increasing concentration of NEM (mean surface 
coverage 0mM and 5mM NEM was 11.8% and 7.1% respectively, p<0.05). (Values shown 
are mean ±SEM of duplicate experiments performed on 3 separate occasions.) 
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5.3.2.3 Control: effect of NEM on VWF-collagen binding under flow 
In order to investigate whether there was a direct effect of NEM on the ability of VWF to 
bind collagen under flow, a control experiment was performed in which VWF±NEM was 
perfused over collagen-coated flow slides in buffer. The technique was previously 
described in section 4.5.8. Briefly, a standard flow slide was coated with collagen and 
blocked. Purified pd VWF was added to buffer rather than plasma-free blood (section 
2.7.5) and then perfused at 1500s-1 over the collagen (in-flow). After 5 minutes the 
perfusion was stopped, the slide was stripped, and then analysed by SDS-PAGE under 
reducing conditions and Western blot. The conditions used were:  
1- BSA but no collagen bound, pdVWF 
2- pdVWF 
3- pdVWF 
4- pdVWF+ 20mM NEM added to buffer (just prior to perfusion) 
5- pdVWF +20mM NEM added to buffer (incubated for 20 minutes prior to perfusion) 
6- bound collagen incubated with 20mM NEM in buffer, washed, then perfusion of pdVWF.  
Purified pdVWF bound to collagen under flow to a similar extent, with or without the 
presence of NEM (Figure 5.9). 
 
 
 
Figure 5.9 Effect of NEM on VWF-collagen binding under flow. Purified pdVWF 
(5µg/ml) in buffer was perfused over a collagen-coated flow slide at 1500s-1 for 5 minutes. 
The conditions used were: 1- BSA but no collagen bound, pdVWF; 2- pdVWF; 3- pdVWF; 
4- pdVWF+ 20mM NEM added to buffer (just prior to perfusion); 5- pdVWF +20mM NEM 
added to buffer (incubated for 20 minutes prior to perfusion); 6- 20mM NEM incubated with 
bound collagen, washed, then perfusion of pdVWF. The slides were washed, stripped, and 
analysed by SDS-PAGE under reducing conditions and Western blot. Purified pdVWF 
bound to collagen under flow to a similar extent, with or without the presence of NEM. (Gel 
is representative of 2 separate experiments.)  
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5.3.3 Effect of pre-treatment NEM on VWF-mediated platelet binding to collagen 
The above controls show that NEM affects direct platelet-collagen binding activity. 
However no effect of NEM VWF-platelet binding or VWF-collagen binding was detected. 
Therefore in order to avoid the confounding factor of a direct effect of platelet-collagen 
binding activity, pdVWF which had been pre-treated with NEM (unbound NEM removed by 
dialysis) was perfused over collagen.  
 
5.3.3.1 Pre-treatment of VWF with NEM 
The purified pd VWF was pre-treated with NEM and then dialysed to remove any unbound 
NEM (section 2.7.6). Briefly, purified pdVWF was incubated with 20mM NEM (in 70% 
EtOH) and any unbound NEM was removed by dialysis in 20mM Tris, pH7.4. In order to 
be certain that there was no NEM remaining, another sample was treated in the same 
way, but the reaction was quenched with 40mM GSH prior to dialysis. Controls, with the 
equivalent volume of 70% EtOH alone, were run in parallel. All the fractions were re-
quantified using the VWF ELISA. 
 
The fractions were run on a multimer gel and Western blot performed. NEM and EtOH had 
no discernible effect on multimer structure (Figure 5.10). GSH resulted in a significant shift 
down in multimer size, suggesting that GSH directly reduces VWF, and that there is some 
free GSH left after it has bound all the NEM (Figure 5.10). 
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Figure 5.10 Multimer gel of purified pdVWF following treatment with NEM and GSH. 
Fraction B10 was treated with 20mM NEM (or 70% EtOH as a control). This was either 
dialysed out directly, or quenched with 40mM GSH prior to dialysis. NEM and EtOH had 
no discernible effect on multimer structure. GSH resulted in a significant shift down in 
multimer size, suggesting that GSH directly reduces VWF, and that there is some free 
GSH left after it has bound all the NEM. (Gel is a representative example of 2 
experiments.) 
 
 
 
Multimer pattern is a determinant of collagen binding activity because the highest 
molecular weight multimers have the greatest collagen binding affinity. Collagen binding 
activity was measured directly using an ELISA-based binding assay (section 2.4.4.3) and 
expressed as a ratio of collagen binding to VWF antigen (VWF:CB/VWF:Ag). The B10 
fraction of purified pdVWF has a relatively high ratio of 1.0 which reflects the greater 
proportion of high molecular weight multimers present on the multimer gel. NEM and EtOH 
did not affect the collagen binding activity (Table 5.3). However, when GSH was added to 
VWF it reduced the collagen binding activity, most marked without the presence of NEM 
(Table 5.3). GSH is a potent reducing agent and as can be seen from the multimer gel 
(Figure 5.10) it reduced VWF. Given the significant shift down of multimers seen on the 
gel, one might have expected an even greater reduction in collagen binding activity. 
 
175 
 
PdVWF B10 B10+NEM B10+EtOH B10+NEM 
(GSH) 
B10+EtOH 
(GSH) 
VWF:CBA/VWF:Ag 1.0 1.2 1.1 0.8 0.4 
 
Table 5.3 VWF:CB/VWF:Ag ratios for pdVWF treated with NEM and GSH. An ELISA 
based collagen binding assay was used to measure the collagen binding activity of pdVWF 
following treatment with NEM and GSH. The collagen binding activity was calculated as a 
ratio of collagen binding to VWF antigen (VWF:CB/VWF:Ag). The B10 fraction of purified 
pdVWF has a relatively high ratio of 1.0. NEM and EtOH did not affect this collagen 
binding activity. However, when GSH was added to VWF it reduced the collagen binding 
activity, most markedly in the absence of NEM. (The values represent the mean ratio of at 
least 3 experiments.) 
 
 
5.3.3.2 Perfusion of pdVWF (pre-treated with NEM) in plasma-free blood over collagen 
The pdVWF which had been pre-treated with 20mM NEM (unbound NEM removed by 
dialysis) was perfused over collagen. Note that the preparations which had been quenched 
with GSH were not used, as these had reduced higher order multimers and collagen-
binding activity. 
 
Briefly, 5µg/ml of pdVWF+20mM NEM (unbound NEM removed by dialysis) was added to 
plasma-free blood and perfused over a collagen coated flow slide as previously described 
at 1500s-1 (section 5.3.1). The control was pdVWF+EtOH which had been treated in a 
similar manner (section 5.3.3.1). PdVWF, pre-treated with 20mM NEM, showed reduced 
platelet capture at 5 minutes (mean 23.7% to 20%, reduction of 15%, paired t-test p<0.05) 
(Figure 5.11, A). This reflected a slower rate of accumulation (Figure 5.11, B) although 
unfortunately this had not plateaued by 5 minutes and so it is not known whether the same 
maximum would eventually be reached. Over the 5 minute time-course, comparing area 
under the curves, pre-treatment with NEM resulted in a 39% decrease in platelet capture. 
These results are broadly similar to the initial work which had suggested a 25-50% effect 
of self-association on VWF-mediated platelet binding at 2 minutes198. This effect could 
therefore be due to prevention of VWF self-association, but it is possible that a small 
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undetected effect of NEM on VWF-collagen binding under shear or on VWF-platelet 
binding might result in this decreased rate of VWF-mediated platelet capture to collagen. 
Because of these possible alternative explanations, to ensure that we could indeed detect 
self-association in this flow system, a series of experiments were planned based on the 
principle of using a platelet-binding mutant to complement a collagen-binding mutant. 
 
 
 
Figure 5.11 Perfusion of plasma-free blood over collagen with pdVWF ± 
pretreatment with 20mM NEM. Plasma-free blood was perfused over a collagen-coated 
flow slide at a wall shear rate of 1500s-1. PdVWF ± pre-treatment with 20mM NEM 
(unbound removed by dialysis) was added at a final concentration of 5µg/ml. Short movies 
(1s, frames every 0.05s) were taken at 30s intervals using a QImaging camera and 
QCapture pro software. The accumulated platelets at each time point were assessed by 
stacking 3 frames (to remove translocating platelets) and measured as surface coverage 
(%) using ImageJ. (A) Accumulated surface coverage at 5 minute endpoint is shown. 
Following pre-treatment with NEM there was mean reduction 15% (paired t-test p<0.05). 
(B) Time course of platelet accumulation. Following pre-treatment with NEM there was a 
slower rate of platelet accumulation. Over this 5 minute time course, area under the curve 
analysis gives a 39% reduction in platelet capture following pre-treatment of VWF with 
NEM. (Values shown are mean ±SEM of duplicate experiments performed on 3 separate 
occasions.) 
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5.4 SHEAR INDUCED SELF-ASSOCIATION: PLATELET- AND COLLAGEN- BINDING 
MUTANTS  
To ensure that we could indeed detect self-association in this flow system, a series of 
experiments were planned based on the principle of using a platelet binding mutant and 
collagen-binding mutant combination (Figure 5.12). ΔA1 and ΔA3 had been used by 
Savage et al198. In order to also use a different combination, with point mutations rather 
than whole domain deletions, we utilised the platelet-binding mutant, G1324S, and the 
collagen-binding mutant, H1786A, both of which have been well-documented260-262. 
 
 
 
Figure 5.12 Schematic of self-association of VWF. At a wall shear rate of 1500s-1 
platelet binding to collagen is VWF-dependent. ΔA1-VWF binds to collagen but cannot 
bind platelets directly as it lacks the receptor for GPIbα. However ΔA3-VWF (which cannot 
bind to collagen directly) binds to ΔA1-VWF by lateral self-association. Platelets bind via 
GPIbα to ΔA3-VWF. Hence VWF-mediated platelet binding to collagen can occur providing 
VWF self-association takes place.   
 
5.4.1 Expression, characterisation and purification of proteins for self-association 
flow assays 
5.4.1.1 Expression 
The platelet-binding mutants, ΔA1 and G1324S, and the collagen-binding mutant, ΔA3, 
had been previously made in the vector pcDNA3.1 FL-VWF by Dr Agata Nowak. The 
collagen-binding mutant, H1786A, had been previously made in the same vector by Dr 
Tom McKinnon. Large scale DNA preparations were made and used for transient 
transfection of mammalian HEK293T cells (section 2.3.3).  
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Wt VWF, platelet- and collagen- binding mutants were initially expressed on a small scale. 
The concentration of each VWF variant in the conditioned media and cell lysate was 
compared by VWF ELISA (section 2.4.4.2). G1423S and H1786A secreted at levels 
comparable to wt (mean media:lysate ratios 2.2 and 1.6 compared to 1.9, p=0.2 and p=0.3 
respectively). Whilst ΔA1 and ΔA3 secreted at reasonable levels they secreted less 
efficiently than wt (mean media:lysate ratios 0.75 and 1.16 compared to 1.9, p<0.05) 
(Figure 5.13).   
 
 
Figure 5.13 Expression of platelet- and collagen- binding mutants. The concentration 
of VWF in media and lysate, determined by the VWF ELISA, is shown. G1423S and 
H1786A secreted at levels comparable to wt (mean media:lysate ratios 2.2 and 1.65 
compared to 1.9, p=0.2 and p=0.3 respectively). Whilst ΔA1 and ΔA3 secreted at 
reasonable levels, they secreted less efficiently than wt (mean media:lysate ratios 0.75 
and 1.16 compared to 1.9 p<0.05).  (Values shown here are mean ±SEM of three separate 
transfections performed in duplicate.) 
 
5.4.1.2 Purification 
In order to express and purify enough protein for analysis in the flow assays, large scale 
transient transfections of HEK293T cells were performed. Approximately 200mls of 
expression media for each mutant were collected and filtered. The recombinant VWF was 
purified by ion exchange chromatography and some by additional Heparin-Sepharose 
chromatography, as discussed previously (section 4.5.6). Briefly, recombinant VWF was 
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purified by ion exchange chromatography using a previously equilibrated Fractogel-EMD-
TMAE+ column. The bound VWF was eluted using 500mM NaCl. For the majority of 
experiments, this level of purification was adequate. A sample of all recombinant proteins 
would ideally have been further purified by Heparin-Sepharose chromatography for direct 
binding to Ibidi flow slides, to remove the concern of protein contaminants interfering with 
this binding. However the main heparin binding site is within the A1 domain263-265, so that 
ΔA1 could not be purified further this way. Only samples of G1324S and H1786A were 
therefore further purified by Heparin-Sepharose chromatography.  The eluted VWF was 
dialysed into 20mM Tris, pH7.4, and the purity of the eluted material was analysed using 
SDS-PAGE, Coomassie and Western blot. The purified VWF was then quantified by VWF 
ELISA, and analysed by multimer gel and static collagen binding assay. The typical VWF 
recovery after ion exchange chromatography was 80%, and this reduced to 50% after 
subsequent Heparin-Sepharose chromatography. The multimer structure and collagen 
binding activity of VWF before and after purification was similar, although there was a 
tendency to lose the highest molecular weight multimers. 
 
 
5.4.1.3 Multimer analysis 
The multimeric composition of expressed recombinant VWF was analysed by agarose gel 
electrophoresis followed by Western blot, both before and after purification. The multimeric 
composition of the mutants was compared to that of recombinant wt VWF and reference 
plasma (RP). The multimeric pattern after purification by ion-exchange chromatography is 
shown (Figure 5.14). The collagen binding mutants (ΔA3 and H1786A) show a similar 
multimeric pattern to wt. The platelet binding mutants both show a slight reduction of high 
molecular weight multimers, more marked for ΔA1, similar to previous reports146,261 (Figure 
5.14).  
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Figure 5.14 Multimer gel of platelet- and collagen- binding mutants. The multimer 
pattern of recombinant VWF was verified before and after purification. The multimer gel 
shown demonstrates the multimer pattern after purification by ion-exchange 
chromatography. The collagen binding mutants (ΔA3 and H1786A) had a similar multimer 
pattern to wt. The platelet binding mutants (ΔA1 and G1324S) both had a slight reduction 
of high molecular weight multimers, more marked for ΔA1. (RP is reference plasma.) (This 
gel is representative of at least 2 experiments.) 
 
 
5.4.1.4 Collagen-binding activity 
The effect of mutations on binding to type III collagen was assessed by an ELISA based 
binding assay and calculated as a ratio of collagen binding to VWF antigen 
(VWF:CB/VWF:Ag). Wt VWF had a VWF:CB/VWF:Ag ratio of 0.49. The platelet binding 
mutants (ΔA1 and G1324S) both showed comparable, though slightly reduced, collagen 
binding activity to wt. This slight reduction is probably a reflection of the reduced number of 
high molecular weight multimers (Table 5.4). Both collagen-binding mutants (ΔA3 and 
H1786A) showed a greatly reduced collagen binding activity to wt despite normal multimer 
pattern (p<0.05) (Table 5.4).  
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Mutant wt ΔA1 ΔA3 G1324S H1786A 
VWF:CBA/VWF:Ag 0.49 0.35 0.15 0.4 0.18 
 
Table 5.4 VWF:CB/VWF:Ag ratios for platelet- and collagen- binding mutants. A static 
ELISA based collagen binding assay was used to measure the collagen binding activity of 
recombinant VWF. It was expressed as a ratio of collagen binding to VWF antigen (VWF 
CBA:VWF Ag). The platelet binding mutants (ΔA1 and G1324S) showed comparable, 
though slightly reduced, collagen binding activity to wt. Both collagen-binding mutants 
(ΔA3 and H1786A) showed a greatly reduced collagen binding activity to wt despite 
normal multimeric pattern (p<0.05). (The values represent the mean ratio of 3 
experiments.) 
 
5.4.1.5 Platelet-binding activity 
To investigate the ability of the recombinant VWF to support GPIbα dependent platelet 
tethering under flow, a suspension of RBCs supplemented with platelets was perfused 
over VWF immobilised directly onto the flow slide, as described previously (4.5.7).   
 
There was no significant difference in platelet binding to the collagen-binding mutants 
(ΔA3 or H1786A) compared to wt VWF at 3 minutes (Figure 5.15). Both the platelet-
binding mutants (ΔA1 and G1324S) showed significantly reduced ability to capture 
platelets (Figure 5.15). Whilst this was expected, the amount of VWF bound to the slide 
using this technique was checked by stripping and analysis by SDS-PAGE and Western 
blot (section 2.7.2).  This was similar for wt, ΔA1 and ΔA3 (Figure 5.16).  
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Figure 5.15 Perfusion of plasma-free blood over collagen- and platelet- binding 
mutants. Plasma-free blood was perfused over purified recombinant VWF bound directly 
to the Ibidi® flow slide at 1500s-1. Recombinant VWF was purified either by ion-exchange 
alone (wt IE, ΔA1 and ΔA3) or by both ion-exchange and Heparin-Sepharose affinity 
chromatography (wt HS, H1786A and G1324S). Short movies (1s, frames every 0.05s) 
were recorded after 3 minutes in 3 fields of view using a QImaging camera and QCapture 
pro software. The accumulated platelets at each time point were assessed by stacking 3 
frames (to remove translocating platelets) and surface coverage (%) measured using 
ImageJ. ΔA3 and H1786A bound platelets comparably to wt. The platelet-binding mutants 
(ΔA1 and G1324S) showed a significantly reduced ability to capture platelets (p<0.05). 
(Values shown are mean ±SEM of duplicate experiments performed on 3 separate 
occasions.) 
 
 
 
Figure 5.16 Recombinant VWF bound to the flow slide. Recombinant VWF was bound 
directly to the standard hydrophobic plastic flow slides. The slides were washed, then 
stripped, and this was analysed by SDS-PAGE under reducing conditions and Western 
blot. Wt, ∆A1 and ∆A3 bound to the flow slides in comparable amounts. (Gel is 
representative of 2 experiments.)  
183 
5.4.2 Perfusion of plasma-free blood with recombinant VWF over collagen 
The optimised perfusion assays were used to study the lateral self-association of the 
different recombinant VWF mutants over a collagen surface under shear. Whilst the 
perfusion of either a collagen-binding mutant or a platelet-binding mutant in plasma-free 
blood over collagen would not result in significant platelet capture; if physiologically 
relevant self-association occurs on a collagen surface the perfusion of both mutants 
simultaneously should result in platelet capture.  
 
As before (section 5.3.1), a standard Ibidi® μ-Slide V0.1 was coated with 100µg/ml human 
type III collagen. Purified recombinant VWF was added to plasma-free blood at a final 
concentration of 5µg/ml. In contrast to other perfusion assays described, either an 
individual VWF mutant was added, or a pair of mutants were added simultaneously 
(5µg/ml each). The plasma-free blood preparation was then perfused at a wall shear rate 
of 1500s-1 for 5 minutes. At this shear rate platelet binding to collagen is dependent on 
VWF, and self-association of VWF has been shown previously198. As expected, when the 
platelet and collagen binding mutants were perfused individually over collagen at 1500s-1 
very little capture of platelets onto collagen was seen (Figure 5.17). However, when the 
collagen-binding mutant and platelet-binding mutant were perfused simultaneously 
(ΔA1+ΔA3 and G1324S+H1786A) no significant additional platelet binding was seen 
(Figure 5.17). This suggests that either no significant lateral self-association was occurring 
in this physiologically relevant system, or that there was an unexpected abnormality in the 
platelet- or collagen- binding activity of these recombinant mutants. 
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Figure 5.17 Perfusion of plasma-free blood with recombinant VWF over collagen. 
Recombinant VWF (5µg/ml) in plasma-free blood was perfused over a collagen coated 
Ibidi® flow slide at 1500s-1 for 5 minutes. Short movies (1s, frames every 0.05s) were 
recorded after 5 minutes using a QImaging camera and QCapture pro software. The 
accumulated platelets were assessed by stacking 3 frames (to remove translocating 
platelets) and surface coverage (%) measured using ImageJ. When the platelet- and 
collagen- binding mutants were perfused individually over collagen at 1500s-1 very little 
capture of platelets onto collagen was seen. When a collagen-binding mutant and platelet-
binding mutant were perfused simultaneously (ΔA1+ΔA3 and G1324S+H1786A) no 
significant additional platelet binding was seen. (Values shown are mean ±SEM of 
duplicate experiments, repeated on 3 separate occasions.)  
 
5.4.2.1 Control of collagen binding activity of recombinant mutants under flow 
The ability of the mutants to capture platelets (section 5.4.1.5), and the static collagen 
binding activity of all the mutants (section 5.4.1.4) had already been demonstrated. The 
ability of the mutants to bind to collagen under flow conditions was next investigated. The 
experiment described above (section 5.4.2) was repeated using buffer rather than plasma-
free blood. That is, recombinant VWF was added to buffer at a final concentration of 
5µg/ml. It was perfused over a collagen-coated flow slide at 1500s-1 for 5 minutes. After 5 
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minutes the perfusion was stopped, the slide was stripped, and the eluate analysed by 
SDS-PAGE and Western blot. wt VWF and ΔA1 bound to collagen under flow conditions to 
a similar extent (Figure 5.18). The collagen-binding mutant ΔA3 could not be detected.  
 
 
 
Figure 5.18 Recombinant VWF bound to collagen under flow. Recombinant VWF 
(5µg/ml) in buffer was perfused over a collagen-coated flow slide at 1500s-1 for 5 minutes. 
The slides were washed, stripped, and analysed by SDS-PAGE under reducing conditions 
and Western blot. Wt and ∆A1 bound to the collagen in comparable amounts. ∆A3 alone 
did not bind to the collagen. (Gel is representative of 2 experiments.) 
 
 
This set of control experiments show that the platelet-binding mutants (ΔA1 and G1324S) 
bound to collagen under both static and flow conditions, whilst having greatly reduced 
ability to bind to platelets. Conversely, the collagen-binding mutants (ΔA3 and H1786A) 
showed greatly reduced binding to collagen under both static and flow conditions, but 
normal platelet binding affinity. When collagen- and platelet- binding mutants were 
perfused simultaneously in plasma-free blood over collagen there was no significant 
platelet capture. This suggests that significant lateral self-association does not occur on a 
collagen surface in this assay at 1500s-1.  
 
5.4.3 Perfusion of whole blood over slides directly coated with recombinant VWF 
As seen in the last section, when collagen- and platelet- binding mutants were perfused 
simultaneously over collagen there was no significant platelet capture. In order to attempt 
to detect self-association under flow, a similar assay to that previously reported198 was 
performed. Savage et al198 perfused platelets over immobilised ΔA1-VWF at 1500s-1. 
Platelets in plasma-free blood failed to bind, but platelets in either whole blood or in 
plasma free blood with additional soluble wt VWF adhered promptly. In this study they 
used glass slides, and a glass surface may be either hydrophobic or hydrophilic. It has 
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been shown that VWF binds differently to different surfaces, unravelling more on a 
hydrophilic surface172. Because the conformation of VWF is likely to be critical for self-
association, we bound ΔA1 to glass Ibidi® slides, standard hydrophobic plastic Ibidi® µ-
Slide V0.1 slides, and hydrophilic plastic Ibidi® µ-Slide V0.1 slides (plastic surface designed 
to be hydrophilic for tissue culture). ΔA3 and wt were used as controls. 
 
Briefly, ΔA1, ΔA3 and wt VWF which had been purified by ion-exchange chromatography 
were bound to the Ibidi® flow slides at a saturating concentration. Fresh whole blood was 
collected into ACD and apyrase, PGE1 and EDTA were added to the whole blood to 
prevent platelet activation as previously198. Platelets were fluorescently labelled using 
10nM DiOC6 (section 2.7.1.3). The whole blood was then perfused over the flow slides at a 
wall shear rate of 1500s-1 for 3 minutes.  
 
Wt and ΔA3 both captured platelets with comparable affinity independent of the surface, 
although they both bound fewer platelets when bound directly to glass compared to plastic 
flow slides (Figure 5.19). However, ΔA1 did not capture platelets from whole blood when 
bound directly to either glass or plastic flow slides (Figure 5.19). Controls to show that ΔA1 
bound to the standard hydrophobic slide in similar quantity to wt and ΔA3 (Figure 5.16); 
and that wt and ΔA3 bound platelets directly from plasma-free blood (Figure 5.15) have 
already been shown. It remained a possibility that whilst self-association had previously 
been shown at a wall shear rate of 1500s-1, as used here, that self-association might be 
seen in this system at a different shear rate.  
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Figure 5.19 Perfusion of whole blood at 1500s-1 over recombinant VWF bound 
directly to flow slides. Whole blood was perfused at 1500s-1 for 3 minutes over 
recombinant VWF coated directly to Ibidi® flow slides with different surfaces (glass, 
hydrophobic plastic, hydrophilic plastic). Short movies (1s) were recorded after 3 minutes 
in 3 fields of view using a QImaging camera and QCapture pro software. The accumulated 
platelets were assessed by stacking 3 frames (to remove translocating platelets) and 
surface coverage (%) measured using ImageJ. Wt and ΔA3 both captured platelets with 
comparable affinity independent of the surface, although they both bound fewer platelets 
when bound directly to glass compared to plastic flow slides. However, ΔA1 did not 
capture platelets from whole blood when bound directly to either glass or plastic flow 
slides. (Values shown are mean ±SEM of duplicate experiments run on 3 separate 
occasions.) 
 
 
In order to investigate whether self-association of VWF could be detected in this system at 
different flow rates, the above experiment was carried out again using wall shear rates 
between 800s-1 and 10000s-1. Purified wt and ΔA1 VWF were bound directly to the 
standard hydrophobic plastic Ibidi® µ-Slide V0.1. Whole blood was treated as before, and 
then perfused over the slides at different wall shear rates (800-10000s-1) for 3 minutes. Wt 
VWF captured platelets from whole blood at all shear rates tested, although fewer platelets 
accumulated at the highest shear rates (Figure 5.20). However no significant capture of 
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platelets was seen onto ΔA1 at any shear rate (Figure 5.20). Self-association of VWF 
could not be detected in this perfusion assay. 
 
 
Figure 5.20 Perfusion at different shear rates of whole blood over recombinant VWF 
coated directly to the slide. Whole blood labelled with DiOC6 was perfused at 800s
-1, 
1500s-1, 5000s-1 and 10000s-1 for 3 minutes over recombinant VWF coated directly to 
hydrophobic plastic Ibidi® flow slides. Short movies (1s) were recorded after 3 minutes in 3 
fields of view using a QImaging camera and QCapture pro software. The accumulated 
platelets were assessed by stacking 3 frames (to remove translocating platelets), 
measured using ImageJ and assessed as surface coverage (%). Wt VWF captured 
platelets from whole blood at all shear rates tested, although fewer platelets accumulated 
at the highest shear rates. However no significant capture of platelets was seen onto ΔA1 
at any shear rate. (Values shown are mean ±SEM of duplicate experiments run on 3 
separate occasions.) 
 
5.4.3.1 Control: effect of blood anticoagulation with PPACK 
During the above experiments we had copied Savage’s techniques198 closely. However, 
our initial collection of blood had been into ACD anticoagulant rather than PPACK. To 
verify that this was not the cause of the discrepant results, the experiment was repeated 
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as described above in (section 5.4.3) but collecting the whole blood into PPACK 
anticoagulant.  
 
Briefly, whole blood was collected into PPACK. Apyrase, PGE1 and EDTA were added to 
the whole blood to prevent platelet activation as previously198 and platelets were rendered 
fluorescent with 10nM DiOC6. The whole blood was then perfused over flow slides coated 
with ΔA1 and wt VWF, at a wall shear rate of 1500s-1 for 3 minutes as previously198.  When 
these results are compared to Figure 5.15 (perfusion of plasma-free blood over bound 
VWF) ΔA1 did not capture a significantly increased amount of platelets from whole blood 
(Figure 5.21)  
 
 
Figure 5.21 Perfusion of whole blood in PPACK over ΔA1. Whole blood, collected into 
PPACK, was perfused at 1500s-1 for 3 minutes over recombinant VWF coated directly to a 
standard hydrophobic plastic Ibidi® µ-Slide V0.1. Short movies (1s) were recorded after 3 
minutes in 3 fields of view using a QImaging camera and QCapture pro software. The 
accumulated platelets at each time point were assessed by stacking 3 frames (to remove 
translocating platelets) and surface coverage (%) measured using ImageJ. ΔA1 did not 
capture significant amount of platelets from whole blood. (Values shown are mean ±SEM 
of duplicate experiments run on 3 separate occasions.) 
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5.4.3.2 Control: perfusion of whole blood over slides directly coated with platelet-binding 
point mutant 
Whilst the ΔA1 mutant expressed from our HEK293T cells should be almost identical to 
that used by Savage et al198, it is conceivable that there is a crucial conformational 
difference (domain boundaries for ΔA1 differ by 3 amino acids). Additionally, a domain 
deletion represents a large conformational change compared to a point mutation. The 
platelet-binding point mutant, G1324S, was therefore also tested in this assay. 
 
Wt VWF, G1324S and H1786A which had been purified by both ion-exchange and 
Heparin-Sepharose affinity chromatography were used. They were bound directly to the 
standard hydrophobic Ibidi® µ-Slide V0.1. Whole blood collected into ACD and treated as 
previously was perfused at a wall shear rate of 1500s-1. The platelet-binding mutant bound 
platelets significantly less effectively than either wt or H1786A (Figure 5.22), and 
comparably to plasma-free blood (Figure 5.15). 
 
Figure 5.22 Perfusion of whole blood over the platelet-binding mutant G1324S.  
Whole blood was perfused at 1500s-1 for 3 minutes over purified recombinant VWF coated 
directly to standard hydrophobic plastic Ibidi® flow slides. Short movies (1s) were recorded 
after 3 minutes in 3 fields of view using a QImaging camera and QCapture pro software. 
The accumulated platelets at each time point were assessed by stacking 3 frames (to 
remove translocating platelets), measured using ImageJ and assessed as surface 
coverage (%). Wt and H1876A both captured platelets with comparable efficiency. 
G1324S did not capture a significant amount of platelets. (Values shown are mean ±SEM 
of duplicate experiments run on 3 separate occasions.) 
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5.5 DISCUSSION 
It has been hypothesised that VWF laterally self-associates by thiol-disulphide exchange, 
and that this is important physiologically in increasing the size of VWF and increasing its 
platelet binding affinity (section 1.5). However, many of the experiments used to report the 
self-association of VWF have not used physiological conditions, and have not directly 
explored the mechanism behind the apparent self-association. Therefore this work aimed 
to develop a physiologically relevant perfusion assay to examine the self-association of 
VWF when perfused over a collagen surface; and to explore the role of free thiols in the 
self-association of VWF, both statically and under physiologically relevant flow conditions. 
 
5.5.1 Static self-association 
Initially I attempted to detect the self-association of VWF under static conditions, and to 
test whether this was dependent on free thiols. I optimised an ELISA assay based on that 
described previously203. Interestingly the type of biotin used had a profound effect (Figure 
5.4). The most convincing binding curve was produced by EZ-link® Sulfo-NHS-SS-biotin 
(ThermoScientific), KD 35±5nM, which was the biotin used in the previous study which 
found a broadly comparable KD of ~90nM.
203. This biotin is attached by a long spacer arm, 
and it may be that whilst biotin is a small molecule it otherwise interferes with the self-
association of VWF. Alternatively, although biotinylation does not usually change the 
conformation of a protein, it is possible that in this instance it does, and self-association 
only occurs because of this. As the VWF concentration in the blood is approximately 30nM 
it is conceivable that the binding demonstrated may play a role physiologically. However, 
this binding is not dependent on free thiols, as blocking them with NEM did not affect the 
binding curve and KD (Figure 5.5). It may simply be an electrostatic interaction between 
domains which seems likely to be a separate mechanism distinct from self-association and 
may have confounded the results. For example, it has also been shown that the A2 
domain can bind to A1, blocking the GPIbα binding site266.  
  
5.5.2 Shear induced self-association and free thiols 
The collagen perfusion assay represents a more physiologically relevant system. Initially, a 
collagen perfusion assay was set up to look at the effect of blocking free thiols on VWF-
mediated platelet binding to collagen. It has previously been reported that 2mM NEM 
prevents VWF from binding to thiol active beads208, and I have previously demonstrated 
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that incubation with 20mM NEM blocked the binding of MPB to VWF (section 4.5.5, Figure 
4.10). Initially 5-50mM NEM was added to plasma-free blood supplemented with pdVWF 
just prior to its perfusion over collagen at a wall shear rate of 1500s-1. This reduced platelet 
binding at all concentrations, most markedly at the higher concentrations so that at 50mM 
NEM there was virtually no binding of platelets to collagen (Figure 5.6). Control studies 
showed that there was no discernible effect of NEM on multimeric structure (Figure 5.10), 
static collagen binding (Table 5.3), binding to collagen under shear (Figure 5.9) and VWF-
platelet binding (Figure 5.7). However there was an effect of NEM on direct platelet-
collagen binding (Figure 5.8). Whilst at 1500s-1 platelets cannot initiate direct binding with 
collagen, following slowing of a translocating platelet by VWF-GPIbα interactions, a 
platelet is able to bind to collagen directly through GPIV. This might therefore have 
confounded the results. The perfusion assay was repeated using pdVWF which had been 
pre-treated with 20mM NEM, with the excess removed by dialysis. This showed a reduced 
rate of VWF-mediated platelet capture and had a 15% reduction in accumulated platelet 
surface coverage at 5 minutes compared to control (39% reduction when the area under 
the curves were compared) (Figure 5.11). These results are broadly similar to the initial 
work which had suggested a 25-50% effect of self-association on VWF-mediated platelet 
binding at 2 minutes198. This effect could therefore be due to prevention of VWF self-
association. However, it is possible that a small undetected effect of NEM on VWF-
collagen binding under shear or on VWF-platelet binding might result in this decreased 
rate of VWF-mediated platelet capture to collagen. Blocking the free thiols with NEM may 
restrict conformational changes of VWF under shear, unrelated to self-association. 
Because of these possible alternative explanations, to ensure that we could indeed detect 
self-association in this flow system, a series of experiments were planned using 
recombinant VWF mutants. 
 
5.5.3 Shear induced self-association: collagen- and platelet- binding mutants 
In order to try to demonstrate clear self-association of VWF perfused over collagen in a 
physiologically relevant system, the principles used by Savage et al198 were adopted. 
Whereas neither a platelet-binding mutant nor a collagen-binding mutant would be able to 
bind platelets to collagen individually, if both types of mutant are perfused together then 
the platelets would be able to bind to collagen in the event of VWF self-association (Figure 
5.12). When a platelet-binding mutant (ΔA1 or G1324S) and a collagen-binding mutant 
(ΔA3 or H1786A) were perfused together over collagen at a wall shear rate of 1500s-1 
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there was no significant VWF-mediated platelet binding to collagen after 5 minutes (Figure 
5.17). Control experiments verified that the platelet-binding mutants both bound to 
collagen statically (Table 5.4) and under flow (Figure 5.18) and that the collagen-binding 
mutants bound to platelets (Figure 5.15). This suggests that self-association does not 
occur in this physiologically relevant flow system. Of note, these results are in contrast to 
Bonnefoy et al260 who used recombinant ΔA3-VWF and H1786A in a perfusion assay and 
reported that the collagen binding site in the A1 domain can substitute for that in the A3 
domain to allow substantial platelet recruitment to collagen under shear conditions. 
However, these experiments were mainly performed using horse tendon collagen. These 
preparations have been found to be sometimes contaminated with VWF, and it is less 
physiologically relevant. Our results which show lack of platelet recruitment to collagen 
under shear for these mutants are consistent with the majority of literature198,262 (section 
1.3.2). 
 
An attempt was made to repeat the original experiments which bound ΔA1 directly to a 
glass slide and found that it could capture circulating VWF198. VWF unravels when bound 
to a surface, and its conformation depends on the type of surface. Glass may be either 
hydrophilic or hydrophobic. To allow for either possibility, the experiments were performed 
binding ΔA1 to glass, hydrophobic plastic and hydrophilic plastic flow slides. When whole 
blood was perfused at a wall shear rate of 1500s-1 over ΔA1 bound directly to any of these 
surfaces, no significant platelet capture was seen (Figure 5.19). It was verified that ΔA1 
bound to the plate in a similar amount to wt and ΔA3 (Figure 5.16). In order to try and 
detect self-association of circulating VWF on VWF bound to a flow slide further 
experiments were then run using the standard hydrophobic plastic flow slides as these 
allowed smaller amounts of blood to be used for each experiment. Whole blood was 
perfused over ΔA1 at different wall shear rates (800-10000s-1) (Figure 5.20); and using 
PPACK anticoagulant as per Savage et al198, rather than ACD (Figure 5.21). Additionally 
whole blood was perfused over another platelet-binding mutant (G1324S) bound directly to 
the flow slide (Figure 5.22). None of these experiments detected significantly increased 
platelet capture when whole blood was perfused rather than plasma-free blood, thus failing 
to provide any evidence for the occurrence of self-association.  
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No evidence could be found for the lateral self-association of VWF under shear, either on 
a collagen surface or to VWF bound directly to a slide. The ΔA1 construct used previously 
had slightly different boundaries (Δ1241-1479)198 to our construct (Δ1239-1480) but given 
the amino acids involved (glycine and proline) it is difficult to attribute the difference in 
findings to this. The ΔA3 constructs had identical boundaries. The constructs were 
previously expressed in baby hamster kidney cells which should give the same post-
translational modifications as HEK293T cells. The proteins were purified by affinity 
chromatography using a monoclonal antibody against the D4 domain which did not appear 
to alter multimer structure, collagen binding activity or ristocetin cofactor activity146. The 
authors only analysed single frames which likely increased background counting. 
However, perhaps most significantly, the perfusion chamber set up used by Savage et 
al198 was not a parallel chamber flow assay. It was a modification of the Hele-Shaw flow 
chamber which consists of a tapered silicon gasket which varies the shear rate at the wall 
in a linear manner as a function of difference (lowest shear at the inlet). Thus platelets may 
have initially rolled over VWF or collagen at a low shear rate, which subsequently affected 
observations further along the slide where the wall shear rate was 1500s-1. Furthermore, 
the alteration in shear gradient along the flow slide may also have affected the results 
compared to our linear flow slides, as this will have affected VWF conformation as it 
‘tumbled’ (section 1.3.5). Indeed a recent paper has demonstrated that the alteration in 
shear gradients affects VWF-mediated platelet capture167,267.  
 
When the other evidence for self-association is examined closely, there is much that is 
either contradictory, or not in a physiologically relevant system. Whilst Savage et al198 
published the first compelling evidence for the self-association of VWF, the self-
association of VWF has subsequently been described as occurring in other assays. Light 
scattering studies showed that pdVWF aggregates in suspension when subjected to high 
shear (2000-6000s-1) in a cone-plate viscometer199. Soluble VWF was also shown to 
associate with VWF bound to GPIbα on platelets at high shear (>6000s-1 in a cone-plate 
viscometer)268. The mechanism of aggregation has not been elucidated. Furthermore, it is 
difficult to know the physiological relevance of results generated using this type of shear. 
Cone-plate viscometers used at standard settings result in radial flow superimposed on 
linear shear, and result in spatial variations in local shear rate. Thus VWF molecules in a 
cone-plate viscometer will be subjected to different levels of shear depending on their 
position199. Parallel chamber flow studies, generating linear flow, showed that at shear 
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stresses above 20dyne/cm² plasma VWF forms filamentous spider-web like structures on 
a collagen surface and this was described as self-association200. However, firstly a very 
high concentration of VWF was required: fibres formed sporadically at 20µg/ml VWF but 
50µg/ml VWF was required for a reproducible intense network at high shear (35dyne/cm2). 
This casts doubt on their physiological relevance, as the physiological concentration of 
VWF is approximately 10µg/ml. Secondly, perhaps the VWF simply binds directly to 
collagen and builds up the appearance of a fibre network, but without self-association. Of 
note, in preliminary experiments using 5-50µg/ml of VWF perfused over collagen at 2000-
5000s-1, I detected globular patches of VWF using anti-VWF antibody and a secondary 
fluorescent antibody, but no string networks were seen. Fuchs et al230 used a similar 
parallel perfusion assay to look at the binding of VWF to collagen at wall shear rates of 
400-4000s-1 for 0.5 to 8 minutes. The authors then stripped the VWF from the flow slide 
and carried out multimer gel analysis. At prolonged perfusion times, and more marked with 
higher shear rates, more higher order multimers than had been detected on the pre-
perfusion sample were seen. It was suggested that one explanation for this was the self-
association of VWF. However, it may simply be that the highest molecular weight 
multimers have the highest affinity to collagen and these are concentrated over time. 
Interestingly they found that buffer perfusion for up to 600s did not alter either the multimer 
pattern or the amount of VWF bound to collagen under flow. If self-association had 
occurred then it represents a different phenomenon from the finding of Savage et al198 who 
found the self-association to be rapidly reversible.  
 
VWF self-association has also been described as occurring on VWF strings released from 
ECs, as well as perhaps attributing to formation of the strings themselves. The strings 
formed on ECs after incubation with NEM appeared more rigid with fewer adherent 
platelets215. Additionally the propagation of these strings following addition of pdVWF into 
the buffer was dose-dependently reduced by blocking the free thiols on pdVWF with NEM, 
both before and during perfusion215. However, the exact nature of strings is still debated, 
the shear rate used (2.5dyne/cm2) was much lower than in the experiments showing a 
decrease in free thiol content of VWF after shear (50 to 100dyne/cm2)208  and whilst 
controls were done it is difficult to be certain than the NEM did not affect other crucial 
cellular processes.  
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The exact conformation of VWF appears to be crucial to detect apparent VWF self-
association. Interestingly, no evidence of interaction between soluble and surface-bound 
purified VWF was detected using SPR (unpublished data, Lenting)198. However, the shear 
forces applied were less than 1500s-1 and VWF was bound to a different type of surface 
(typically carboxymethylated dextran matrices or streptavidin-derivatised surfaces used). 
Self-association of VWF has been reported to occur under certain static conditions which 
are known to cause a conformational change. Light scattering and turbidimetry were used 
to show that VWF can self-aggregate in solution in the presence of high ristocetin 
concentration and in the absence of shear or any protein adsorbing surface201. Ristocetin 
binds to the A1 domain of VWF and induces a conformational change in VWF allowing 
binding to platelet GPIbα, mimicking the conformational change which occurs under 
shear202. However the concentrations of ristocetin used in this study were high (2.5 and 
3mg/ml), and at these concentrations there may be non-specific protein aggregation. 
Ulrichts et al203 described self-association in an ELISA based assay, as replicated here. 
Whilst we also detected that VWF can bind to itself, this was not mediated by free thiols 
(Figure 5.5).  
 
Whilst soluble VWF homotypically associates with VWF bound to a plate under static 
conditions, this interaction is not dependent on free thiols, and may simply be due to 
electrostatic attraction between domains, especially as it is known that VWF has a 
preference to be in globular formation. A parallel perfusion assay was optimised in order to 
study the self-association of VWF in a physiologically relevant system. No self-association 
of VWF could be detected when complementary mutants (collagen-binding and platelet-
binding mutants) were perfused over collagen in this system. However, as shear gradients 
have been recently been shown to affect VWF mediated-platelet capture, stenotic flow 
slides are being developed, and future work will use the above combination of collagen-
binding and platelet-binding mutants to look for self-association under these 
circumstances. Although an effect of pre-treating VWF with NEM was seen in reducing 
platelet-capture in this system, given my other data showing no self-association while 
using platelet- and collagen- binding mutants in this assay, I do not believe that self-
association of VWF accounts for this difference. It may be that blocking the free thiols on 
VWF prevents some conformational changes under shear. This would be interesting to 
explore further. A different assay, such as SPR, might detect a difference in VWF function 
in these circumstances. However, currently the role of these free thiols remains unclear.  
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CHAPTER 6: ΔD4-C6 VWF 
6.1 INTRODUCTION 
A series of mutants involving deletions of the C terminus of VWF were made and 
described in Chapter 3. The only deletion mutant to secrete at comparable levels to wt 
VWF was ΔD4-C6 (del 1875-2720). However, the fact that this mutant is secreted meant 
that it could be utilised to study the function of the D4-C6 region. Little is known of the 
function of the D4 and C domains, other than that they contain the 2507RGDS sequence 
important for GPIIbIIIa binding and a fibrin binding site (section 1.3.3). It has been 
proposed that the C domains may have an important role in the lateral self-association of 
VWF because they have been shown to contain the majority of the free thiols on VWF208. 
Whilst we could find no evidence for the self-association of VWF in our perfusion assays 
using a combination of platelet- and collagen- binding mutants (Chapter 5), the lack of 
significant self-association would be supported if there was no difference between wt VWF 
and ΔD4-C6 in their ability to mediate platelet binding to collagen. As the C domains 
contain the RGDS binding site for GPIIbIIIa on platelets and fibrinogen, it is possible that 
any functional difference seen between ΔD4-C6 and wt VWF in perfusion assays might 
simply be due to loss of the GPIIbIIIa binding site, rather than the C domains. In order to 
provide a control for this I made an RGDS mutant, D2509G or RGGS, as had been 
reported previously159,198.  
 
6.1.1 Hypothesis 
If the D4-C6 domains are important for lateral self-association then this will be detectable 
in a flow based system and result in reduced VWF-mediated platelet capture to collagen 
with ΔD4-C6 compared to wt VWF. 
 
6.1.2 Aims 
To study the role of the D4-C6 region of VWF; its importance in synthesis and secretion, in 
multimeric structure, in binding to platelets and collagen, and in the possible lateral self-
association of VWF. 
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6.2 EXPRESSION OF ΔD4-C6 AND RGGS 
The construction of ΔD4-C6 (del 1875-2720) in pcDNA3.1 FL-VWF has already been 
described (section 3.5.1). In order to control for the loss of the 2507RGDS sequence from 
ΔD4-C6 in functional perfusion assays, an RGDS mutant was made (mutating 
aspartate2509 to glycine, creating RGGS). The RGGS mutant was initially made in the 
pcDNA3.1 A2-CK vector and then the DNA containing the VWF mutant was subcloned into 
pcDNA3.1 FL-VWF.  Large scale DNA preparations of both mutants were made and used 
for transient transfection of mammalian HEK293T cells (section 2.3.3).  
 
Initially wt VWF, RGGS and ΔD4-C6 were expressed on a small scale. The concentration 
of each VWF variant in the conditioned media and cell lysate was compared using the 
VWF ELISA. ΔD4-C6 and RGGS both secreted with comparable efficiency to wt when 
their media:lysate ratios were compared (p=0.5 and 0.8 respectively) (Figure 6.1). 
However, it was noted that whilst the media:lysate ratios were similar, less ΔD4-C6 was 
detected in both the media and lysate compared to wt and RGGS. The standard VWF 
ELISA uses a polyclonal anti-VWF antibody which recognises a range of epitopes229; both 
as the capture antibody and as the detection antibody (section 2.4.4.2). Some of the 
epitopes detected by the polyclonal anti-VWF antibody lie within the D4-C6 region229, and 
the concentration of ΔD4-C6 may therefore be underestimated by this method. This would 
have an impact on analysis of future functional flow assays. 
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Figure 6.1 Expression of RGGS and ΔD4-C6 VWF. The concentration of VWF in the 
media and lysate of HEK293T cells, as determined by the VWF ELISA, is shown. Both 
ΔD4-C6 and RGGS secreted with comparable efficiency to wt (media:lysate ratios p=0.5 
and 0.8 respectively). However, the absolute level of VWF detected in the media and 
lysate is lower for ΔD4-C6 than wt and RGGS. (Values shown are mean ±SEM of 3 
separate transfections performed in duplicate.) 
 
 
6.3 PURIFICATION OF RECOMBINANT AND PLASMA-DERIVED VWF 
In order to study ΔD4-C6 and RGGS further, a large amount of purified protein was 
required. Large scale transient transfections of HEK293T cells were performed. 
Approximately 200mls of expression media of each recombinant mutant was collected and 
filtered. The purification of recombinant VWF has been described previously (sections 
2.4.3 and 4.5.6). Briefly, the recombinant VWF was purified by ion exchange 
chromatography using a previously equilibrated Fractogel-EMD-TMAE+ column. The 
bound VWF was eluted using 500mM NaCl. The elution fraction was analysed by SDS-
PAGE under reducing conditions, followed by both Coomassie stain and Western blot. The 
elution fraction contained a band of approximately 250kDa for wt and RGGS and 150kDa 
for ΔD4-C6, corresponding to monomeric VWF (Figure 6.2). Other proteins were still 
present but this level of purification was adequate for the majority of experiments. Samples 
requiring further purification (such as for studying quantification and direct binding to Ibidi 
flow slides) were subsequently purified by Heparin-Sepharose affinity chromatography 
(sections 2.4.3 and 4.5.6). Following purification, samples were dialysed into 20mM Tris, 
pH7.4. The purity of the eluted material was analysed using SDS-PAGE, Coomassie and 
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Western blot as before (Figure 6.2). Interestingly ΔD4-C6 was less pure following Heparin-
Sepharose chromatography than wt (section 4.5.6, Figure 4.12B)ii. The purified VWF was 
then quantified by VWF ELISA, and the multimeric pattern analysed by multimer gel. The 
typical VWF recovery after ion exchange chromatography was 80%, and this reduced to 
55% after subsequent Heparin-Sepharose chromatography. ΔD4-C6 showed a similar 
recovery to wt VWF. The multimer structure of recombinant VWF before and after 
purification was similar, although there was a tendency to lose the highest molecular 
weight multimers (Figure 6.3).  
 
 
         
 
Figure 6.2. Purification of recombinant ΔD4-C6. Recombinant ΔD4-C6 VWF was 
purified by ion exchange (IE) and then Heparin-Sepharose chromatography (HS). Samples 
were analysed by SDS-PAGE under reducing conditions: (a) pre-IE, (b) flow-through IE, 
(c) elution IE, (d) flow-through HS, and (e) elution HS. Neat samples were loaded except 
for the elution samples which were diluted 1 in 3. Detection with (A) Coomassie stain, 
where ΔD4-C6 is detected as a band at approximately 150kDa (B) Western blot with 
polyclonal anti-VWF-HRP.   
 
____________________________________ 
ii
 The main heparin binding site is in the A1 domain, with evidence of a secondary site in D3. No heparin 
binding site has been detected in the C domains (sections 1.3.2 and 5.4.1.2). Heparin-Sepharose purification 
of ΔD4-C6 was only performed once. If it was performed again, and the purification of ΔD4-C6 was 
consistently less good than that of wt VWF, then it might be explained by ΔD4-C6 binding to the column with 
a different affinity than wt due to a difference in conformation. The purification method could be optimised for 
ΔD4-C6 by adjusting the binding and elution buffers. 
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PdVWF was purified from Haemate P by ion-exchange chromatography and Heparin-
Sepharose affinity chromatography as previously described (sections 2.4.2 and 5.2.1). 
 
6.4 MULTIMER ANALYSIS OF ΔD4-C6 AND RGGS VWF 
The multimer composition of expressed recombinant VWF was analysed by agarose gel 
electrophoresis followed by Western blot. The multimer composition of the mutants was 
compared to that of recombinant wt VWF and VWF in reference plasma. Both ΔD4-C6 and 
RGGS showed a similar multimer structure to wt, albeit ΔD4-C6 was shifted downwards 
consistent with the smaller size of each monomer (Figure 6.3). The presence of D4 and C 
domains is therefore not essential for the normal multimerisation of VWF. 
 
 
            
 
Figure 6.3. Multimer gels of recombinant wt, ΔD4-C6 and RGGS VWF. (A) Multimer 
gel before and after purification by ion exchange (IE) chromatography. ΔD4-C6 has a 
similar multimer pattern to wt, albeit the multimers are smaller in size which is consistent 
with the smaller size of each monomer. Following IE purification the multimer pattern 
remains similar, but with slightly reduced proportion of HMWMs. (B) Multimer gel before IE 
purification of RGGS, demonstrating that it has a similar multimer pattern to wt. (RP is 
reference plasma.) (These gels are representative of 2 separate experiments.) 
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6.5 QUANTIFICATION OF ΔD4-C6 VWF 
Following purification by both ion-exchange and Heparin-Sepharose affinity 
chromatography, the recombinant VWF was quantified using the standard VWF ELISA. In 
order to determine the accuracy of this method of quantification for ΔD4-C6 a 
polyacrylamide gel was loaded with 30µg/ml of purified pdVWF (fraction B10), wt and ΔD4-
C6 (concentrations derived using the standard VWF ELISA). Following SDS-PAGE and 
Coomassie staining, analysis of the gel using ImageJ showed that the ΔD4-C6 band was 
2.2x more intense than the average of the bands for pdVWF and wt, demonstrating that 
the VWF ELISA underestimates the concentration of ΔD4-C6 (Figure 6.4, A). Of note, 
when a similar gel was analysed by Western blot using the polyclonal anti-hVWF-HRP, the 
ΔD4-C6 was only 1.6x more intense than the average for pdVWF and wt (Figure 6.4, B). 
This shows that ΔD4-C6 is underdetected by the polyclonal anti-VWF antibody on Western 
blot, though by less than the VWF ELISA (as one might expect given that the VWF ELISA 
uses this antibody at 2 stages, for both capture and detection). When the VWF ELISA 
derived concentration of ΔD4-C6 was corrected, by increasing by 2.2x, and equal 
concentrations were again analysed by SDS-PAGE and Coomassie, the ΔD4-C6 band 
was a similar intensity to both wt and RGGS (Figure 6.4, C). This 2.2x adjustment of the 
ELISA-determined concentration of ΔD4-C6 was used in all the following experiments. 
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A                                                      B   
                          
 
C              
 
 
Figure 6.4 Coomassie stain to determine the accuracy of VWF ELISA to quantify 
ΔD4-C6 VWF. Polyacrylamide gels were analysed by SDS-PAGE and Coomassie stain or 
Western blot with polyclonal anti-hVWF-HRP. The density of the bands was analysed 
using ImageJ software. (A) 30µg/ml of purified pdVWF (fraction B10), wt and ΔD4-C6 
(concentration derived using the standard VWF ELISA). The ΔD4-C6 band was 2.2x more 
intense than the average of the bands for pdVWF and wt when detected by Coomassie. 
(B) 30µg/ml of pdVWF (B10), wt and ΔD4-C6 (concentration derived using the standard 
VWF ELISA). The ΔD4-C6 band was 1.6x more intense than the average of the bands for 
pdVWF and wt. (C) 30µg/ml of pdVWF (B10), wt and ΔD4-C6, following correction of the 
VWF ELISA-derived concentration by 2.2x. The ΔD4-C6 band was a comparable density 
to the bands for wt and pdVWF. (Gels are typical of 3 separate experiments.) 
 
 
 
6.6 STATIC COLLAGEN BINDING ACTIVITY OF ΔD4-C6 AND RGGS VWF 
The collagen binding function of VWF is highly sensitive to VWF multimer size because 
individual A3 domains have a low binding affinity. Therefore an alteration in collagen 
binding may simply reflect an effect on multimerisation rather than a direct change in 
binding affinity itself.  The effect of mutations on binding to type III collagen was assessed 
by an ELISA based binding assay (section 2.4.4.3) and expressed as a ratio of collagen 
binding to VWF antigen (VWF:CB/VWF:Ag). The normal observed ratio is >0.7 for pdVWF. 
Wt VWF had a VWF:CB/VWF:Ag ratio of 0.56 (Table 6.1). This difference in collagen 
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binding is due to differences in multimer pattern, with pdVWF having greater HMWMs. 
RGGS VWF demonstrated a normal ratio (Table 6.1). Whilst ΔD4-C6 VWF also 
demonstrated a normal ratio, this is not entirely accurate. In order to measure the 
VWF:CBA/VWF:Ag ratio, 2 ELISAs are performed in parallel: both the VWF ELISA and the 
collagen ELISA use polyclonal anti-hVWF-HRP as detection antibody, but the VWF ELISA 
additionally uses the polyclonal anti-hVWF as a capture antibody (sections 2.4.4.2 and 
2.4.4.3). As has been described, polyclonal anti-VWF does not bind to ΔD4-C6 as well as 
it does to wt VWF as it lacks some of the epitopes. The VWF ELISA will therefore 
underestimate the ΔD4-C6 antigen relative to the collagen binding ELISA, resulting in an 
overestimation of the static VWF:CBA/VWF Ag ratioiii. 
 
 
 
Mutant pdVWF (B10) wt RGGS ΔD4-C6 
VWF:CBA/VWF: Ag 0.9 0.56 0.48 0.43 
 
 
Table 6.1 VWF:CB/VWF:Ag ratios for ΔD4-C6 and RGGS. An ELISA based collagen 
binding assay was used to measure the collagen binding activity of recombinant VWF. It 
was expressed as a ratio of collagen binding to VWF antigen (VWF:CBA/VWF:Ag). ΔD4-
C6 and RGGS showed a comparable static collagen binding activity to wt (p=0.20 and 
0.41 respectively). (The values represent the mean ratio of 3 separate experiments.) 
 
 
 
 
 
______________________________ 
iii
 It is not possible to accurately correct this over-calculation of the static collagen binding activity of ΔD4-C6, 
only a rough estimated correction. Western blot (1x use of polyclonal antibody) underestimated the 
concentration of ΔD4-C6 (1.6 compared to 2.2 by Coomassie, that is by 37%) whereas the VWF ELISA (2 
stages use the polyclonal antibody) underestimates the concentration by 2.2x. One could estimate that the 
VWF ELISA overestimates the antigen compared to the collagen ELISA by about 50%. This would result in a 
static collagen binding ratio for ΔD4-C6 of 0.29. Monoclonal anti-VWF antibodies (binding to epitopes other 
than in D4-C6) would need to be used in both ELISAs for an accurate determination of static collagen 
binding affinity. 
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6.7 PERFUSION ASSAYS: RECOMBINANT VWF BOUND DIRECTLY TO THE SLIDE 
To investigate the ability of the recombinant VWF to support GPIbα dependent platelet 
tethering under flow, a suspension of RBCs supplemented with platelets was perfused 
over VWF immobilised directly onto the flow slide. The flow slides and blood were 
prepared, and the assay performed, as previously described (sections 2.7 and 4.5.7). Of 
note, the concentrations used were based on the corrected ELISA quantification. The 
recombinant mutants were bound to the plate at 30µg/ml. 
 
After 3 minutes at 1500 s-1, there was no statistically significant difference in binding of 
platelets to wt and ΔD4-C6 or RGGS (Figure 6.5).  
 
Figure 6.5 Platelet binding to VWF immobilised directly to flow slide. Platelets in a 
suspension of RBCs were perfused at 1500s-1 over purified recombinant VWF bound 
directly to a flow slide. Platelet attachment was analysed after 3 minutes by taking a short 
movie in 3 fields of view. The accumulated platelets were assessed by stacking 3 frames 
(to remove translocating platelets) and then measured using ImageJ and assessed as 
surface coverage (%). A control of BSA alone (no VWF) was used. Both ΔD4-C6 and 
RGGS bound a similar proportion of platelets to wt (paired t-test, p=0.42 and p=0.13 
respectively). (Values shown are mean ±SEM of duplicate experiments, repeated on 3 
separate occasions.)   
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The amount of recombinant VWF bound to the slide using this technique was checked by 
stripping (section 2.7.2) and analysis by SDS-PAGE under reducing conditions and 
Western blot using polyclonal anti-hVWF-HRP (Figure 6.6). Whilst it would have been 
preferable to use a Coomassie stain, as the Western blot is known to underestimate the 
concentration of ΔD4-C6 by about 37% (sections 6.4 and 6.6), the concentrations of VWF 
were too small to be detected by this method. Analysis of band intensity by ImageJ 
showed that the ΔD4-C6 band was 1.5x more intense than the average of wt and RGGS 
(Figure 6.6). When the known underdetection is corrected for, this suggests that the 
amount of ΔD4-C6 bound to the plate was 2x more than wt and RGGS. The difference in 
molecular size between ΔD4-C6 and wt/RGGS (~150kDa compared to 250kDa) might 
allow more monomers to bind per unit area, and perhaps additionally the difference in 
conformation results in ΔD4-C6 having a greater binding affinity. It is therefore difficult to 
interpret the results of the perfusion assay when plasma-free blood was perfused over 
immobilised recombinant VWF (Figure 6.6). There were was no significant difference in 
platelet binding, whilst more monomers were bound to the slide. This suggests that ΔD4-
C6 may have reduced affinity for GPIbα on platelets.  
 
 
 
 
Figure 6.6 VWF bound directly to the slide. Recombinant VWF was bound directly to 
the standard hydrophobic plastic flow slides. The slides were washed, then stripped, and 
the eluate analysed by SDS-PAGE under reducing conditions and Western blot with the 
polyclonal anti-hVWF-HRP. Analysis of band intensity by ImageJ showed that ΔD4-C6 
band was 1.5x more intense than the average of wt and ΔD4-C6 (Figure 6.6). When the 
known underdetection is corrected for, this indicates that the amount of ΔD4-C6 
bound/stripped from the slide was 2x more than wt and RGGS. The control (C) used 
bicarbonate buffer with no additional recombinant VWF. (Gel is representative of 2 
experiments.) 
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6.8 PERFUSION ASSAYS: RECOMBINANT VWF PERFUSED OVER COLLAGEN  
To investigate the ability of the recombinant VWF mutants to support platelet tethering to 
collagen under flow, plasma-free blood was perfused over a slide coated with human type 
III collagen, with or without the addition of recombinant VWF at a final concentration of 
5µg/ml (based on the corrected ELISA quantification). The slides and plasma-free blood 
were prepared, and the assay performed, as previously described (sections 2.7 and 4.5.8). 
There was no statistical difference in platelet binding at 5 minutes between wt-VWF and 
either RGGS or ΔD4-C6 VWF (Figure 6.7, A). When platelet accumulation was analysed 
over the 5 minute time course, and the recombinant proteins compared using paired t-tests 
on AUC, again there was no statistically significant difference in the results (Figure 6.7, B). 
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Figure 6.7 Perfusion of plasma-free blood with recombinant VWF over collagen. 
Plasma-free blood was perfused over collagen-coated flow slides at 1500s-1, 
supplemented with purified recombinant VWF at 5µg/ml. Short movies (1s, frames every 
0.05s) were recorded every minute for 5 minutes and the accumulated platelets at each 
time point were assessed by stacking 3 frames (to remove translocating platelets) and 
then surface coverage (%) analysed using ImageJ. (A) Surface coverage of platelets at 5 
minute endpoint. There was no statistically significant difference between wt VWF and 
either RGGS or ΔD4-C6. (B) Accumulation of platelets shown over 5 minute time course. 
AUC analysis did not demonstrate a statistically significant difference between wt VWF 
and either RGGS or ΔD4-C6. (Values shown are mean ±SEM of duplicate experiments 
performed on 3 separate occasions.) 
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As a control, in order to determine that the mutants and wt VWF bound to collagen under 
flow with a similar affinity, 5µg/ml recombinant VWF in buffer (rather than plasma-free 
blood) was perfused over a collagen-coated flow slide at 1500s-1 (pre-flow) (section 2.7.5). 
After 5 minutes the perfusion was stopped. The buffer which had been perfused over the 
collagen was collected for analysis (post-flow). The slide was stripped. The bound/stripped 
samples were loaded undiluted onto a gel, whereas the pre-flow and post-flow samples 
were diluted 1 in 3 before loading onto the gel. The samples were analysed by SDS-PAGE 
under reducing conditions and Western blot with polyclonal anti-hVWF-HRP. Interestingly, 
the amount of ΔD4-C6 recovered from the slide was consistently greater than either 
RGGS or wt VWF (1.8x before correction, 2.5x after correction for underdetection by the 
polyclonal anti-hVWF antibody) (Figure 6.8). 
 
 
 
 
Figure 6.8 Recombinant VWF bound to collagen under flow. Recombinant VWF 
(5µg/ml) in buffer was perfused over a collagen-coated flow slide at 1500s-1 for 5 minutes. 
The slides were washed, stripped, and analysed by SDS-PAGE under reducing conditions 
and Western blot. ImageJ was used to analyse band intensity. The amount of ΔD4-C6 
recovered from the slide was consistently greater than either RGGS or wt VWF (1.8x 
before correction, 2.5x after correction for underdetection by the polyclonal anti-hVWF 
antibody). (Gel is representative of 3 experiments.) 
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6.9 DISCUSSION 
Little is known about the function of the D4 and C domains of VWF other than that C4 
contains the 2507RGDS sequence important for GPIIbIIIa binding to VWF (section 1.3.3). 
The secretion of ΔD4-C6 (1875-2720) allows the function of this region to be studied in 
more detail, and the RGGS mutant provides a control for loss of the GPIIbIIIa binding site 
in functional perfusion assays 
 
ΔD4-C6 secreted with similar efficiency to wt VWF (Figure 6.1). Its media:lysate ratio was 
comparable to wt, and when the ELISA determined antigen levels are corrected by 2.2x 
(section 6.5) the amount secreted is at least as great as wt VWF. The presence of the D4 
and C domains is therefore not critical for synthesis and secretion. Although intriguingly if 
this region is disrupted, rather than removed intact (as seen with the C domain deletion 
mutants in section 3.5), it has drastic consequences on synthesis and secretion. The 
multimer pattern of ΔD4-C6 is similar to wt, albeit shifted downwards due to the smaller 
size of each monomer (Figure 6.3). These data demonstrate that the presence of the D4 
and C domains is not necessary for the correct multimerisation of VWF.  
 
In order to study the function of ΔD4-C6, and to compare it to wt VWF, it is important that it 
is quantified accurately.  The standard VWF ELISA uses a polyclonal anti-hVWF antibody 
which recognises epitopes throughout VWF229 and as a result it underestimates the 
concentration of ΔD4-C6 compared to wt and RGGS (Figure 6.4). By using ImageJ to 
compare the density of protein bands on a Coomassie stain, it was calculated that the 
standard VWF ELISA underestimated the concentration of ΔD4-C6 by 2.2x. This value 
was used to correct the VWF ELISA determined concentration for use in all subsequent 
assays. It should be noted that as the Coomassie dye binds to protein, and each ΔD4-C6 
monomer is smaller than a wt monomer (MW ~150kDa compared to 250kDa), that when 
the 2.2x correction is applied to the ELISA determined antigen concentration of ΔD4-C6, it 
underestimates the molar concentration of ΔD4-C6. However, this correction was deemed 
to be reasonable for use in the subsequent assays. As ΔD4-C6 is smaller than wt VWF it 
also raises the question of what method of quantification results in a fair comparison of 
these proteins; equal concentrations determined in µg/ml, or equal molar concentrations. It 
was decided to compare equivalent µg/ml concentrations initially, whilst bearing in mind 
the molar discrepancy. 
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There was no statistically significant difference between ΔD4-C6 and RGGS and wt VWF 
in the ability of the recombinant VWF to support GPIbα dependent platelet tethering under 
flow at 1500s-1 (Figure 6.5). However, a control in which bound VWF was stripped from the 
slide, demonstrated that the amount of ΔD4-C6 bound directly to the slide was 2x more 
than wt or RGGS (Figure 6.6). All the recombinant proteins were bound to the slide at 
30µg/ml. However, the smaller size of each ΔD4-C6 monomer might allow more 
monomers to bind per unit area, and the difference in conformation may result in ΔD4-C6 
binding with a greater affinity. This would result in a greater platelet-binding capacity 
(higher number of A1 domains per unit area). As there were was no significant difference 
in platelet binding (Figure 6.5), whilst apparently more monomers were bound to the slide, 
this suggests that ΔD4-C6 may have reduced affinity for GPIbα on platelets. As this assay 
immobilised VWF to the plate, it would be important to further investigate this in other 
assays. Our laboratory has published an ELISA based GPIbα binding assay33 but this is 
optimised for polyclonal anti-hVWF antibody and so currently cannot be used to accurately 
compare ΔD4-C6 to RGGS and wt VWF. Studying the rolling pattern of platelets on bound 
VWF may provide further information33. 
 
The recombinant mutants were then perfused over collagen at 1500s-1. Intriguingly, there 
was no statistically significant difference in the time course of platelet accumulation over 
the course of 5 minutes (Figure 6.7). The lack of difference between wt VWF and the 
RGGS mutant suggests that the addition of EDTA during platelet processing had 
effectively blocked the activation of the platelet GPIIbIIIa receptor. As with the direct-
binding experiment, interpretation of platelet binding depends on the amount of VWF 
bound to the substrate; in this case collagen.  Surprisingly, when VWF was perfused in 
buffer over collagen, and subsequently stripped, analysis consistently showed recovery of 
more ΔD4-C6 than either wt or RGGS (Figure 6.8). It seems unlikely that ΔD4-C6 would 
be stripped from collagen more easily than RGGS or wt, making it likely that more ΔD4-C6 
bound to collagen under flow than wt and RGGS. This may be because the A3 domain is 
more exposed and able to bind to collagen more readily when the D4-C6 domains are 
removed, especially under shear. It may also be because there are more A3 domains 
available per µg/ml of ΔD4-C6 compared to wt/RGGS due to the smaller size of the 
monomers. Thus ΔD4-C6 mediated similar capture of platelets to collagen compared to wt 
VWF and RGGS in this assay, possibly due to a combination of increased collagen-
binding balanced by reduced direct platelet-binding affinity.  
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The ability of recombinant RGGS to capture platelets under flow has been studied 
previously. When recombinant mutants were bound to a glass coverslip there was no 
significant difference in platelet capture between wt and RGGS159,198, consistent with these 
results. In another study unprocessed whole blood from a patient with type 3 VWD was 
perfused at 1600s-1 over recombinant VWF which was bound to collagen. The slides were 
then fixed and stained. Platelet adhesion to RGGS was similar to wt, but platelet spreading 
and aggregation were abolished159. This is again consistent with the results presented 
here, as EDTA, apyrase and PGE1 were added to prevent platelet activation and 
aggregation. Interestingly, mouse models of the RGGS mutant suggest that in vivo this 
GPIIbIIIa interaction may be particularly important for arterial thrombosis but not bleeding 
(section 1.3.3). 
 
The data presented here demonstrate that the D4 and C domains are not required for 
synthesis, normal multimeric structure or secretion of recombinant VWF. It is puzzling that 
mutants with deletion of smaller regions within D4-C6 are not expressed. As discussed in 
section 3.7.2, possible explanations include exposure of hydrophobic amino acids on 
neighbouring domains, loss of glycoproteins, or a decrease in the conformational stability 
of the protein. Loss of the D4-C6 domains appears to reduce the ability of the VWF to bind 
to GPIbα on platelets when immobilised direct to a slide. However, ΔD4-C6 demonstrated 
a similar ability to mediate platelet capture to a collagen surface under flow, although the 
apparently greater capacity of ΔD4-C6 to bind to collagen under flow remains a potential 
confounding factor. However, this functional perfusion data is limited by the method of 
quantification of ΔD4-C6 (section 6.5) and therefore only preliminary conclusions can be 
drawn from it.  
 
Whilst the method that was used to quantify ΔD4-C6 is reasonable, it would be preferable 
to develop a VWF ELISA for quantification using monoclonal anti-VWF antibodies (to a 
region other than D4-C6) for both capture and detection. Such a monoclonal antibody 
could also be optimised for use in the static collagen binding assay, in the ELISA based 
GPIbα binding assay, and in Western blot. This would allow a more accurate comparison 
of ΔD4-C6 with RGGS and wt, and determination of their specific activities. The question 
of whether these mutants are best compared using equivalent concentrations in µg/ml or 
moles/litre would remain, but an accurate antigenic quantification by ELISA would allow 
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both methods of comparison to be used more accurately than the present quantification 
method. Following this, the perfusion assays could then be re-run over a range of shear 
rates, using a range of concentrations of recombinant VWF. It would be interesting to 
perfuse the recombinant mutants over collagen in whole blood from a patient with type 3 
VWD, as this would further investigate the role of RGDS and D4-C6 domains in thrombus 
formation. The VWF knockout mouse model could help to study ΔD4-C6 in vivo, and might 
elucidate the role of this region in arterial thrombosis and bleeding. Lastly, the role of D4-
C6 domains in the synthesis and packaging of VWF into WPBs and secretion of VWF 
could be investigated further. Electron microscopy could be used to study the shape and 
structure of WPBs in HEK293 cells expressing ΔD4-C6. VWF string formation could be 
studied by stimulating HEK293 cells expressing ΔD4-C6 under flow conditions269. 
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CHAPTER 7: CONCLUSION AND FUTURE WORK 
 
This project aimed to study the self-association of VWF, especially the proposed role of 
thiol-disulphide exchange, and the possible intrinsic thiol isomerase activity of conserved 
CXXC motifs in VWF by designing and expressing recombinant VWF mutants and 
studying their structure and function. 
 
7.1 VWF SELF-ASSOCIATION 
The functional lateral self-association of VWF was first described in a perfusion assay198. 
ΔA1, immobilised onto a glass surface, mediated platelet capture when whole blood was 
perfused but not when plasma-free blood was perfused at 1500s-1.  Whilst the self-
association of VWF has subsequently been described by other groups in other 
experimental conditions (section 1.5.1), some of these are not as convincing as this first 
description, and some use conditions which may not occur physiologically (such as very 
high concentrations of VWF, or shear generated in a cone-plate viscometer). A parallel-
plate perfusion assay was optimised in our laboratory and different combinations of 
mutants (the platelet-binding mutants ΔA1 and G1324S, and the collagen-binding mutants 
ΔA3 and H1786A) were designed and expressed. Whole-blood was perfused over these 
mutants immobilised on different surfaces (glass, hydrophobic and hydrophilic plastic) at 
1500s-1 and additionally the mutants were combined in plasma-free blood and perfused 
over collagen at a wide range of shear rates (800s-1-10000s-1). Self-association of VWF 
was not detected in any of these assays. These data demonstrate that self-association of 
VWF does not occur in this physiologically relevant assay using linear shear. Given these 
results the data on self-association, when it occurs and its importance, require re-
evaluation. Data have recently been published demonstrating that an alteration in shear 
gradient, such as exists around a stenosis, affects VWF-mediated platelet capture267. 
Indeed the slides used in the original experiments were tapered, resulting in the soluble 
VWF being exposed to shear gradients as it was perfused198. For this reason, stenotic flow 
slides are being developed, and future work will use the above combination of collagen-
binding and platelet-binding mutants to look for self-association under these specific 
circumstances.  
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7.2 FREE THIOLS AND THIOL-DISULPHIDE EXCHANGE 
The free thiols on VWF were studied as it had been hypothesised that these might play an 
important role in extracellular thiol-disulphide exchange, perhaps promoting the lateral self-
association of VWF. Intriguingly, whilst specific cysteines have been found to be free on 
both recombinant and pdVWF, when these were mutated to alanine in FL-VWF (singly or 
as a pair based on predicted disulphide pattern) they were retained intracellularly within 
the ER. These cysteines therefore appear to be absolutely crucial for correct intracellular 
folding. These data unfortunately cannot be used to support the specific mechanism of 
thiol-disulphide exchange proposed by Ganderton et al155, which was based on 
oligomerisation patterns in the media of expressed fragments of mutant VWF. As these 
same mutants were retained intracellularly when expressed in FL-VWF it was not possible 
to study their potential to laterally self-associate. One explanation for these findings is that 
the cysteines form critical disulphide bonds during the assembly and folding of the VWF C 
domains; possibly in a sequential fashion so that the formation of later disulphide bonds is 
dependent on the formation of preceding ones. However, once the monomer/dimer is 
correctly folded, some disulphide bonds may be broken without loss of tertiary structure.  
The subsequent breaking of disulphide bonds may occur either intracellularly, or 
extracellularly, mediated by shear forces during secretion, or the presence of isomerases 
(platelet PDI or intrinsic isomerase activity of VWF) and allow for thiol-disulphide 
exchange. Proposed future work includes the ultracentrifugation of cell lysates from 
HEK293 cells transfected with wt VWF. This technique allows separation of the different 
compartments of the cell (such as ER, Golgi, cytoplasm)270 and may allow us to identify 
where in the cell (or after secretion in the media) these disulphide bonds, which are critical 
for initial synthesis, are subsequently broken. 
 
Perhaps even more intriguingly, when intact domains were deleted within the C-terminus, 
the mutants expressed in FL-VWF were also retained intracellularly, and it was only when 
the whole of the C domains and the D4 domain were removed that the mutant VWF 
secreted comparably to wt VWF. Possible reasons for ER retention of the C domain 
deletion mutants include exposure of hydrophobic amino acids on neighbouring domains, 
loss of glycoproteins resulting in recognition by the calnexin-calreticulin cycle, or a 
decrease the conformational stability of the protein236,237,271,272.  
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The initial work I carried out looking at the role of free thiols on VWF, studied the effect of 
NEM on pdVWF in our perfusion assays. When the free thiols on VWF were blocked with 
NEM, the data did not demonstrate a significant difference in either VWF-collagen binding 
or VWF-platelet binding. However, there was a difference in the VWF-mediated platelet 
binding to collagen. Given my other data, showing no self-association while using platelet- 
and collagen- binding mutants in this assay, I do not believe that self-association of VWF 
accounts for this difference. It may be that blocking the free thiols on VWF prevents some 
conformational changes under shear. A different assay, such as SPR, might detect a small 
difference in VWF function in these circumstances. However, currently the role of these 
free thiols remains unclear.  
 
Thiol-disulphide exchange has been shown to occur between VWF molecules under high 
shear (50-100dynes/cm2) in a cone-plate viscometer208. Cone-plate viscometers generate 
a different type of flow to linear flow (in a normal blood vessel) or even probably to the 
turbulent flow at a site of injury such as a stenosis. Future planned work proposes to look 
at the free thiols on VWF before and after continuous laminar flow at different shear rates 
and following flow through a stenotic channel. It would also be interesting to label the free 
thiols on FL-VWF (pd and recombinant wt) before and after incubation with thioredoxin and 
identify the free thiols using mass spectroscopy. This would identify whether any thiols 
were labile, and therefore likely to play a role in thiol-disulphide exchange in vivo.   
 
 
7.3 ΔD4-C6 VWF 
Remarkably, when the whole of the D4-C6 region was deleted the mutant VWF secreted 
comparably to wt. The fact that this mutant secreted means that it may be possible to 
study the function of the D4-C6 region. Little is known of the function of the D4 and C 
domains, other than that they contain the 2507RGDS sequence important for GPIIbIIIa 
binding and a fibrin binding site. The data for ΔD4-C6 demonstrates that these domains 
are not critical for the synthesis, multimerisation or secretion of VWF. Planned future work 
includes electron microscopy of HEK293 cells expressing ΔD4-C6 to investigate the role of 
D4-C6 domains in the synthesis and packaging of VWF into WPBs. The role of these 
domains in basal release, regulated release, secretion and string formation could be 
studied by stimulating HEK293 cells expressing ΔD4-C6 under flow conditions. 
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Data from functional flow assays suggest that ΔD4-C6 has increased collagen binding 
affinity under flow but a decreased affinity for GPIbα on the surface of platelets. Obtaining 
these functional data has been limited by difficulties in the accurate quantification of ΔD4-
C6 compared to wt (using the standard VWF ELISA) and also by the use of polyclonal 
anti-hVWF antibody in most of the optimised assays for VWF (static collagen binding 
assay, static GPIbα binding assay and Western blot). This polyclonal antibody recognises 
epitopes throughout VWF229 and therefore underestimates ΔD4-C6 VWF compared to wt. 
Therefore an alternative ELISA or method of quantification needs to be developed. A VWF 
ELISA using monoclonal anti-VWF antibodies (to regions of VWF other than D4-C6) is 
currently being optimised. Following this, future plans include repeat of the perfusion 
assays shown here at a wider range of shear rates and with adjustment of the 
concentrations of the recombinant mutants compared (µg/ml and molar); and repeat of the 
static collagen binding and static GPIbα binding assays using monoclonal anti-VWF 
antibodies. It would be interesting to study the rolling pattern of platelets on bound VWF as 
well33. Finally, SPR could also be used to investigate the binding of ΔD4-C6 to collagen.  
 
Perfusion of ΔD4-C6, RGGS and wt in whole blood (from a patient with type 3 VWD) over 
collagen would further investigate the role of the RGDS motif and D4-C6 domains in 
thrombus formation. However, this may be best seen in a whole animal system and we 
plan to investigate the role of this region in arterial thrombosis and bleeding using the VWF 
knockout mouse model in collaboration with Prof. Karen Vanhoorelbeke (KU Leuven, 
Belgium). In order to study VWF function in this murine model I have made ΔD4-C6 in 
pBG+mVWF (MV1), a mouse expression vector containing murine FL-VWF. This can be 
injected hydrodynamically into the murine tail vein for in vivo expression of murine VWF.   
 
 
7.4 CONSERVED CXXC MOTIFS IN VWF AND POTENTIAL INTRINSIC THIOL 
ISOMERASE ACTIVITY 
The CGLC motifs in D1 and D2 are thought to have intrinsic isomerase activity essential 
for multimerisation although this has not been demonstrated directly. Interestingly, VWF 
contains 3 other similar CG(L/I)C motifs which are conserved across domains and species. 
Insertion of a glycine between vicinal cysteines, which is known to disrupt thiol isomerase 
activity, in D4 and C1 domains did not affect intracellular synthesis. Nor did it have a 
significant effect on platelet capture in our functional perfusion assays. However, the free 
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thiol content of GlyD4 and GlyC1 was increased. Future plans include labelling these free 
thiols and performing mass spectroscopy to investigate exactly how the pattern of free 
thiols differs from wt VWF. Whilst no difference was seen in the functional assays 
performed, given the difference in free thiol content of these two mutants it may also be 
interesting to express GlyD4 and GlyC1 in small VWF fragments (that is, D4 and C1C2 
respectively) and look for thiol isomerase activity in a PDI activity assay.  
 
The CGLC motif in D3 is particularly interesting. The data presented here demonstrate that 
this motif must be intact for intracellular secretion, and there is a suggestion that it may 
play a role in reducing the formation of non-native disulphide bonds in the ER. Future work 
includes labelling the free thiols on wt D’D3 fragment before and after incubation with 
thioredoxin and performing mass spectroscopy to see if the pattern of free thiols differs, 
thereby identifying any that are labile and therefore likely to have a role in thiol-disulphide 
exchange in vivo. Furthermore, I have started to optimise an in vitro PDI activity assay273 
to look for thiol isomerase activity of this D’D3 VWF fragment. 
 
 
In conclusion, the work presented in this thesis clearly demonstrates that during VWF 
synthesis in the ER, pairing of the nine cysteines implicated in free thiol-exchange is 
essential for correct folding of the VWF molecule. These cysteines must become unpaired 
either following exit from the ER or secretion from the cell. The C terminus also plays a 
critical role in the processing of VWF: whilst the intact D4 and C domains are not required 
for normal synthesis, mutimerisation and secretion; it is intriguing that if part of this region 
is disrupted it also results in intracellular retention. The integrity of the conserved CG(L/I)C 
motifs in D4 and C1 is not essential for secretion, normal multimeric structure or static 
collagen binding activity but alters the free thiol content of VWF. The CGLC motif in D3 
may play a critical role intracellularly. VWF does not self-associate under linear flow to 
either VWF coated directly to a slide or when perfused over a collagen surface. These 
data demonstrate a critical role for specific cysteines, the C domains, and conserved 
CG(L/I)C motifs in the structure of VWF, but their precise role, the factors triggering thiol-
disulphide exchange (intrinsic PDI, extrinsic PDI or shear forces) and their relative 
importance inside and outside the cell remain uncertain. Additionally, the data demonstrate 
that self-association of VWF does not occur in this physiologically relevant linear flow 
system.
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APPENDIX I - PRIMERS 
All amino acids are numbered from the start of the signal peptide, as recommended by the 
ISTH Scientific Subcommittee on von Willebrand disease274. 
 
Primers for cysteine to alanine point mutations and C domain deletion mutants 
 
Amino acid position Original nucleotides 
encoding cysteine     
Substituted nucleotides 
encoding alanine 
889 
898 
2431 
2448 
2351 
2453 
2468 
2490 
2528 
2533 
TGC 
TGC 
TGT 
TGC 
TGC 
TGT 
TGC 
TGT 
TGC 
TGT 
GCC 
GCC 
GCT 
GCC 
GCC 
GCT 
GCC 
GCT 
GCC 
GCT 
Table to show the nucleotide substitutions used in primers to make individual cysteine to 
alanine point mutations. 
 
Mutant  Amino acids 
deleted 
(inclusive) 
Forward primer  5’- 3’ Reverse primer  5’- 3’ 
∆C3-C6- 
∆C3C4- 
∆D4-C6 
∆C1-C6 
∆C1C2 
∆C3 
2400-2662 
2400-2515 
1875-2720 
2255-2720 
2255-2428 
2431-2494 
CGTGATGAGACGCTCCAG 
AGTGTCGGCTCCCAGTGG 
GAGCCTGAGTGCAACGACA  
GAGCCTGAGTGCAACGACA 
AAGGTGTGTGTCCACCGAA 
CTGCCATCTGCCTGTGAG 
GACACAGTTGCAGGCACAC 
GACACAGTTGCAGGCACAC 
TCCAGAGCACAGTTTGTGGA 
GCAGGCCTCTTCAGGGAC 
GCAGGCCTCTTCAGGGAC 
CACCTTGTCGGGAAGGCA 
Table of primers for deletion of C domains using PCR.  
 
Primers used to insert TGA stop codon after amino acid 2723 (cysteine2724 TGC mutated 
to TGA) 
Fwd GAGGAGCCTGAGTGAAACGACATCACTG 
Rev  CAGTGATGTCGTTTCACTCAGGCTCCTC  
242 
Primers used for glycine insertion mutants  
 
Mutant  Amino acid position into 
which glycine inserted to 
form CXGXC 
Inserted nucleotides 
GlyD2 
GlyD3 
GlyD4 
GlyC1 
523 
995 
2087 
2306 
GGT 
GGT 
GGT 
GGT 
Table to show the nucleotide insertions used in primers for glycine insertion mutants 
 
Primers to make pcDNA3.1 D’D3 (764-1270) from pcDNA3.1 D’CK (764-2813) using PCR 
(without His-tag)   
Fwd TGAACCGGTCATCATCACCA 
Rev GAAATCGTGCAACGGCGGT 
 
Primers to make pcDNA3.1 D’D3-His (764-1271) from pcDNA3.1 D’D3 (764-1270) by 
mutating the TGA stop codon, prior to His-tag, into tyrosine (TAC) 
Fwd CCGTTGCACGATTTCTACACCGGTCATCATCAC 
Rev GTGATGATGACCGGTGTAGAAATCGTGCAACGG 
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Primers used to make D2 replacement mutants 
 
Primers to make ∆D2 pBS-VWF (∆387-598) from pBS-VWF 
Fwd GTCAGCCCGCTGCCCTAC 
Rev CCCTGGACATTCTTCATTGC 
 
Primers used to remove BamHI restriction site at position 907 of pGEMXhoI-KpnI (nucleotide 
coding sequence for isoleucine907 changed from ATC to ATA) 
Fwd GGGACCTTTCGGATACTAGTGGGGAATAAG 
Rev CTTATTCCCCACTAGTATCCGAAAGGTCCC 
 
Primers to make and amplify D3 (with VWF flanking regions) from pGEMXhoI-KpnI  
Fwd GCAATGAAGAATGTCCAGGGACGTGCTCCACGATCGGCAT 
Rev AGGTAGGGCAGCGGGCTGACCAGCTTGTTGCAGTCCTGGA 
 
Primers to make and amplify D4 (with VWF flanking regions) from pcDNA3.1 A2-CK 
Fwd GCAATGAAGAATGTCCAGGGGTGTGCACAGGCAGCTCCAC 
Rev AGGTAGGGCAGCGGGCTGACGACCTTGTGGCATTCAGCAA 
 
 
 
 
 
 
 
Primers used to make the RGGS mutant 
Primers to mutate aspartate2509 GAC to glycine GGC  
Fwd CTCACCGCGGGGGGGCTCCCAGTCTTCC 
Rev GGAAGACTGGGAGCCCCCCCGCGGTGAG 
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APPENDIX II – BUFFERS AND SOLUTIONS 
 
6x Protein Loading buffer 
150mM Tris-HCl, 20%(v/v) glycerol, 4%(w/v) SDS, 0.125%(w/v) bromophenol blue, pH 6.8 
 
10x DNA loading buffer 
20%(v/v) glycerol, 0.625%(w/v) SDS, 0.125%(w/v) xilene cyanol, 0.125%(w/v) 
bromophenol blue in ddH20 
 
10x TBE buffer 
0.89M Tris-borate, 20 mM EDTA, pH 8.3. Diluted to 1 xTBE buffer with ddH20 prior to use. 
 
HEPES-Tyrodes (HT) buffer 
10mM HEPES, 140mM NaCl, 2.7mM KCl, 0.4mM NaH2PO4, 10mM NaHCO3, 5mM 
dextrose, pH 6.5 or 7.4 
 
LB (Luria-Bertani) broth 
1%(w/v) NaCl, 1%(w/v) bacto-tryptone, 0.5%(w/v) bacto-yeast extract in ddH20 
(autoclaved) 
 
LB (Luri-Bertani) agar 
1.5%(w/v) bacto-agar, 1% (w/v) NaCl, 1%(w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast 
extract in ddH20 (autoclaved) 
 
Multimer gel sample buffer 
10mM Tris, 8M urea, 1mM EDTA, 2%(w/v) SDS, 0.01%(w/v) bromophenol blue, pH 8.0 
 
Multimer gel running buffer 
100mM Tris, 150mM glycine, 0.1%(w/v) SDS, pH 8.4 
 
PBS buffer 
5x PBS tablets (Sigma, USA) dissolved in 1 litre of ddH20 
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PBS-T buffer 
5x PBS tablets (Sigma, USA) dissolved in 1 litre of ddH20, 0.1%(v/v) Tween 20  
 
SDS-PAGE electrophoresis buffer 
25 mM Tris-HCl, 192 mM glycine, 0.1%(w/v) SDS, pH 8.3 
 
Transfer buffer 
25 mM Tris-HCl, 192 mM glycine, 20%(v/v) methanol, pH8.3 
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